<html lang="en" class="pb-page js" data-request-id="94d6a1b4040e8828-SJC"><head data-pb-dropzone="head"><style type="text/css" nonce="94d6a1b4040e8828-SJC">@font-face {font-family: "Source Sans Pro";src: url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.ttf) format("truetype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.woff) format("woff"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.otf) format("opentype"),url(https://consent.trustarc.com/get?name=SourceSansPro-Regular.eot) format("embedded-opentype");}.truste_cursor_pointer {cursor: pointer;}.truste_border_none {border: none;}.truste_accessible_link {font-family: "Source Sans Pro", sans-serif;color: #1D4ED8;font-size: 14px;font-weight: 600;text-decoration: underline;}.truste_accessible_link:hover {color: #1D4ED8;text-decoration: none !important;}.truste_accessible_link:focus-visible {outline: none;border-radius: 4px;box-shadow: 0 0 0 1px #FFFFFF, 0 0 0 4px #3699F1;}</style><script src="https://ssl-cdn.janraincapture.com/widget_data/flow.js:7h8bznq6j7bvyvzqcrwvyp8dfb:en-US:20240514181256512029:standard" type="text/javascript"></script><script src="https://cssjs.nejm.org/akamai/capture:login" type="text/javascript"></script><script src="https://ssl-widget-cdn.rpxnow.com/translations/login/en-US" type="text/javascript"></script><script type="text/javascript" id="janrainAuthWidget" src="https://cssjs.nejm.org/akamai/mms-prod.js"></script><script type="text/javascript" src="https://www.nejm.org/HoVLcTNIcDGIKffo7p7LzpGcX7BYocDccHHSDNUjsLi_o6QuO2gj0VMmBoNjOcz4iSdklz7Ux0wV3uh-XQ3Jug=="></script>
            

<meta charset="UTF-8">






    
        
            
        
    
        
            
        
    
        
            
        
    
        
            
        
    
        
    
        
    
        
            
                
                
<title>A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH | New England Journal of Medicine</title>





                
            
        
    







    
        
            
        
    
        
            
        
    
        
            
                
                



                
            
        
    
        
            
        
    
        
    
        
    
        
            
        
    











    








    

    
    

    
    
    
    
        
            
                <link rel="stylesheet" type="text/css" href="/wro/1125813~article-metrics.css">
            
            
            
        
    

    
    
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_nejm_1-994b0160d1eb33dc79517ef0295aab1b.ico" type="image/x-icon">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_16-4aa032aa775940f725817b7ff42f0e2c.png" type="image/png" sizes="16x16">
        
        
            <link rel="icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_32-0a94fa44823476ffa0bb15bdb320fb34.png" type="image/png" sizes="32x32">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_152-d6c3522864a8e483996b7e9c132c901a.png" sizes="152x152">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_180-f2538afc53a365d4cd3f10ab73c56aad.png" sizes="180x180">
        
        
            <link rel="apple-touch-icon" href="/products/mms-nextgen/mms/releasedAssets/images/favicon/fav_167-8e888012bbdd31a00c3e54bc5b8ca5b6.png" sizes="167x167">
        
    

    
    
            <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-5b89b331018866a4a965.css" media="all">
        <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/print-5b89b331018866a4a965.css" media="print">
           <link rel="stylesheet" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css" media="all" id="article-style-sheet">
    
        <script nonce="94d6a1b4040e8828-SJC">
        try {
            document.documentElement.classList.add('js');
        } catch (e) {
        }
    </script>
     
    

















    
        
            
                
                
                
                    
                    <!-- TrustArc Scripts -->
<script async="async" src="https://consent.trustarc.com/notice?domain=nejm.com&amp;c=teconsent&amp;js=nj&amp;noticeType=bb&amp;gtm=1&amp;text=true&amp;pcookie" crossorigin="" id="truste_0.38403486028835476"></script>
<script src="https://consent.trustarc.com/autoblockasset/core.min.js?domain=nejm.com"></script>
<script src="https://consent.trustarc.com/autoblockoptout?domain=nejm.com"></script>
<!-- /TrustArc Scripts -->
<!-- BlueConic Scripts -->
<script src="https://bc.nejm.org/script.js"></script>
    <!-- /BlueConic Scripts -->
<!-- Printing Meta Tags -->
    <meta name="Specialties" content="Gastroenterology">
<meta name="articleType" content="Original Article">
<meta name="articleCategory" content="Research">
<meta name="topics" content="Diet/Nutrition (Gastroenterology)|Gastroenterology General|Liver Disease"><script type="text/javascript">var mmsData = {"access":{"isFreeCountry":"n"},"ad":{"category":"article"},"imageChallenge":{"id":null},"article":{"doi":"10.1056/NEJMoa2036205","title":"A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","category":"Research","type":"Original Article","topics":"Diet/Nutrition (Gastroenterology)|Gastroenterology General|Liver Disease","specialties":"Gastroenterology","seriesTitle":"","viewType":"Full","age":"2Years-1990","issueDate":"2021-10-21T00:00Z","isFree":"y","broadTopics":"","perspectiveTopics":"","granularTopics":"","methodologicalArea":"","isOnlineFirst":"n","isCurrentIssue":"n","metaTags":"\u003cmeta name\u003d\"Specialties\" content\u003d\"Gastroenterology\"/\u003e\n\u003cmeta name\u003d\"articleType\" content\u003d\"Original Article\"/\u003e\n\u003cmeta name\u003d\"articleCategory\" content\u003d\"Research\"/\u003e\n\u003cmeta name\u003d\"topics\" content\u003d\"Diet/Nutrition (Gastroenterology)|Gastroenterology General|Liver Disease\"/\u003e"},"page":{"activity":"showFullText","url":"www.nejm.org/doi/full/10.1056/NEJMoa2036205","viewType":"desktop","journal":"NEJM"},"user":{"ucid":null,"audienceSegment":null,"specialtyGroupCode":null,"meterCountRemaining":null,"totalMeterCount":null},"object":[{"type":"Quick Take","title":"A Pan-PPAR Agonist in NASH","doi":"10.1056/NEJMdo006200","issueDate":"2021-10-21T00:00Z","age":"6Months-1990","isFree":"n","topics":"Diet/Nutrition (Gastroenterology)|Gastroenterology General|Liver Disease","viewType":"Full","specialties":"Gastroenterology"},{"type":"Research Summary","title":"A Randomized Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH","doi":"10.1056/NEJMdo006201","issueDate":"2021-10-21T00:00Z","age":"6Months-1990","isFree":"n","topics":"Diet/Nutrition (Gastroenterology)|Gastroenterology General|Liver Disease","viewType":"Full","specialties":"Gastroenterology"}]};</script>
    <script type="text/javascript">var mmsDataAdd = {"user":{"customerType":"null","accessInstitutionID":"null"}};</script>
    <!-- Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- placeholder id=null, description=Adobe-Target-Prehiding-Snippet --><!--
  Adobe Target - Prehiding Snippet
  v2.0.0
-->
<script nonce="94d6a1b4040e8828-SJC">
function tgtNoFlicker(e,n,t,o,i,c,l,r){function d(){return n.getElementsByTagName("head")[0]}function a(e,t){if(e){var o=n.getElementById(t);o&&e.removeChild(o)}}function f(e,o){!function(e,t,o){if(e){var i=n.createElement("style");i.id=t,i.innerHTML=o,e.appendChild(i)}}(d(),t,e),setTimeout(function(){a(d(),t)},o)}var m;n.location.href.indexOf(c)>-1?f(l,r):f(o,i),n.location.href.indexOf("mboxDisable")>-1?(a(d(),t),console.log("[TARGET] - Disabled, removing prehiding style")):(m=function(e){e&&(a(d(),t),console.log("[TARGET] - Blocked, removing prehiding style"))},fetch("//cdn.tt.omtrdc.net/cdn/target-vec.js",{method:"HEAD",mode:"no-cors"}).then(e=>m(!1)).catch(e=>m(!0)))}

tgtNoFlicker(window, document, 'at-body-style', 'div[data-location-name="Anonymous Module"], div[data-location-name="Anonymous Banner"], main > div.page-body > div > div > div > div.col-md-2-3.o-col.o-col--primary > div[class*="u-hide"], main > div.page-body > div > div > div > div.col-md-1-3.o-col.o-col--secondary > aside, header > h1#mainContent, a.m-article__link[href*="/10.1056/NEJMoa2116747"] > span.m-article__blurb > p, li.g-nejm-group__user-tool-secondary {opacity: 0 !important}', 3000);

tgtNoFlicker(window, document, 'at-mbox-style', '.N-ad-global-top-right, #N-ad-myNEJM-contextual-top, .N-ad-recentArticles, #N-ad-article-rightRail-1, #N-ad-siteWide-rightRail-1, #N-ad-imageChallenge-rightRail-2 {opacity: 0 !important}', 3000);
</script><!-- /Prehiding snippet for Adobe Target with asynchronous Launch deployment -->
    <!-- Launch Header Embed Code -->
    <script src="//assets.adobedtm.com/launch-ENcd6450fae3ae4870becbe6a2b01ab2e1.min.js" async="" type="ta-blocked" data-ta-blocked="1"></script>
    <!-- /Launch Header Embed Code -->

                    
                
            
        
    
        
            
                
                
                
                    
                    <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/"><meta name="citation_journal_title" content="New England Journal of Medicine"><meta name="dc.Title" content="A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH"><meta name="dc.Creator" content="Sven M. Francque"><meta name="dc.Creator" content="Pierre Bedossa"><meta name="dc.Creator" content="Vlad Ratziu"><meta name="dc.Creator" content="Quentin M. Anstee"><meta name="dc.Creator" content="Elisabetta Bugianesi"><meta name="dc.Creator" content="Arun J. Sanyal"><meta name="dc.Creator" content="Rohit Loomba"><meta name="dc.Creator" content="Stephen A. Harrison"><meta name="dc.Creator" content="Rozalina Balabanska"><meta name="dc.Creator" content="Lyudmila Mateva"><meta name="dc.Creator" content="Nicolas Lanthier"><meta name="dc.Creator" content="Naim Alkhouri"><meta name="dc.Creator" content="Christophe Moreno"><meta name="dc.Creator" content="Jörn M. Schattenberg"><meta name="dc.Creator" content="Diana Stefanova-Petrova"><meta name="dc.Creator" content="Luisa Vonghia"><meta name="dc.Creator" content="Régine Rouzier"><meta name="dc.Creator" content="Maeva Guillaume"><meta name="dc.Creator" content="Alexander Hodge"><meta name="dc.Creator" content="Manuel Romero-Gómez"><meta name="dc.Creator" content="Philippe Huot-Marchand"><meta name="dc.Creator" content="Martine Baudin"><meta name="dc.Creator" content="Marie-Paule Richard"><meta name="dc.Creator" content="Jean-Louis Abitbol"><meta name="dc.Creator" content="Pierre Broqua"><meta name="dc.Creator" content="Jean-Louis Junien"><meta name="dc.Creator" content="Manal F. Abdelmalek"><meta name="dc.Description" content="Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need. Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that modulates key metabolic, inflammato..."><meta name="Description" content="Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need. Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that modulates key metabolic, inflammato..."><meta name="dc.Publisher" content="Massachusetts Medical Society"><meta name="dc.Date" scheme="WTN8601" content="2021-10-21"><meta name="dc.Type" content="research-article"><meta name="dc.Format" content="text/HTML"><meta name="dc.Identifier" scheme="doi" content="10.1056/NEJMoa2036205"><meta name="dc.Identifier" scheme="publisher-id" content="NJ202110213851705"><meta name="dc.Language" content="EN"><meta name="dc.Relation" content="10.1056/NEJMoa2029349"><meta name="dc.Relation" content="10.1056/NEJMe2110989"><meta name="dc.Relation" content="YXQYoa2036205"><meta name="dc.Coverage" content="world"><meta name="dc.Rights" content="Copyright © 2021 Massachusetts Medical Society. All rights reserved.">




<link rel="meta" type="application/atom+xml" href="https://doi.org/10.1056%2FNEJMoa2036205">
<link rel="meta" type="application/rdf+json" href="https://doi.org/10.1056%2FNEJMoa2036205">
<link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1056%2FNEJMoa2036205">


                    
                
            
        
    
        
            
                
                
                
                
                
            
        
    
        
            
                
                
                
                    
                    





<meta name="robots" content="noarchive">





    





    
    
        
        <meta name="twitter:title" content="A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH | NEJM">
        <meta property="og:title" content="A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH | NEJM">
    


    <meta property="og:type" content="article">


    
    
        <meta property="og:url" content="https://www.nejm.org/doi/full/10.1056/NEJMoa2036205">
    
    


    
    
        <meta property="og:image" content="https://www.nejm.org/cms/asset/a58cb036-8840-44da-9a72-6e144a75ed7a/nejmoa2036205_f0.jpg">
        <meta name="twitter:image" content="https://www.nejm.org/cms/asset/a58cb036-8840-44da-9a72-6e144a75ed7a/nejmoa2036205_f0.jpg">
    



    <meta property="og:site_name" content="The New England Journal of Medicine">


    
    
        
        <meta property="og:description" content="Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need. Lanifibranor
is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that modulates
key metabolic, inflammato...">
        <meta name="twitter:description" content="Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need. Lanifibranor
is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that modulates
key metabolic, inflammato...">
    


    
    
        <meta property="og:image:width" content="2640">
    


    
    
        <meta property="og:image:height" content="3416">
    


    <meta name="twitter:card" content="summary">


    <meta name="twitter:site" content="@NEJM">


<meta name="viewport" content="width=device-width,initial-scale=1"><meta name="publication_doi" content="10.1056/NEJMoa2036205">


    















                    
                
            
        
    
        
    
        
    
        
            
                
                
                
                
                
            
        
    




<meta name="format-detection" content="telephone=no">

<meta http-equiv="X-UA-Compatible" content="IE=edge">
    




    
        
        
        <link rel="canonical" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2036205">
    
    







<meta name="pbContext" content=";requestedJournal:journal:nejm;article:article:doi\:10.1056/NEJMoa2036205;page:string:Article/Chapter View;ctype:string:Journal Content;issue:issue:doi\:10.1056/nejm_2021.385.issue-17;wgroup:string:MMS NextGen Website Group;pageGroup:string:Publication Pages;subPage:string:Full Text;website:website:mms-site;journal:journal:nejms">
        <link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-933-8e181dff8b36ea01dc4c.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-34-6ea546d794fb7a1cea52.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-743-ddd329e1530654ec0846.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-305-9eee37798fdfe5196307.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-388-bb098c62445f518c0b46.css"><link rel="stylesheet" type="text/css" href="https://cssjs.nejm.org/custreg-556-8e58ca05fb5497e541ef.css"><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/0-dfd243c732a07d3608f6.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/7-10d355ba95f7ec1fddf2.js"></script><script charset="utf-8" src="https://www.nejm.org/products/mms-nextgen/mms/releasedAssets/js/11-04bf2a0da30146b4a5d0.js"></script><script src="https://static.addtoany.com/menu/modules/core.pt5ow5lr.js" type="module"></script><link rel="preconnect" href="https://use.typekit.net"><link rel="stylesheet" href="https://quilt-cdn.janrain.com/HEAD/providers.css" type="text/css"><script id="altmetric-embed-js" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/altmetric_badges-288192a491f0ad9cc434f05ea175659426f5ab0cfd6befb3f3592f96bb90b0d1.js"></script><link id="altmetric-embed-css" rel="stylesheet" type="text/css" href="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed-59614f5c46b49b21eeef3bb28c4fb38d1e7069e8d014752fcb66e84942556802.css"><style type="text/css">.a2a_hide{display:none}.a2a_logo_color{background-color:#0166ff}.a2a_menu,.a2a_menu *{-moz-box-sizing:content-box;-webkit-box-sizing:content-box;box-sizing:content-box;float:none;margin:0;padding:0;position:static;height:auto;width:auto}.a2a_menu{border-radius:6px;display:none;direction:ltr;background:#FFF;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;color:#000;line-height:12px;border:1px solid #CCC;vertical-align:baseline;overflow:hidden}.a2a_mini{min-width:200px;position:absolute;width:300px;z-index:9999997}.a2a_overlay{display:none;background:#616c7deb;backdrop-filter:blur(4px);-webkit-backdrop-filter:blur(4px);position:fixed;top:0;right:0;left:0;bottom:0;z-index:9999998;-webkit-tap-highlight-color:transparent;transition:opacity .14s,backdrop-filter .14s}.a2a_full{background:#FFF;border:1px solid #FFF;box-shadow:#2a2a2a1a 0 0 20px 10px;height:auto;height:calc(320px);top:15%;left:50%;margin-left:-320px;position:fixed;text-align:center;width:640px;z-index:9999999;transition:transform .14s,opacity .14s}.a2a_full_footer,.a2a_full_header,.a2a_full_services{border:0;margin:0;padding:12px;box-sizing:border-box}.a2a_full_header{padding-bottom:8px}.a2a_full_services{height:280px;overflow-y:scroll;padding:0 12px;-webkit-overflow-scrolling:touch}.a2a_full_services .a2a_i{display:inline-block;float:none;width:181px;width:calc(33.334% - 18px)}div.a2a_full_footer{font-size:12px;text-align:center;padding:8px 14px}div.a2a_full_footer a,div.a2a_full_footer a:visited{display:inline;font-size:12px;line-height:14px;padding:8px 14px}div.a2a_full_footer a:focus,div.a2a_full_footer a:hover{background:0 0;border:0;color:#0166FF}div.a2a_full_footer a span.a2a_s_a2a,div.a2a_full_footer a span.a2a_w_a2a{background-size:14px;border-radius:3px;display:inline-block;height:14px;line-height:14px;margin:0 3px 0 0;vertical-align:top;width:14px}.a2a_modal{height:0;left:50%;margin-left:-320px;position:fixed;text-align:center;top:15%;width:640px;z-index:9999999;transition:transform .14s,opacity .14s;-webkit-tap-highlight-color:transparent}.a2a_modal_body{background:0 0;border:0;font:24px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;position:relative;height:auto;width:auto}.a2a_thanks{color:#fff;height:auto;margin-top:20px;width:auto}.a2a_thanks>div:first-child{margin:0 0 40px 0}.a2a_thanks div *{height:inherit}#a2a_copy_link{background:#FFF;border:1px solid #FFF;cursor:pointer;margin-top:15%}label.a2a_s_link#a2a_copy_link_icon,label.a2a_w_link#a2a_copy_link_icon{background-size:48px;border-radius:0;display:inline-block;height:48px;left:0;line-height:48px;margin:0 3px 0 0;position:absolute;vertical-align:top;width:48px}#a2a_modal input#a2a_copy_link_text{background-color:transparent;border:0;color:#2A2A2A;cursor:pointer;font:inherit;height:48px;left:62px;max-width:initial;min-height:auto;padding:0;position:relative;width:564px;width:calc(100% - 76px)}#a2a_copy_link_copied{background-color:#0166ff;color:#fff;display:none;font:inherit;font-size:16px;margin-top:1px;padding:3px 8px}@media (forced-colors:active){.a2a_color_buttons a,.a2a_svg{forced-color-adjust:none}}@media (prefers-color-scheme:dark){.a2a_menu a,.a2a_menu a.a2a_i,.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more,i.a2a_i{border-color:#2a2a2a!important;color:#fff!important}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover,.a2a_menu_find_container{border-color:#444!important;background-color:#444!important}.a2a_menu:not(.a2a_thanks){background-color:#2a2a2a;border-color:#2a2a2a}.a2a_menu_find{color:#fff!important}.a2a_menu label.a2a_s_find svg{background-color:transparent!important}.a2a_menu label.a2a_s_find svg path{fill:#fff!important}.a2a_full{box-shadow:#00000066 0 0 20px 10px}.a2a_overlay{background-color:#373737eb}}@media print{.a2a_floating_style,.a2a_menu,.a2a_overlay{visibility:hidden}}@keyframes a2aFadeIn{from{opacity:0}to{opacity:1}}.a2a_starting{opacity:0}.a2a_starting.a2a_full,.a2a_starting.a2a_modal{transform:scale(.8)}@media (max-width:639px){.a2a_full{border-radius:0;top:15%;left:0;margin-left:auto;width:100%}.a2a_modal{left:0;margin-left:10px;width:calc(100% - 20px)}}@media (min-width:318px) and (max-width:437px){.a2a_full .a2a_full_services .a2a_i{width:calc(50% - 18px)}}@media (max-width:317px){.a2a_full .a2a_full_services .a2a_i{width:calc(100% - 18px)}}@media (max-height:436px){.a2a_full{bottom:40px;height:auto;top:40px}}@media (max-height:550px){.a2a_modal{top:30px}}@media (max-height:360px){.a2a_modal{top:20px}.a2a_thanks>div:first-child{margin-bottom:20px}}.a2a_menu a{color:#0166FF;text-decoration:none;font:16px sans-serif-light,HelveticaNeue-Light,"Helvetica Neue Light","Helvetica Neue",Arial,Helvetica,"Liberation Sans",sans-serif;line-height:14px;height:auto;width:auto;outline:0}.a2a_menu a.a2a_i:visited,.a2a_menu a.a2a_more{color:#0166FF}.a2a_menu a.a2a_i:active,.a2a_menu a.a2a_i:focus,.a2a_menu a.a2a_i:hover,.a2a_menu a.a2a_more:active,.a2a_menu a.a2a_more:focus,.a2a_menu a.a2a_more:hover{color:#2A2A2A;border-color:#EEE;border-style:solid;background-color:#EEE;text-decoration:none}.a2a_menu label.a2a_s_find{background-size:24px;height:24px;left:8px;pointer-events:auto;position:absolute;top:7px;width:24px}.a2a_menu label.a2a_s_find svg{background-color:#FFF}.a2a_menu label.a2a_s_find svg path{fill:#CCC}#a2a_menu_container{display:inline-block}.a2a_menu_find_container{border:1px solid #CCC;border-radius:6px;padding:2px 24px 2px 0;position:relative;text-align:left}.a2a_cols_container .a2a_col1{overflow-x:hidden;overflow-y:auto;-webkit-overflow-scrolling:touch}#a2a_modal input,#a2a_modal input[type=text],.a2a_menu input,.a2a_menu input[type=text]{display:block;background-image:none;box-shadow:none;line-height:100%;margin:0;outline:0;overflow:hidden;padding:0;-moz-box-shadow:none;-webkit-box-shadow:none;-webkit-appearance:none}#a2afeed_find_container input,#a2afeed_find_container input[type=text],#a2apage_find_container input,#a2apage_find_container input[type=text]{background-color:transparent;border:0;box-sizing:content-box;color:#2A2A2A;float:none;font:inherit;font-size:16px;height:28px;line-height:20px;left:38px;outline:0;margin:0;max-width:initial;min-height:initial;padding:2px 0;position:relative;width:99%}.a2a_clear{clear:both}.a2a_svg{background-repeat:no-repeat;display:block;overflow:hidden;height:32px;line-height:32px;padding:0;pointer-events:none;width:32px}.a2a_svg svg{background-repeat:no-repeat;background-position:50% 50%;border:none;display:block;left:0;margin:0 auto;overflow:hidden;padding:0;position:relative;top:0;width:auto;height:auto}a.a2a_i,i.a2a_i{display:block;float:left;border:1px solid #FFF;line-height:24px;padding:6px 8px;text-align:left;white-space:nowrap;overflow:hidden;text-overflow:ellipsis;width:132px}a.a2a_i span,a.a2a_more span{display:inline-block;overflow:hidden;vertical-align:top}a.a2a_i .a2a_svg{margin:0 6px 0 0}a.a2a_i .a2a_svg,a.a2a_more .a2a_svg{background-size:24px;height:24px;line-height:24px;width:24px}a.a2a_sss:hover{border-left:1px solid #CCC}a.a2a_more{border-bottom:1px solid #FFF;border-left:0;border-right:0;line-height:24px;margin:6px 0 0;padding:6px;-webkit-touch-callout:none}a.a2a_more span{height:24px;margin:0 6px 0 0}.a2a_kit .a2a_svg{background-repeat:repeat}.a2a_default_style a:empty,.a2a_flex_style a:empty,.a2a_floating_style a:empty,.a2a_overlay_style a:empty{display:none}.a2a_color_buttons a,.a2a_floating_style a{text-decoration:none}.a2a_default_style:not(.a2a_flex_style) a{float:left;line-height:16px;padding:0 2px}.a2a_default_style a:hover .a2a_svg,.a2a_floating_style a:hover .a2a_svg,.a2a_overlay_style a:hover .a2a_svg svg{opacity:.7}.a2a_overlay_style.a2a_default_style a:hover .a2a_svg{opacity:1}.a2a_default_style .a2a_count,.a2a_default_style .a2a_svg,.a2a_floating_style .a2a_svg,.a2a_menu .a2a_svg,.a2a_vertical_style .a2a_count,.a2a_vertical_style .a2a_svg{border-radius:4px}.a2a_default_style .a2a_counter img,.a2a_default_style .a2a_dd,.a2a_default_style .a2a_svg{float:left}.a2a_default_style .a2a_img_text{margin-right:4px}.a2a_default_style .a2a_divider{border-left:1px solid #000;display:inline;float:left;height:16px;line-height:16px;margin:0 5px}.a2a_kit a{cursor:pointer;transition:none}.a2a_floating_style{background-color:#fff;border-radius:6px;position:fixed;z-index:9999995}.a2a_overlay_style{z-index:2147483647}.a2a_floating_style,.a2a_overlay_style{animation:a2aFadeIn .2s ease-in;padding:4px}.a2a_vertical_style:not(.a2a_flex_style) a{clear:left;display:block;overflow:hidden;padding:4px}.a2a_floating_style.a2a_default_style{bottom:0}.a2a_floating_style.a2a_default_style a,.a2a_overlay_style.a2a_default_style a{padding:4px}.a2a_count{background-color:#fff;border:1px solid #ccc;box-sizing:border-box;color:#2a2a2a;display:block;float:left;font:12px Arial,Helvetica,sans-serif;height:16px;margin-left:4px;position:relative;text-align:center;width:50px}.a2a_count:after,.a2a_count:before{border:solid transparent;border-width:4px 4px 4px 0;content:"";height:0;left:0;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:50%;width:0}.a2a_count:before{border-right-color:#ccc}.a2a_count:after{border-right-color:#fff;margin-left:-3px}.a2a_count span{animation:a2aFadeIn .14s ease-in}.a2a_vertical_style .a2a_counter img{display:block}.a2a_vertical_style .a2a_count{float:none;margin-left:0;margin-top:6px}.a2a_vertical_style .a2a_count:after,.a2a_vertical_style .a2a_count:before{border:solid transparent;border-width:0 4px 4px 4px;content:"";height:0;left:50%;line-height:0;margin:-4px 0 0 -4px;position:absolute;top:0;width:0}.a2a_vertical_style .a2a_count:before{border-bottom-color:#ccc}.a2a_vertical_style .a2a_count:after{border-bottom-color:#fff;margin-top:-3px}.a2a_color_buttons .a2a_count,.a2a_color_buttons .a2a_count:after,.a2a_color_buttons .a2a_count:before,.a2a_color_buttons.a2a_vertical_style .a2a_count:after,.a2a_color_buttons.a2a_vertical_style .a2a_count:before{background-color:transparent;border:none;color:#fff;float:none;width:auto}.a2a_color_buttons.a2a_vertical_style .a2a_count{margin-top:0}.a2a_flex_style{display:flex;align-items:flex-start;gap:0}.a2a_default_style.a2a_flex_style{left:0;right:0;width:100%}.a2a_vertical_style.a2a_flex_style{flex-direction:column;top:0;bottom:0}.a2a_flex_style a{display:flex;justify-content:center;flex:1;padding:4px}.a2a_flex_style.a2a_vertical_style a{flex-direction:column}.a2a_floating_style.a2a_color_buttons,.a2a_floating_style.a2a_flex_style{border-radius:0;padding:0}.a2a_floating_style.a2a_default_style.a2a_flex_style{bottom:0}.a2a_kit.a2a_flex_style .a2a_counter img,.a2a_kit.a2a_flex_style .a2a_dd,.a2a_kit.a2a_flex_style .a2a_svg{float:none}.a2a_nowrap{white-space:nowrap}.a2a_note{margin:0 auto;padding:9px;font-size:12px;text-align:center}.a2a_note .a2a_note_note{margin:0;color:#2A2A2A}.a2a_wide a{display:block;margin-top:3px;border-top:1px solid #EEE;text-align:center}.a2a_label{position:absolute!important;clip-path:polygon(0px 0px,0px 0px,0px 0px);-webkit-clip-path:polygon(0px 0px,0px 0px,0px 0px);overflow:hidden;height:1px;width:1px}.a2a_kit,.a2a_menu,.a2a_modal,.a2a_overlay{-ms-touch-action:manipulation;touch-action:manipulation;outline:0}.a2a_dd{-webkit-user-drag:none}.a2a_dd img{border:0}.a2a_button_facebook_like iframe{max-width:none}</style></head>
    

    



    
        
        
        
            <body class="pb-ui website-mms-site loaded">
            






    
    
        





    
    
        
        
    
    
    







<input type="hidden" id="isRoMode" name="isRoMode" value="false">

        <div id="pb-page-content" data-ng-non-bindable="">
                
            <div data-pb-dropzone="main" data-pb-dropzone-name="Main">
                
                    
                        



        
        <header data-sticky="false" class="ng-header js_stickyAd"><a href="#mainContent" class="ng-skipToMainContent">Skip to main content</a><div class="ng-header_topAd"><div class="ng-header_topAd-content d-flex justify-content-center align-items-center">



        
        <div id="DTM_Position_Topbanner" class="ad">
 <!--emptycomment-->
</div>
</div></div><div class="ng-header_journal-navbar"><div class="ng-header_journal-navbar-content"><div class="container-fluid"><div class="row"><div class="ng-header_journal-navbar_left col-lg-8 col-sm-12 pr-lg-0 d-flex align-items-center"><div data-location="nejm_group_product_nav" class="ng-header_journalNavMenu">



        
        <nav data-location="nejm_group_product_nav" role="navigation" class="ng-journalNavMenu">
<ul class="ng-journalNavMenu_list">
<li class="ng-journalNavMenu_list-item"><a href="/" class="ng-journalNavMenu_mainLink active" aria-current="page" aria-label="The New England Journal of Medicine selected item"><span class="ng-journalNavMenu_mainLink-text d-lg-block d-none">The New England Journal of Medicine</span><span class="ng-journalNavMenu_mainLink-text d-lg-none d-block">NEJM</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://evidence.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Evidence</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://ai.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> AI</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://catalyst.nejm.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Catalyst</span></a></li>
<li class="ng-journalNavMenu_list-item"><a href="https://www.jwatch.org/" class="ng-journalNavMenu_mainLink"><span class="ng-journalNavMenu_mainLink-text"><span class="ng-journalNavMenu_mainLink-text-firstWord">NEJM</span> Journal Watch</span></a></li>
</ul>
</nav>

</div></div><div class="ng-header_journal-navbar_right col-lg-4 pl-lg-0 d-none d-xl-flex align-items-center justify-content-end"><div class="ng-header_loginBar d-xl-flex align-items-lg-center">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2036205" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div></div><div class="ng-header_instBanner d-none d-lg-block"></div><div class="ng-header_logoBar"><div class="container-fluid"><div class="row"><div data-location="logo" class="ng-header_logoBar_left col-lg-4 col-6 d-flex align-items-center justify-content-start"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-logo-166667e91992a5212bc723b03e45d39f.svg" alt="The New England Journal of Medicine homepage" width="366" height="58" class="ng-header_logo-image"></a></div><div class="ng-header_logoBar_right ng-header_navBar col-lg-8 col-sm-12 p-lg-0 align-items-center justify-content-end"><div class="ng-header_navBar-content"><div class="container-fluid"><div class="row"><div class="ng-header_instBanner-md col-12 d-block d-lg-none"></div><div class="ng-header_loginBar-md col-12 d-block d-xl-none">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2036205" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div><div class="ng-header_navBar_left col-lg-8 col-sm-12 d-flex align-items-center"><div class="ng-header_stickyLogo mr-32"><a href="/" title="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/nejm-small-logo-070df7a3f4d8cfa2e71c3c45bb4b172f.svg" alt="The New England Journal of Medicine homepage" class="ng-header_stickyLogo-image"></a></div><div class="ng-header_mainMenu">









    
    
        <div data-widget-def="menuWidget" data-widget-id="97fb3983-db63-4b0b-97dd-d9bb7929fce1" data-location="main_nav">
        



        
        <nav class="ng-menu"><ul class="ng-menu_list ng-simple-menu"><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/toc/nejm/current" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">current issue</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/toc/nejm/current" class="ng-simple-menu_list-link">VIEW CURRENT ISSUE</a></li><li class="ng-simple-menu_list-item"><a href="/toc/nejm/recently-published" class="ng-simple-menu_list-link">BROWSE RECENTLY PUBLISHED</a></li><li class="ng-simple-menu_list-item"><a href="/loi/nejm" class="ng-simple-menu_list-link">BROWSE ALL ISSUES</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/medical-specialties" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">SPECIALTIES</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/browse/specialty/cardiology" class="ng-simple-menu_list-link">Cardiology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/clinical-medicine" class="ng-simple-menu_list-link">Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/endocrinology" class="ng-simple-menu_list-link">Endocrinology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/gastroenterology" class="ng-simple-menu_list-link">Gastroenterology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/hematology-oncology" class="ng-simple-menu_list-link">Hematology/Oncology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/infectious-disease" class="ng-simple-menu_list-link">Infectious Disease</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/nephrology" class="ng-simple-menu_list-link">Nephrology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/neurology-neurosurgery" class="ng-simple-menu_list-link">Neurology/Neurosurgery</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/obstetrics-gynecology" class="ng-simple-menu_list-link">Obstetrics/Gynecology</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pediatrics" class="ng-simple-menu_list-link">Pediatrics</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/pulmonary-critical-care" class="ng-simple-menu_list-link">Pulmonary/Critical Care</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/surgery" class="ng-simple-menu_list-link">Surgery</a></li><li class="ng-simple-menu_list-item"><a href="/medical-specialties" class="ng-simple-menu_list-link">View All Specialties</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/topics" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">TOPICS</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/ai-in-medicine" class="ng-simple-menu_list-link">AI in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/climate-change" class="ng-simple-menu_list-link">Climate Change</a></li><li class="ng-simple-menu_list-item"><a href="/coronavirus" class="ng-simple-menu_list-link">Coronavirus</a></li><li class="ng-simple-menu_list-item"><a href="/equity" class="ng-simple-menu_list-link">Efforts toward Equity</a></li><li class="ng-simple-menu_list-item"><a href="/firearm-injury-prevention" class="ng-simple-menu_list-link">Firearm Injury Prevention</a></li><li class="ng-simple-menu_list-item"><a href="/nam" class="ng-simple-menu_list-link">From the National Academy of Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/fundamentals-of-medical-ethics" class="ng-simple-menu_list-link">Fundamentals of Medical Ethics</a></li><li class="ng-simple-menu_list-item"><a href="/gray-matters" class="ng-simple-menu_list-link">Gray Matters</a></li><li class="ng-simple-menu_list-item"><a href="/browse/specialty/health-policy" class="ng-simple-menu_list-link">Health Policy</a></li><li class="ng-simple-menu_list-item"><a href="/medicine-and-society" class="ng-simple-menu_list-link">Medicine and Society</a></li><li class="ng-simple-menu_list-item"><a href="/nutrition-in-medicine" class="ng-simple-menu_list-link">Nutrition in Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/outbreaks" class="ng-simple-menu_list-link">Outbreaks Center</a></li><li class="ng-simple-menu_list-item"><a href="/race-and-medicine" class="ng-simple-menu_list-link">Race and Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/recognizing-historical-injustices" class="ng-simple-menu_list-link">Recognizing Historical Injustices and the Journal</a></li><li class="ng-simple-menu_list-item"><a href="/tobacco-use-reduction" class="ng-simple-menu_list-link">Tobacco Use Reduction</a></li><li class="ng-simple-menu_list-item"><a href="/topics" class="ng-simple-menu_list-link">View All Topics</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/multimedia" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">MULTIMEDIA</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/rss-feed" class="ng-simple-menu_list-link">Podcasts</a></li><li class="ng-simple-menu_list-item"><a href="/double-take" class="ng-simple-menu_list-link">Double Takes</a></li><li class="ng-simple-menu_list-item"><a href="https://illustrated-glossary.nejm.org/" class="ng-simple-menu_list-link">Illustrated Glossary</a></li><li class="ng-simple-menu_list-item"><a href="/image-challenge" class="ng-simple-menu_list-link">Image Challenge</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/images-in-clinical-medicine" class="ng-simple-menu_list-link">Images in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/interactive-medical-case" class="ng-simple-menu_list-link">Interactive Medical Cases</a></li><li class="ng-simple-menu_list-item"><a href="/plain-language-research-summaries" class="ng-simple-menu_list-link">Plain Language/Research Summaries</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia/quick-take-video" class="ng-simple-menu_list-link">Quick Takes</a></li><li class="ng-simple-menu_list-item"><a href="/browse/nejm-media-type/videos-in-clinical-medicine" class="ng-simple-menu_list-link">Videos in Clinical Medicine</a></li><li class="ng-simple-menu_list-item"><a href="/multimedia" class="ng-simple-menu_list-link">View All Multimedia</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item hasChildren"><a href="/learning" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">LEARNING/CME</span><span class="ng-simple-menu_mainLink-arrowIcon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-down"></use></svg></span></span></a><div class="ng-simple-menu_dropblock"><div class="ng-simple-menu_dropblock-cont"><div class="ng-simple-menu_list"><ul class="ng-simple-menu_list-items"><li class="ng-simple-menu_list-item"><a href="/continuing-medical-education" class="ng-simple-menu_list-link">Weekly CME</a></li><li class="ng-simple-menu_list-item"><a href="/cme-ce/obesity" class="ng-simple-menu_list-link">Obesity CME/CE</a></li><li class="ng-simple-menu_list-item"><a href="/learning" class="ng-simple-menu_list-link">VIEW ALL LEARNING/CME</a></li></ul></div></div></div></li><li class="ng-menu_list-item ng-simple-menu_item"><a href="/author-center/home" class="ng-simple-menu_mainLink"><span class="ng-simple-menu_mainLink-text">AUTHOR CENTER</span></a></li></ul></nav>

        </div>
    

</div><button aria-label="Search" class="ng-header_searchBtn searchBtnNav d-block ml-24"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button></div><div class="ng-header_loginBar ng-header_loginBar-sticky col-4">



        
        <div data-location="authstring_nav" class="ng-header_loginBar-menu"><span class="ng-simple-menu_mainLink-icon signIn newIcon-2"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#user2"></use></svg></span></span><span class="ng-header_loginBar-signIn"><a href="/sign-in?uri=/doi/full/10.1056/NEJMoa2036205" class="ng-header_loginBar-signIn-link">Sign In</a></span><span class="ng-header_loginBar-separator">|</span><span class="ng-header_loginBar-createAcc"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC1" class="ng-header_loginBar-createAcc-link ro-mode_disabled">Create Account</a></span></div><div data-location="authstring_nav" class="ng-header_loginBar-subscribe pl-xl-16"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS1" class="ng-header_loginBar-subscribe-btn ng-btn_primary ro-mode_disabled">Subscribe</a></div>
</div></div></div></div></div><div class="ng-header_logoBar_right-lg col-lg-8 col-6 d-flex align-items-center justify-content-end d-xl-none"><button aria-label="Search" class="ng-header_searchBtn d-flex justify-content-end"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><div class="ng-header_openCloseBtns d-flex align-items-center justify-content-end"><button aria-label="Open" class="ng-header_openBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#burger"></use></svg></span></button><button aria-label="Close" class="ng-header_closeBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></button></div></div><div class="ng-header_quickSearch col-12"><div class="ng-header_quickSearch-content">



        
        <div class="ng-quick-search js-ng-quick-search"><form action="/search" method="get" class="ng-quick-search_form js-form"><div class="ng-quick-search_inputArea js-inputArea"><input type="search" name="q" placeholder="Enter keyword, author, title or citation" autocomplete="off" value="" required="required" class="ng-quick-search_allField ng-large-text-input js-allField js-allField-def-tmpl ui-autocomplete-input"><button type="submit" aria-label="Search Button" class="ng-quick-search_iconBtn d-xl-none d-block js-submitBtn"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#search"></use></svg></span></button><ul id="ui-id-1" tabindex="0" class="ui-menu ui-widget ui-widget-content ui-autocomplete ui-front" style="display: none;"></ul></div><div class="ng-quick-search_btnsArea d-none d-xl-flex align-items-center justify-content-end"><a href="/search/advanced" class="ng-quick-search_advSearchLink ng-btn_link js-advancedSearchLink">Advanced Search</a><button type="submit" class="ng-quick-search_textBtn ng-btn_secondary ng-btn_iconRight js-submitBtn"><span class="ng-btn_text">SEARCH</span><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-right"></use></svg></span></button></div></form></div>
</div></div></div></div></div></header><div class="ng-header_overlay"></div><div class="ng-header_after">









    
    
        <div data-widget-def="literatumAd" data-widget-id="4931ddbd-d46e-4597-b4fd-92549e9847ca" id="ad-global-banner-FULLx64-1">
        



        
        



    

    

    
        
    



        </div>
    

</div>

                    
                        



        
        <div>









    
    
        <main data-widget-def="axelPublicationContent" data-widget-id="fcdb5261-d6a2-4a9c-81d5-3a3e2304e9c1" id="mainContent">
        



        
        <div class="article-tools__savePopup"><div class="ng-save"><input type="hidden" value="/action/getSavedTags" class="getKeywordsServiceUrl"><input type="hidden" value="/action/mmsSaveItemsService?itemType=article" class="saveServiceUrl"><input type="hidden" value="article" class="saveType"><input type="hidden" value="10.1056/NEJMoa2036205" class="inputDoi"><input type="hidden" value="S.M. Francque and Others" class="inputAuthor"><input type="hidden" value="N Engl J Med 2021;385:1547-1558" class="inputCitation"><input type="hidden" value="10-20-2021" class="inputEPubDate"><input type="hidden" value="October 2021" class="inputCoverDate"><input type="hidden" value="Original Article" class="inputContentType"><input type="hidden" value="A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH" class="inputArticleTitle"><input type="hidden" value="/browse/nejm-article-type/original-article" class="inputContentTypeUrl"><button type="button" id="saveArticleShowPopupBtn" aria-hidden="true" tabindex="-1" class="ng-save-btn ng-btn_secondary isLoggedOut">Save</button></div></div><div class="article-tools__articleAlertPopup"><div id="articleAlertModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="articleAlertModalTitle" class="ng-modal_title modal-title">Create an E-mail Alert for This Article</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><div class="ng-do-media_popup"><div id="doPopup" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body"></div></div></div></div></div><link id="build-style-article" rel="stylesheet" type="text/css" href="/products/mms-nextgen/mms/releasedAssets/css/build-article-5b89b331018866a4a965.css"><article xmlns="http://www.w3.org/1999/xhtml" data-design="pill" data-has="right-rail" data-type="research-article" vocab="http://schema.org/" typeof="ScholarlyArticle" lang="en" dir="ltr"><header data-extent="frontmatter" data-location="header_article"><div class="core-container"><div data-article-access="free" data-article-access-type="free" class="meta-panel"><div class="meta-panel__left-content"><div class="meta-panel__type"><a href="/browse/nejm-article-type/original-article">Original Article</a></div></div><div class="meta-panel__right-content"><div class="meta-panel__share">









    
    
        <div data-widget-def="UX3share" data-widget-id="eee5f139-16f2-48f8-97ea-1b114367da16" data-location="share_tools_article">
        



        
        <!-- Go to https://www.addtoany.com/buttons/customize/ to customize your tools --><script type="text/javascript" defer="defer" src="https://static.addtoany.com/menu/page.js" nonce="94d6a1b4040e8828-SJC"></script><div class="share"><div class="share__block share__inline-links"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="d-flex list-unstyled a2a a2a_kit a2a_default_style mb-0 a2a_kit_size_32" style="line-height: 32px;"><li class="a2a_listitem_custom"><a role="link" title="Facebook" data-interactiontype="social" class="share__link a2a_button_facebook" target="_blank" rel="nofollow noopener" href="/#facebook"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-facebook"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="X (formerly Twitter)" data-interactiontype="social" class="share__link a2a_button_twitter" target="_blank" rel="nofollow noopener" href="/#twitter"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-twitter"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Linked In" data-interactiontype="social" class="share__link a2a_button_linkedin" target="_blank" rel="nofollow noopener" href="/#linkedin"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-linkedin"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Email" data-interactiontype="content_email_click" class="share__link a2a_button_email" target="_blank" rel="nofollow noopener" href="/#email"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-email"></use></svg></span></a></li><li class="a2a_listitem_custom"><a role="link" title="Bluesky" data-interactiontype="social" class="share__link a2a_button_bluesky" target="_blank" rel="nofollow noopener" href="/#bluesky"><span class="icon-component " style="height: 24px; width: 24px"><svg aria-hidden="true" style="height: 24px; width: 24px"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#social-bluesky"></use></svg></span></a></li><div style="clear: both;"></div></ul></div></div>

        </div>
    

</div></div></div><h1 property="name">A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH</h1><div class="core-relations my-3"></div><div class="contributors"><span class="authors"><span class="heading">Authors</span>: <span role="list"><span property="author" typeof="Person" role="listitem"><span property="givenName">Sven M.</span> <span property="familyName">Francque</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-7527-4714" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-7527-4714</a></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Pierre</span> <span property="familyName">Bedossa</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Vlad</span> <span property="familyName">Ratziu</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Quentin M.</span> <span property="familyName">Anstee</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Elisabetta</span> <span property="familyName">Bugianesi</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Arun J.</span> <span property="familyName">Sanyal</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person" role="listitem"><span property="givenName">Rohit</span> <span property="familyName">Loomba</span>, <span property="honorificSuffix">M.D., M.H.Sc.</span></span><span data-displayed-on="all">, <span data-action="reveal" tabindex="0" role="listitem">+20</span> </span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Stephen A.</span> <span property="familyName">Harrison</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Rozalina</span> <span property="familyName">Balabanska</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Lyudmila</span> <span property="familyName">Mateva</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Nicolas</span> <span property="familyName">Lanthier</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-7651-9314" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-7651-9314</a></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Naim</span> <span property="familyName">Alkhouri</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Christophe</span> <span property="familyName">Moreno</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jörn M.</span> <span property="familyName">Schattenberg</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-4224-4703" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-4224-4703</a></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Diana</span> <span property="familyName">Stefanova-Petrova</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Luisa</span> <span property="familyName">Vonghia</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Régine</span> <span property="familyName">Rouzier</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Maeva</span> <span property="familyName">Guillaume</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Alexander</span> <span property="familyName">Hodge</span>, <span property="honorificSuffix">M.B., B.S., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Manuel</span> <span property="familyName">Romero-Gómez</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Philippe</span> <span property="familyName">Huot-Marchand</span>, <span property="honorificSuffix">M.Sc.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Martine</span> <span property="familyName">Baudin</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Marie-Paule</span> <span property="familyName">Richard</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jean-Louis</span> <span property="familyName">Abitbol</span>, <span property="honorificSuffix">M.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Pierre</span> <span property="familyName">Broqua</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, <span property="author" typeof="Person" role="listitem"><span property="givenName">Jean-Louis</span> <span property="familyName">Junien</span>, <span property="honorificSuffix">Ph.D.</span></span></span><span data-hidden-on="all">, and <span property="author" typeof="Person" role="listitem"><span property="givenName">Manal F.</span> <span property="familyName">Abdelmalek</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span></span>, for <span property="author" typeof="Person" role="listitem">the NATIVE Study Group<sup><a href="#fn1" role="doc-noteref">*</a></sup></span><span data-displayed-on="none" data-on-display="all" aria-hidden="true"> <span data-action="hide" tabindex="0" role="listitem">-20</span></span></span></span><a href="#tab-contributors" class="to-authors-affiliations" data-id="article-authors-viewall">Author Info &amp; Affiliations</a></div><div class="core-self-citation"><div class="core-date-published">Published <span property="datePublished">October 20, 2021</span></div><div property="isPartOf" typeof="Periodical"><span property="name">N Engl J Med</span> 2021<span property="isPartOf" typeof="PublicationVolume">;<span property="volumeNumber">385</span></span>:<span property="pageStart">1547</span>-<span property="pageEnd">1558</span></div><div class="doi">DOI: 10.1056/NEJMoa2036205</div><div class="core-enumeration"><a href="/toc/nejm/385/17"><span property="isPartOf" typeof="PublicationVolume">VOL. <span property="volumeNumber">385</span></span> <span property="isPartOf" typeof="PublicationIssue">NO. <span property="issueNumber">17</span></span></a></div><div><a href="#tab-information">Copyright © 2021</a></div></div><div class="info-panel"><div class="info-panel__left-content"><div class="info-panel__metrics info-panel__item"></div></div><div data-location="tools_article" class="info-panel__right-content"><div class="info-panel__article_tools info-panel__item">



        
        <div data-permission="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DSven%2BM.%2BFrancque%252C%2BPierre%2BBedossa%252C%2BVlad%2BRatziu%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D385%26issueNum%3D17%26contentID%3D10.1056%252FNEJMoa2036205%26title%3DA%2BRandomized%252C%2BControlled%2BTrial%2Bof%2Bthe%2BPan-PPAR%2BAgonist%2BLanifibranor%2Bin%2BNASH%26publicationDate%3D10%252F21%252F2021" class="article-tools"><button id="articleToolsAlertBtn" data-url="/action/addCitationAlert?doi=10.1056%2FNEJMoa2036205" data-toggle="" data-target="#articleAlertModal" aria-label="Sign in or create account to add an article alert" data-interactiontype="article_alert" class="article-tools__citation btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to add an article alert"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#alerts"></use></svg></span></span></button><button id="articleToolsSaveBtn" data-toggle="modal" data-target="#saveArticle" aria-label="Sign in or create account to save this article" data-interactiontype="article_tools_save_click" class="article-tools__favorite btn btn--slim isLoggedOut"><span title="" data-toggle="tooltip" class="d-inline-block" data-original-title="Sign in or create account to save this article"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#bookmarkFilled"></use></svg></span></span></button><a href="/servlet/linkout?type=rightslink&amp;url=publisherName%3Dmassmed%26author%3DSven%2BM.%2BFrancque%252C%2BPierre%2BBedossa%252C%2BVlad%2BRatziu%252C%2Bet%2Bal%26publication%3Dnejm%26orderBeanReset%3Dtrue%26volumeNum%3D385%26issueNum%3D17%26contentID%3D10.1056%252FNEJMoa2036205%26title%3DA%2BRandomized%252C%2BControlled%2BTrial%2Bof%2Bthe%2BPan-PPAR%2BAgonist%2BLanifibranor%2Bin%2BNASH%26publicationDate%3D10%252F21%252F2021" target="_blank" title="" data-toggle="tooltip" aria-label="Permissions" data-interactiontype="article_tools_permissions_click" class="article-tools__permissions btn btn--slim" data-original-title="Permissions"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#permissions"></use></svg></span></a><a href="/about-nejm/reprints" title="" data-toggle="tooltip" aria-label="Reprints" data-interactiontype="article_tools_reprints_click" class="article-tools__reprints btn btn--slim" data-original-title="Reprints"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#reprints"></use></svg></span></a><a href="/cms/asset/e38fb1f8-d2fb-4be5-a352-28d55e497581/nejmoa2036205.pptx" target="_blank" title="" data-toggle="tooltip" aria-label="Download Slides" data-interactiontype="article_tools_slide_set_download" data-multimedia-type="Article Slideset" data-multimedia-filename="nejmoa2036205.pptx" class="article-tools__downloadSlides btn btn--slim" data-original-title="Download Slides"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#download"></use></svg></span></a><div class="article-tools__permissionsPopup"><div id="permissionsModal" tabindex="-1" role="dialog" aria-labelledby="exampleModalCenterTitle" aria-hidden="true" class="ng-modal modal"><div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered"><div class="ng-modal_content modal-content"><div class="ng-modal_header modal-header"><h5 id="permissionsModalTitle" class="ng-modal_title modal-title">Permissions</h5><button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#close"></use></svg></span></span></button></div><div class="ng-modal_body modal-body">For permission requests, please contact NEJM Reprints at <a href="mailto:reprints@nejm.org">reprints@nejm.org</a></div></div></div></div></div></div>
</div><div class="info-panel__citations info-panel__item"><a href="#tab-citations" class="btn btn--slim" aria-label="View Citations" data-toggle="tooltip" data-original-title="View Citations" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><i aria-hidden="true" class="icon-format_quote"></i></a></div><div class="info-panel__formats info-panel__item"><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2036205" class="btn btn--pdf btn--slim" aria-label="View PDF" data-toggle="tooltip" data-original-title="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2036205" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2036205.pdf"><i aria-hidden="true" class="icon-PDF"></i></a></div></div></div></div></header><div data-core-nav="header" data-extent="frontmatter"><div class="core-nav-wrapper core-container" aria-label="Article navigation"><div class="core-sections-menu"><button data-id="article-toolbar-showhide" aria-controls="article_sections_menu" aria-expanded="false" aria-label="Toggle section navigation menu" style="margin-top: 0px;"><i class="icon-list" aria-hidden="true"></i><span>Contents</span></button><nav id="article_sections_menu" aria-label="Contents" data-core-nav="article" style="margin-top: 0px;"><ul><li><a href="#summary-abstract" aria-current="true">Abstract</a></li><li><a href="#sec-1" aria-current="false">Methods</a></li><li><a href="#sec-2" aria-current="false">Results</a></li><li><a href="#sec-3" aria-current="false">Discussion</a></li><li class="bordered"><a href="#backnotes" aria-current="false">Notes</a></li><li><a href="#supplementary-materials" aria-current="false">Supplementary Material</a></li><li><a href="#bibliography" aria-current="false">References</a></li></ul></nav></div><nav id="article_collateral_menu"><ul data-core-nav="collateral" class="collateral-pill" style="margin-top: 0px;"><li><a href="#core-collateral-info" data-id="article-nav-menubar-info" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Information &amp; Authors"><i aria-hidden="true" class="icon-info"></i><span class="sr-only">Information &amp; Authors</span></a></li><li><a href="#core-collateral-metrics" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Metrics &amp; Citations"><i aria-hidden="true" class="icon-timeline"></i><span class="sr-only">Metrics &amp; Citations</span></a></li><li><a href="#core-collateral-fulltext-options" data-id="article-nav-menubar-metrics" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="View Options"><i aria-hidden="true" class="icon-eye"></i><span class="sr-only">View Options</span></a></li><li><a href="#core-collateral-references" data-id="article-nav-menubar-references" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="References"><i aria-hidden="true" class="icon-references"></i><span class="sr-only">References</span></a></li><li><a href="#core-collateral-media" data-id="article-nav-menubar-media" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Media"><i aria-hidden="true" class="icon-photo"></i><span class="sr-only">Media</span></a></li><li><a href="#core-collateral-tables" data-id="article-nav-menubar-tables" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Tables"><i aria-hidden="true" class="icon-tables"></i><span class="sr-only">Tables</span></a></li><li><a href="#core-collateral-share" data-id="article-nav-menubar-share" title="" tabindex="0" data-toggle="tooltip" data-placement="left" data-offset="4px, 16px" data-original-title="Share"><i aria-hidden="true" class="icon-share"></i><span class="sr-only">Share</span></a></li></ul></nav></div></div><div data-core-wrapper="content"><div id="abstracts" data-extent="frontmatter" data-location="articleTab_article"><div class="core-container"><section id="summary-abstract" property="abstract" typeof="Text" role="doc-abstract"><h2 property="name">Abstract</h2><section id="abs-sec-1"><h3>Background</h3><div role="paragraph">Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need. Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that modulates key metabolic, inflammatory, and fibrogenic pathways in the pathogenesis of NASH.</div></section><section id="abs-sec-2"><h3>Methods</h3><div role="paragraph">In this phase 2b, double-blind, randomized, placebo-controlled trial, patients with noncirrhotic, highly active NASH were randomly assigned in a 1:1:1 ratio to receive 1200 mg or 800 mg of lanifibranor or placebo once daily for 24 weeks. The primary end point was a decrease of at least 2 points in the SAF-A score (the activity part of the Steatosis, Activity, Fibrosis [SAF] scoring system that incorporates scores for ballooning and inflammation) without worsening of fibrosis; SAF-A scores range from 0 to 4, with higher scores indicating more-severe disease activity. Secondary end points included resolution of NASH and regression of fibrosis.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><!-- There is no content. --><nav><a href="#f0" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2036205_f0.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f0" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2036205_f0.jpg"><img src="/cms/10.1056/NEJMoa2036205/asset/a58cb036-8840-44da-9a72-6e144a75ed7a/assets/images/large/nejmoa2036205_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure></div></section><section id="abs-sec-3"><h3>Results</h3><div role="paragraph">A total of 247 patients underwent randomization, of whom 103 (42%) had type 2 diabetes mellitus and 188 (76%) had significant (moderate) or advanced fibrosis. The percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher among those who received the 1200-mg dose, but not among those who received the 800-mg dose, of lanifibranor than among those who received placebo (1200-mg dose vs. placebo, 55% vs. 33%, P=0.007; 800-mg dose vs. placebo, 48% vs. 33%, P=0.07). <a id="exam-tint-two-d"></a><span id="tint1" class="named-content" data-type="exam-tint" data-answer-ids="two-d">The results favored both the 1200-mg and 800-mg doses of lanifibranor over placebo for resolution of NASH without worsening of fibrosis (49% and 39%, respectively, vs. 22%), improvement in fibrosis stage of at least 1 without worsening of NASH (48% and 34%, respectively, vs. 29%), and resolution of NASH plus improvement in fibrosis stage of at least 1 (35% and 25%, respectively, vs. 9%).</span> Liver enzyme levels decreased and the levels of the majority of lipid, inflammatory, and fibrosis biomarkers improved in the lanifibranor groups. The dropout rate for adverse events was less than 5% and was similar across the trial groups. Diarrhea, nausea, peripheral edema, anemia, and weight gain occurred more frequently with lanifibranor than with placebo.</div></section><section id="abs-sec-4"><h3>Conclusions</h3><div role="paragraph">In this phase 2b trial involving patients with active NASH, the percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher with the 1200-mg dose of lanifibranor than with placebo. These findings support further assessment of lanifibranor in phase 3 trials. (Funded by Inventiva Pharma; NATIVE ClinicalTrials.gov number, <a href="http://clinicaltrials.gov/show/NCT03008070" target="_blank">NCT03008070</a>.)</div></section></section><div class="core-digital-object quick-take">
<div class="ng-do-media" style="border-top: 1px solid #e5e5e5; padding-top: 1.5rem;" data-location="inlineArticlePreview">
    <div class="ng-do-media_item">
        <div class="ng-do-media_item-left">
            <a href="/do/10.1056/NEJMdo006200/full/" class="ng-do-media_item-img-link">
                <img src="/cms/asset/4c6e7d99-2587-43eb-8348-b8c94865dfb9/media/NEJMdo006200_300x200.jpg" class="ng-do-media_item-img">
                <span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#tooltip-video"></use></svg></span>
            </a>
        </div>
        <div class="ng-do-media_item-right">
            <div class="ng-do-media_item-type">
                <a href="/browse/nejm-media-type/quick-take" class="ng-do-media_item-type-link">Quick Take</a>
            </div>
            <h6 class="ng-do-media_item-title">
                <a href="/do/10.1056/NEJMdo006200/full/" class="ng-do-media_item-title-link">A Pan-PPAR Agonist in NASH</a>
            </h6>
            <div class="ng-do-media_item-duration">2m 4s</div>
        </div>
    </div>
</div>
</div></div></div><section id="bodymatter" data-extent="bodymatter" property="articleBody" typeof="Text" data-location="articleTab_article"><div class="core-container"><div role="paragraph">Nonalcoholic steatohepatitis (NASH), a condition that results from a combination of adipose-tissue insulin resistance, adipocytokine imbalance, and systemic inflammation, is currently a major worldwide cause of chronic liver disease, contributing to cirrhotic morbidity, hepatocellular carcinoma and liver transplantation, worsening cardiovascular disease, and metabolic dysfunction.<sup><a href="#core-r1" role="doc-biblioref" data-xml-rid="r1 r2 r3" id="body-ref-r3-1" href-manipulated="true">1-3</a></sup> Peroxisome proliferator–activated receptors (PPARs) are nuclear receptors with key regulatory functions in metabolism, inflammation, and fibrogenesis.<sup><a href="#core-r4" role="doc-biblioref" data-xml-rid="r4 r5" id="body-ref-r5" href-manipulated="true">4,5</a></sup> In preclinical models, the indole sulfonamide lanifibranor (IVA337), a pan-PPAR agonist, improved insulin sensitivity and macrophage activation and reduced liver fibrosis and inflammatory gene expression with higher efficacy than single or dual PPAR agonists.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6 r7" id="body-ref-r7" href-manipulated="true">6,7</a></sup> Resolution of NASH and regression of fibrosis are currently considered to be likely surrogate outcomes for the prevention of progression to cirrhosis and associated complications.<sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8" id="body-ref-r8-1" href-manipulated="true" aria-label="Reference 8">8</a></sup> Here, we report the results of the NASH Trial to Validate IVA337 Efficacy (NATIVE), a phase 2b, double-blind, randomized, placebo-controlled trial evaluating the efficacy and safety of lanifibranor in patients with biopsy-proven, noncirrhotic NASH with severe disease activity.</div><section id="sec-1" data-type="methods"><h2>Methods</h2><section id="sec-1-1"><h3>Trial Oversight</h3><div role="paragraph">NATIVE was approved by independent ethics committees and the appropriate authorities in 16 countries where at least one patient underwent randomization (Table S1 in the <a href="#ap2">Supplementary Appendix</a>, available with the full text of this article at NEJM.org). The trial was conducted in accordance with the principles of the Declaration of Helsinki, the International Council for Harmonisation Good Clinical Practice guidelines, and all relevant regulations. Written informed consent was obtained from all participants. The sponsor (Inventiva Pharma) designed the trial and monitored the trial sites, collected the data, and analyzed the data. All the authors had access to the data and reviewed the manuscript. The first and last authors and four of the authors employed by Inventiva Pharma participated in the analysis and interpretation of the data and vouch for the accuracy and completeness of the data and for the fidelity of the trial to the <a href="#ap1">protocol</a>, available at NEJM.org. An earlier version of the manuscript was drafted with the assistance of a medical writer (funded by the sponsor) under the guidance of the authors.</div></section><section id="sec-1-2"><h3>Trial Design</h3><div role="paragraph">The trial rationale and design have been described previously.<sup><a href="#core-r9" role="doc-biblioref" data-xml-rid="r9" id="body-ref-r9" href-manipulated="true" aria-label="Reference 9">9</a></sup> Patients were eligible for inclusion if they were 18 years of age or older and had noncirrhotic NASH (the diagnosis of which required a Steatosis, Activity, Fibrosis [SAF] grade of 1 or higher for steatosis [range, 0 to 3], hepatocellular ballooning [range, 0 to 2], and lobular inflammation [range, 0 to 2] on liver biopsy); higher grades indicate more-severe disease activity.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10-1" href-manipulated="true" aria-label="Reference 10">10</a></sup> The diagnosis was confirmed by a centrally read biopsy sample obtained at screening or in the preceding 6 months (patients whose diagnosis was not confirmed at screening had to have a stable body weight, defined as no more than a 5% loss of initial body weight between the time of biopsy and screening). Patients with stage F4 fibrosis, classified according to the criteria of both the SAF and NASH Clinical Research Network (NASH CRN) (stages range from F0 [no fibrosis] to F4 [cirrhosis]),<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10 r11" id="body-ref-r11" href-manipulated="true">10,11</a></sup> were excluded. <a id="exam-tint-one-d"></a><span id="tint2" class="named-content" data-type="exam-tint" data-answer-ids="one-d">A score of 3 or higher on the SAF-A (the activity part of the SAF scoring system that incorporates the scores for hepatocellular ballooning and lobular inflammation) was also a criterion for eligibility.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10-3" href-manipulated="true" aria-label="Reference 10">10</a></sup> Steatosis was assessed separately because it does not reflect liver-cell damage and inflammation per se, outcomes that are included in the SAF concept of “activity” (Fig. S1).</span> Additional details of the inclusion and exclusion criteria are provided in the <a href="#ap2">Supplementary Appendix</a>.</div></section><section id="sec-1-3"><h3>Trial End Points</h3><div role="paragraph">The primary end point was a decrease of at least 2 points from baseline to week 24 in the SAF-A score and no worsening of fibrosis (i.e., no increase in fibrosis stage based on SAF–NASH CRN criteria). Secondary histologic end points included resolution of NASH (defined as a ballooning grade of 0 and a lobular inflammation grade of ≤1) and no worsening of fibrosis; improvement in fibrosis stage of at least 1 and no worsening of NASH (i.e., no worsening in either steatosis, ballooning, or lobular inflammation); Nonalcoholic Fatty Liver Disease Activity Score (NAS) improvement (defined as a decrease of ≥2 points from baseline to week 24 in the NAS, which is the sum of the scores for steatosis [range, 0 to 3], ballooning [range, 0 to 2], and lobular inflammation [range, 0 to 3], with higher scores indicating greater disease activity) and no worsening of fibrosis<sup><a href="#core-r12" role="doc-biblioref" data-xml-rid="r12" id="body-ref-r12" href-manipulated="true" aria-label="Reference 12">12</a></sup>; resolution of NASH and an improvement in fibrosis stage of at least 1 (a composite end point); change in scores for the components of the SAF and NASH CRN scoring system (steatosis, activity, inflammation, ballooning, and fibrosis); and change in the modified Ishak score. All biopsy samples were read serially by one pathologist who was unaware of the time at which the samples were obtained (baseline or end of assigned regimen), the trial-group assignment, and the identity of the person who assessed the adequacy of the samples.</div><div role="paragraph">Nonhistologic secondary end points included changes in liver enzyme levels (alanine aminotransferase, aspartate aminotransferase, and γ-glutamyltransferase); changes in measures of glucose metabolism (fasting levels of glucose, insulin, and glycated hemoglobin and homeostatic model assessment of insulin resistance [HOMA-IR] index score); changes in lipid levels (total cholesterol, high-density lipoprotein [HDL] cholesterol, low-density lipoprotein [LDL] cholesterol, triglycerides, and apolipoprotein A1); change in adiponectin level; and changes in inflammatory markers (fibrinogen, high-sensitivity C-reactive protein, α2-macroglobulin, and haptoglobin). Exploratory end points included change in the apoptosis marker cytokeratin 18 M30; changes in serum markers of fibrosis and collagen turnover (ratio of tissue inhibitor of metalloproteinase 1 to matrix metalloproteinase 2, N-terminal type III collagen propeptide [Pro-C3] level, and scores on the Enhanced Liver Fibrosis test and Fibrosis-4 index); changes in other lipid levels (apolipoprotein B and C3); changes on transient elastography (FibroScan, Echosens) with controlled attenuation parameter; and change in quality of life.</div></section><section id="sec-1-4"><h3>Randomization</h3><div role="paragraph">Patients were randomly assigned in a 1:1:1 ratio to receive 1200 mg or 800 mg of oral lanifibranor or placebo once daily for 24 weeks; randomization was stratified according to diabetic status (absence or presence). The full analysis population included all patients who underwent randomization and received at least one dose of the assigned regimen and was identical to the safety analysis population. All patients who had undergone randomization received at least one dose of the assigned regimen, and no patient was excluded from the full analysis population. The per-protocol population included all patients who had biopsy data available at the end of the treatment period and no major protocol deviations.</div></section><section id="sec-1-5"><h3>Statistical Analysis</h3><div role="paragraph">The sample-size calculation is described in the Supplementary Methods section of the <a href="#ap2">Supplementary Appendix</a>. For statistical tests, the type I error risk was set at 5% (two-sided) in accordance with the <a href="#ap1">protocol</a>. Adjustments for multiplicity testing in the primary analysis were performed with the use of the Hochberg procedure; each active-treatment group was compared with the placebo group. No multiplicity adjustments for the secondary and exploratory end points were defined. Therefore, only point estimates and 95% confidence intervals are provided. The confidence intervals have not been adjusted for multiple comparisons and should not be used to infer definitive treatment effects.</div><div role="paragraph">Comparisons of histologic responses among the trial groups were performed with the use of the Cochran–Mantel–Haenszel test stratified according to diabetic status at baseline. The risk ratios that were calculated with this test are reported with the corresponding 95% confidence intervals. The primary analyses that we report here were performed in the full analysis population with the use of multiple imputation for missing data, including missing or inadequate biopsy data at the end of the treatment period (see the <a href="#ap2">Supplementary Appendix</a>). We also report the analyses that were performed with the use of single imputation to treat missing data as nonresponses, as specified in the statistical analysis plan. In addition, sensitivity analyses were conducted on the basis of complete cases (i.e., those with biopsy samples available at both baseline and the end of assigned regimen), as specified in the statistical analysis plan. Other analyses were performed in the per-protocol population and in the subgroups defined according to significant (moderate) or advanced fibrosis and diabetic status. Comparisons of quantitative secondary end points among the trial groups were assessed with the use of mixed models for repeated measures, with the absolute change in the value of the continuous variable from baseline as the end point; the time, trial group, diabetic status, trial-group–by–time interaction, and baseline value of the variable as fixed effects; a time-repeated effect within each subject; and an unstructured variance–covariance matrix.</div></section></section><section id="sec-2" data-type="results"><h2>Results</h2><section id="sec-2-1"><h3>Patients</h3><div role="paragraph">From February 2017 through July 2019, a total of 868 patients underwent screening, and 247 patients were randomly assigned in a 1:1:1 ratio to receive 1200 mg of lanifibranor (83 patients), 800 mg of lanifibranor (83 patients), or placebo (81 patients) orally once daily for 6 months (Fig. S3). Baseline characteristics of the patients who underwent randomization are shown in <a href="#t1">Table 1</a>. The mean age of the patients was 54 years, and the mean body-mass index (the weight in kilograms divided by the square of the height in meters) was 33; 144 (58%) were female, 232 (94%) were White, and 103 (42%) had type 2 diabetes mellitus. Significant or advanced fibrosis (stages F2 and F3, respectively) was present in 188 patients (76%), and most patients had highly active NASH (the mean [±SD] SAF-A score was 3.3±0.5, and 73% had an NAS of ≥6, which indicates high disease activity). The median duration between screening biopsy and randomization was 2.3 months (range, 0.5 to 9.2). The histologic characteristics of screening biopsy samples according to SAF-A scores are shown in Table S2.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 1</div><nav><a href="#t1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2036205_t1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t1" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2036205_t1.jpg"><img src="/cms/10.1056/NEJMoa2036205/asset/230be9c3-6e81-4301-bc47-be5bd7d33c6a/assets/images/large/nejmoa2036205_t1.jpg" height="2445" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Lanifibranor,<br>1200 mg<br>(N=83)</th><th class="txxx-borders">Lanifibranor,<br>800 mg<br>(N=83)</th><th class="txxx-borders">Placebo<br>(N=81)</th><th class="txxr-borders">Overall<br>(N=247)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders shading">49 (59)</td><td class="xxxx-borders shading">54 (65)</td><td class="xxxx-borders shading">41 (51)</td><td class="xxxr-borders shading">144 (58)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Age — yr</td><td class="xxxx-borders">52.2±13.8</td><td class="xxxx-borders">55.0±10.4</td><td class="xxxx-borders">53.4±13.1</td><td class="xxxr-borders">53.6±12.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">White race — no. (%)<a href="#t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">78 (94)</td><td class="xxxx-borders shading">80 (96)</td><td class="xxxx-borders shading">74 (91)</td><td class="xxxr-borders shading">232 (94)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Weight — kg</td><td class="xxxx-borders">93.0±19.9</td><td class="xxxx-borders">91.6±19.3</td><td class="xxxx-borders">95.1±17.3</td><td class="xxxr-borders">93.2±18.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Body-mass index</td><td class="xxxx-borders shading">33.3±5.5</td><td class="xxxx-borders shading">32.5±5.5</td><td class="xxxx-borders shading">32.8±5.1</td><td class="xxxr-borders shading">32.9±5.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Type 2 diabetes mellitus — no. (%)</td><td class="xxxx-borders">35 (42)</td><td class="xxxx-borders">33 (40)</td><td class="xxxx-borders">35 (43)</td><td class="xxxr-borders">103 (42)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Median time between screening biopsy and randomization (range) — mo</td><td class="xxxx-borders shading">2.4 (0.5–7.0)</td><td class="xxxx-borders shading">2.6 (0.5–9.2)</td><td class="xxxx-borders shading">2.0 (0.5–7.4)</td><td class="xxxr-borders shading">2.3 (0.5–9.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Steatosis grade<a href="#t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">2.6±0.6</td><td class="xxxx-borders">2.6±0.7</td><td class="xxxx-borders">2.5±0.7</td><td class="xxxr-borders">2.5±0.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Lobular inflammation grade<a href="#t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">1.5±0.5</td><td class="xxxx-borders shading">1.5±0.5</td><td class="xxxx-borders shading">1.5±0.5</td><td class="xxxr-borders shading">1.5±0.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Ballooning grade<a href="#t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">1.8±0.4</td><td class="xxxx-borders">1.7±0.4</td><td class="xxxx-borders">1.8±0.4</td><td class="xxxr-borders">1.8±0.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Fibrosis stage<a href="#t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">2.1±0.8</td><td class="xxxx-borders shading">2.1±0.8</td><td class="xxxx-borders shading">2.0±0.9</td><td class="xxxr-borders shading">2.1±0.8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Fibrosis stage F2 or F3 — no. (%)</td><td class="xxxx-borders">63 (76)</td><td class="xxxx-borders">68 (82)</td><td class="xxxx-borders">57 (70)</td><td class="xxxr-borders">188 (76)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">SAF-A score<a href="#t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">3.3±0.5</td><td class="xxxx-borders shading">3.2±0.5</td><td class="xxxx-borders shading">3.3±0.5</td><td class="xxxr-borders shading">3.3±0.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">NAS<a href="#t1fn8" role="doc-noteref">††</a></td><td class="xxxx-borders">5.9±0.9</td><td class="xxxx-borders">5.9±1.0</td><td class="xxxx-borders">5.9±1.1</td><td class="xxxr-borders">5.9±1.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">NAS ≥6 — no. (%)</td><td class="xxxx-borders shading">61 (73)</td><td class="xxxx-borders shading">63 (76)</td><td class="xxxx-borders shading">56 (69)</td><td class="xxxr-borders shading">180 (73)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Alanine aminotransferase level — IU/liter</td><td class="xxxx-borders">63.6±43.4</td><td class="xxxx-borders">64.1±41.4</td><td class="xxxx-borders">56.9±31.6</td><td class="xxxr-borders">61.6±39.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Aspartate aminotransferase level — IU/liter</td><td class="xxxx-borders shading">43.9±24.8</td><td class="xxxx-borders shading">53.9±43.4</td><td class="xxxx-borders shading">43.3±24.1</td><td class="xxxr-borders shading">47.1±32.3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">γ-Glutamyltransferase level — IU/liter</td><td class="xxxx-borders">67.1±93.1</td><td class="xxxx-borders">101.6±146.1</td><td class="xxxx-borders">67.9±80.4</td><td class="xxxr-borders">78.9±111.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Fasting HDL cholesterol level — mmol/liter</td><td class="xxxx-borders shading">1.2±0.3</td><td class="xxxx-borders shading">1.3±0.3</td><td class="xxxx-borders shading">1.2±0.3</td><td class="xxxr-borders shading">1.2±0.3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Fasting triglyceride level — mmol/liter</td><td class="xxxx-borders">2.0±0.9</td><td class="xxxx-borders">1.9±0.9</td><td class="xxxx-borders">2.0±0.8</td><td class="xxxr-borders">2.0±0.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Fasting glucose level — mmol/liter</td><td class="xxxx-borders shading">5.9±1.1</td><td class="xxxx-borders shading">6.2±1.8</td><td class="xxxx-borders shading">6.0±1.6</td><td class="xxxr-borders shading">6.0±1.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Glycated hemoglobin level — %</td><td class="xxxx-borders">6.1±0.7</td><td class="xxxx-borders">6.1±0.8</td><td class="xxxx-borders">6.0±0.7</td><td class="xxxr-borders">6.0±0.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01 shading" data-xml-align="left">Fasting insulin level — pmol/liter</td><td class="xbxx-borders shading">274.7±321.2</td><td class="xbxx-borders shading">231.9±191.9</td><td class="xbxx-borders shading">234.0±254.6</td><td class="xbxr-borders shading">246.9±260.7</td></tr></tbody></table></div><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline (Full Analysis Population).<a href="#t1fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t1fn1" role="paragraph">Plus–minus signs are means ±SD. To convert the values for high-density lipoprotein (HDL) cholesterol to milligrams per deciliter, divide by 0.02586. To convert the values for triglycerides to milligrams per deciliter, divide by 0.01129. To convert the values for glucose to milligrams per deciliter, divide by 0.01129. To convert the values for insulin to micrograms per liter, divide by 172.2.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t1fn2" role="paragraph">Race or ethnic group is reported according to the record in the electronic case-report form, which included American Indian or Alaskan, Asian, Black or African American, Native Hawaiian or other Pacific Islander, White, or other.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t1fn3" role="paragraph">Steatosis was assessed as the percentage of hepatocytes containing large and medium-sized intracytoplasmic lipid droplets (but not foamy microvesicles) and graded as 0 (&lt;5%), 1 (5 to 33%), 2 (34 to 66%), or 3 (≥67%), according to the Steatosis, Activity, Fibrosis (SAF) scoring system. Patients with grade 0 steatosis were excluded from the trial.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t1fn4" role="paragraph">Lobular inflammation was classified as grade 1 (two small foci of inflammatory cells) or grade 2 (more than two foci of inflammatory cells), according to the SAF scoring system.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t1fn5" role="paragraph">Ballooning was classified as grade 1 (round hepatocytes with pale cytoplasm and size similar to that of normal hepatocytes) or grade 2 (presence of enlarged hepatocytes with a diameter at least twice that of normal hepatocytes in a background of clear and round hepatocytes), according to the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) grading system.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t1fn6" role="paragraph">Fibrosis was classified as stage F0 (no fibrosis), stage F1 (mild fibrosis), stage F2 (significant [moderate] fibrosis), stage F3 (advanced fibrosis), or stage F4 (cirrhosis), according to the SAF–NASH CRN staging system. Patients with stage F4 fibrosis were excluded from the trial.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t1fn7" role="paragraph">The SAF-Activity (SAF-A) score ranges from 0 to 4; with higher scores indicating more-severe disease activity.</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="t1fn8" role="paragraph">The Nonalcoholic Fatty Liver Disease Activity Score (NAS) ranges from 0 to 8. A score of 2 or less indicates “not NASH”; a score of 3 or 4, “borderline NASH,” and a score of 5 to 8, “definite NASH.”</div></div></div></figcaption></figure></div><div role="paragraph">Among the 247 patients in the full analysis population, 228 completed the trial (77 patients in each lanifibranor group and 74 in the placebo group). Reasons for discontinuation of the trial regimen are shown in Figure S3. Major protocol deviations occurred in 53 patients (34 did not have biopsy data available at the end of the treatment period and 19 had other major protocol deviations), who were not included in the per-protocol population, which comprised 194 patients (Table S3).</div></section><section id="sec-2-2"><h3>Primary End Point</h3><div role="paragraph"><a id="exam-tint-two-b"></a><a id="exam-tint-two-c"></a><span id="tint3" class="named-content" data-type="exam-tint" data-answer-ids="two-b two-c">In the full analysis population in which missing data were handled with multiple imputation, the percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis (the primary end point) was significantly higher among those who received the 1200-mg dose (55%), but not among those who received the 800-mg dose (48%), of lanifibranor than among those who received placebo (33%) (risk ratio for a response in the 1200-mg lanifibranor group vs. the placebo group, 1.7; 95% confidence interval [CI], 1.2 to 2.3; P=0.007; risk ratio in the 800-mg lanifibranor group vs. the placebo group, 1.5; 95% CI, 1.0 to 2.1; P=0.07) (<a href="#f1">Figure 1</a>).</span> Results were similar in the prespecified analyses in which missing data were imputed as nonresponses and in the complete-case analyses (Fig. S9 and Tables S4 and S5). The results were also similar in the per-protocol population and among 188 patients with significant or advanced fibrosis.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Figure 1</div><nav><a href="#f1" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2036205_f1.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="f1" class="graphic"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2036205_f1.jpg"><img src="/cms/10.1056/NEJMoa2036205/asset/e1e19e7c-f802-4ca6-b949-9a3d304d32fe/assets/images/large/nejmoa2036205_f1.jpg" height="1307" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Response for Primary and Secondary Histologic End Points at Week 24.</div><div class="notes"><div role="doc-footnote">Analyses were performed with multiple imputation of missing data. Risk ratios, 95% confidence intervals, and P values were calculated with the Cochran–Mantel–Haenszel test stratified according to diabetic status at baseline. In the analysis of the primary end point, an ascending Hochberg procedure was used to adjust for multiplicity testing (each dose of lanifibranor was compared with placebo). Missing data for the 34 patients in the full analysis population (11 in the 800-mg lanifibranor group, 9 in the 1200-mg lanifibranor group, and 14 in the placebo group had missing biopsy samples at week 24) were handled with multiple imputation (details are provided in the <a href="#ap2">Supplementary Appendix</a>). The Steatosis, Activity, Fibrosis–Activity (SAF-A) score represents the activity part of the SAF scoring system that incorporates the scores for hepatocellular ballooning and lobular inflammation; SAF-A scores range from 0 to 4, with higher scores indicating more-severe disease activity. NASH denotes nonalcoholic steatohepatitis.</div></div></figcaption></figure></div></section><section id="sec-2-3"><h3>Secondary End Points</h3><div role="paragraph">Resolution of NASH without worsening of fibrosis at week 24 from baseline was observed in 49% of patients who received the 1200-mg dose of lanifibranor, in 39% of patients who received the 800-mg dose, and in 22% of patients who received placebo (risk ratio for a response in the 1200-mg lanifibranor group vs. the placebo group, 2.2; 95% CI, 1.5 to 3.3; and risk ratio in the 800-mg lanifibranor group vs. the placebo group, 1.7; 95% CI, 1.1 to 2.7) (<a href="#f1">Figure 1</a> and Table S5). Improvement in fibrosis stage of at least 1 without worsening of NASH was observed in 48% of patients in the 1200-mg lanifibranor group, in 34% of patients in the 800-mg lanifibranor group, and in 29% of patients in the placebo group (risk ratio in the 1200-mg lanifibranor group vs. the placebo group, 1.7; 95% CI, 1.2 to 2.5; and risk ratio in the 800-mg lanifibranor group vs. the placebo group, 1.2; 95% CI, 0.7 to 1.9) (<a href="#f1">Figure 1</a>). Among patients with significant or advanced fibrosis, the results were also better in the lanifibranor groups than in the placebo group. Resolution of NASH and improvement in fibrosis stage of at least 1 (composite end point) was observed in 35% of patients in the 1200-mg lanifibranor group, in 25% of patients in the 800-mg lanifibranor group, and in 9% of patients in the placebo group (risk ratio in the 1200-mg lanifibranor group vs. the placebo group, 4.0; 95% CI, 2.0 to 7.7; and risk ratio in the 800-mg lanifibranor group vs. the placebo group, 2.6; 95% CI, 1.2 to 5.5) (<a href="#f1">Figure 1</a>). The results of analyses in which missing data were imputed as nonresponses, per-protocol analyses, and complete-case analyses are provided in Tables S4 and S5. The effects on the individual histologic features of NASH are provided in Table S6.</div><div role="paragraph">Changes in the levels of aminotransferases, HDL and LDL cholesterol, and glycated hemoglobin are reported in Figure S6. The adjusted mean decrease in alanine aminotransferase level was 25 U per liter in the 1200-mg lanifibranor group, 26 U per liter in the 800-mg lanifibranor group, and 1 U per liter in the placebo group (<a href="#t2">Table 2</a>). The decreases in the aspartate aminotransferase and γ-glutamyltransferase levels were in a similar direction, with greater decreases in the lanifibranor groups than in the placebo group. The adjusted mean change in glycated hemoglobin level was −0.4% in the 1200-mg lanifibranor group, −0.4% in the 800-mg lanifibranor group, and 0.1% in the placebo group. Changes in other secondary end points (serum adiponectin level; fasting levels of insulin, glucose, triglycerides, total cholesterol, LDL and HDL cholesterol, and apolipoprotein A1; fasting HOMA-IR index score; and inflammatory markers) are reported in <a href="#t2">Table 2</a>.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 2</div><nav><a href="#t2" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2036205_t2.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t2" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2036205_t2.jpg"><img src="/cms/10.1056/NEJMoa2036205/asset/d9835b28-f05d-4335-863c-24b1e449c7b9/assets/images/large/nejmoa2036205_t2.jpg" height="2393" width="1999" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">End Point</th><th class="txxx-borders">Lanifibranor, 1200 mg<br>(N=77)</th><th class="txxx-borders">Lanifibranor, 800 mg<br>(N=77)</th><th class="txxr-borders">Placebo<br>(N=74)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Change from baseline in secondary end points (95% CI)</b><a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Total cholesterol — mmol/liter</td><td class="xxxx-borders">−0.07 (−0.22 to 0.07)</td><td class="xxxx-borders">−0.02 (−0.17 to 0.13)</td><td class="xxxr-borders">0.01 (−0.14 to 0.16)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Fasting HDL cholesterol — mmol/liter</td><td class="xxxx-borders shading">0.11 (0.06 to 0.15)</td><td class="xxxx-borders shading">0.16 (0.12 to 0.21)</td><td class="xxxr-borders shading">0.01 (−0.04 to 0.05)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Fasting LDL cholesterol — mmol/liter</td><td class="xxxx-borders">0.03 (−0.11 to 0.16)</td><td class="xxxx-borders">0.03 (−0.11 to 0.16)</td><td class="xxxr-borders">0.01 (−0.12 to 0.15)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Fasting triglycerides — mmol/liter</td><td class="xxxx-borders shading">−0.44 (−0.61 to −0.27)</td><td class="xxxx-borders shading">−0.49 (−0.66 to −0.31)</td><td class="xxxr-borders shading">0.06 (−0.12 to 0.23)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Fasting apolipoprotein A1 — mg/dl</td><td class="xxxx-borders">−4.39 (−8.64 to −0.13)</td><td class="xxxx-borders">−0.29 (−4.61 to 4.04)</td><td class="xxxr-borders">0.03 (−4.27 to 4.33)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Aspartate aminotransferase — U/liter</td><td class="xxxx-borders shading">−12.04 (−18.29 to −5.79)</td><td class="xxxx-borders shading">−15.11 (−21.43 to −8.80)</td><td class="xxxr-borders shading">−0.08 (−6.43 to 6.26)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Alanine aminotransferase — U/liter</td><td class="xxxx-borders">−24.54 (−32.06 to −17.01)</td><td class="xxxx-borders">−26.08 (−33.67 to −18.50)</td><td class="xxxr-borders">−1.40 (−9.04 to 6.25)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">γ-Glutamyltransferase — U/liter</td><td class="xxxx-borders shading">−27.87 (−38.88 to −16.86)</td><td class="xxxx-borders shading">−43.38 (−54.46 to −32.29)</td><td class="xxxr-borders shading">4.41 (−6.76 to 15.58)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Fasting glucose — mmol/liter</td><td class="xxxx-borders">−0.60 (−0.83 to −0.37)</td><td class="xxxx-borders">−0.78 (−1.01 to −0.55)</td><td class="xxxr-borders">0.24 (0.01 to 0.47)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Glycated hemoglobin — %</td><td class="xxxx-borders shading">−0.41 (−0.51 to −0.32)</td><td class="xxxx-borders shading">−0.38 (−0.47 to −0.28)</td><td class="xxxr-borders shading">0.07 (−0.02 to 0.17)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Fasting insulin — pmol/liter</td><td class="xxxx-borders">−114.91 (−138.09 to −91.73)</td><td class="xxxx-borders">−118.66 (−141.66 to −95.67)</td><td class="xxxr-borders">−35.7 (−58.59 to −12.82)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Fasting HOMA-IR index score<a href="#t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">−5.46 (−6.60 to −4.32)</td><td class="xxxx-borders shading">−5.79 (−6.92 to −4.65)</td><td class="xxxr-borders shading">−1.47 (−2.59 to −0.35)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Adiponectin — μg/ml</td><td class="xxxx-borders">17.12 (14.29 to 19.96)</td><td class="xxxx-borders">11.95 (8.97 to 14.94)</td><td class="xxxr-borders">−0.35 (−3.20 to 2.50)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">High-sensitivity CRP — mg/liter</td><td class="xxxx-borders shading">−1.37 (−2.28 to −0.46)</td><td class="xxxx-borders shading">−2.05 (−2.97 to −1.13)</td><td class="xxxr-borders shading">0.11 (−0.81 to 1.03)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Fibrinogen — g/liter</td><td class="xxxx-borders">−0.10 (−0.24 to 0.05)</td><td class="xxxx-borders">−0.17 (−0.32 to −0.02)</td><td class="xxxr-borders">0.02 (−0.12 to 0.17)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">α2-Macroglobulin — g/liter</td><td class="xxxx-borders shading">0.13 (0.04 to 0.22)</td><td class="xxxx-borders shading">0.15 (0.06 to 0.24)</td><td class="xxxr-borders shading">0.05 (−0.04 to 0.13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Haptoglobin — g/liter</td><td class="xxxx-borders">−0.07 (−0.13 to 0)</td><td class="xxxx-borders">−0.05 (−0.12 to 0.01)</td><td class="xxxr-borders">0.05 (−0.01 to 0.12)</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Change from baseline in exploratory end points (95% CI)</b><a href="#t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Fasting apolipoprotein B — mg/dl</td><td class="xxxx-borders">−11.61 (−15.64 to −7.57)</td><td class="xxxx-borders">−11.51 (−15.61 to −7.41)</td><td class="xxxr-borders">−1.85 (−5.79 to 2.09)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Fasting apolipoprotein C3 — μg/dl</td><td class="xxxx-borders shading">−9.98 (−17.74 to −2.22)</td><td class="xxxx-borders shading">−8.08 (−16.02 to −0.13)</td><td class="xxxr-borders shading">10.31 (2.67 to 17.94)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Pro-C3 — μg/liter</td><td class="xxxx-borders">−1.79 (−3.07 to −0.52)</td><td class="xxxx-borders">−3.93 (−5.26 to −2.61)</td><td class="xxxr-borders">−1.01 (−2.30 to 0.28)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">TIMP-1 to MMP-2 ratio</td><td class="xxxx-borders shading">−0.75 (−0.93 to −0.57)</td><td class="xxxx-borders shading">−0.69 (−0.88 to −0.50)</td><td class="xxxr-borders shading">−0.11 (−0.29 to 0.08)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Cytokeratin 18 M30 — pmol/liter</td><td class="xxxx-borders">−315.55 (−441.55 to −189.55)</td><td class="xxxx-borders">−331.71 (−463.78 to −199.65)</td><td class="xxxr-borders">−105.03 (−232.86 to 22.80)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Enhanced Liver Fibrosis test score<a href="#t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">0.11 (−0.04 to 0.26)</td><td class="xxxx-borders shading">−0.19 (−0.35 to −0.04)</td><td class="xxxr-borders shading">−0.08 (−0.23 to 0.06)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">Fibrosis-4 index score<a href="#t2fn5" role="doc-noteref">¶</a></td><td class="xbxx-borders">0.03 (−0.13 to 0.19)</td><td class="xbxx-borders">0 (−0.17 to 0.16)</td><td class="xbxr-borders">−0.03 (−0.19 to 0.13)</td></tr></tbody></table></div><figcaption><div class="caption">Laboratory Measures at Week 24 among the Patients in the Full Analysis Population Who Completed the Trial.<a href="#t2fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t2fn1" role="paragraph">A total of 228 patients completed their week-24 visit. The analysis of each variable was conducted with data from approximately the same number of patients; there were some missing data from a small number of patients for certain variables. To convert the values for cholesterol to milligrams per deciliter, divide by 0.02586. To convert the values for fibrinogen to micromoles per liter, multiply by 2.94. CRP denotes C-reactive protein, LDL low-density lipoprotein, MMP-2 matrix metalloproteinase 2, Pro-C3 N-terminal type III collagen propeptide, and TIMP-1 tissue inhibitor of metalloproteinase 1.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t2fn2" role="paragraph">Adjusted mean absolute changes and 95% confidence intervals were derived with the use of mixed models for repeated measures, with the absolute change from baseline of the continuous outcome as the end point, the time, trial group, diabetic status, trial-group–by–time interaction, and baseline value of the outcome as fixed effects; a time repeated effect within each subject; and an unstructured variance–covariance matrix.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t2fn3" role="paragraph">The score on the homeostatic model assessment of insulin resistance (HOMA-IR) was calculated as follows: (fasting insulin [in micro–international units per milliliter]×fasting glucose [in milligrams per deciliter])/405. The conversion factor that was used for insulin was that 1 μU per milliliter was equal to 6.00 pmol per liter. Higher values indicate greater insulin resistance.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t2fn4" role="paragraph">An Enhanced Liver Fibrosis test score of less than 7.7 indicates none to mild fibrosis, and a score of 11.3 or greater indicates cirrhosis.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t2fn5" role="paragraph">A Fibrosis-4 index score of less than 1.45 indicates low probability of stage F3 or F4 fibrosis, and a score greater than 3.25 indicates a high probability of stage F3 or F4 fibrosis.</div></div></div></figcaption></figure></div></section><section id="sec-2-4"><h3>Exploratory Efficacy Analyses</h3><div role="paragraph">Changes in markers of apoptosis, fibrosis, and collagen turnover are reported in <a href="#t2">Table 2</a>. Mean transient elastography values decreased by 1.7 in the 1200-mg lanifibranor group, 1.0 in the 800-mg lanifibranor group, and 0.7 in the placebo group. The results with respect to controlled attenuation parameter were in a similar direction, with greater decreases in the lanifibranor groups than in the placebo group (Table S9). With regard to quality of life, no substantial changes from baseline in the various dimensions of the Medical Outcomes Study 36-Item Short-Form Health Survey and the score on the Flinders Fatigue Scale were observed at week 24 (Table S10).</div><div role="paragraph">A total of 103 patients who underwent randomization had type 2 diabetes mellitus; the mean age of these patients was 56 years, the mean body-mass index was 33, 62 (60%) were women, 83 (81%) had significant or advanced fibrosis, and 84 (82%) had an NAS of 6 or greater. The diabetes regimens are reported in Table S8. The patients with diabetes had improvements in histologic features of NASH that were similar to those in the full analysis population, and they had more pronounced reductions in fasting levels of glucose, insulin, and glycated hemoglobin than those observed in the full analysis population.</div></section><section id="sec-2-5"><h3>Safety</h3><div role="paragraph">The assigned regimen was discontinued because of adverse events in three patients (4%) in the 1200-mg lanifibranor group, in four patients (5%) in the 800-mg lanifibranor group, and in three patients (4%) in the placebo group. Most adverse events were mild or moderate in severity (<a href="#t3">Table 3</a>). In each trial group, three patients (4%) had a severe adverse event during the treatment period (defined as the period after the first dose up to 28 days after the last dose). There were two serious adverse events (mild heart failure and urticaria, both in the placebo group) that were determined by the investigator to be related to the placebo. <a id="exam-tint-three-a"></a><a id="exam-tint-three-b"></a><a id="exam-tint-three-c"></a><a id="exam-tint-three-d"></a><span id="tint4" class="named-content" data-type="exam-tint" data-answer-ids="three-a three-b three-c three-d">Nausea, diarrhea, peripheral edema, anemia, and weight gain occurred more frequently with lanifibranor than with placebo.</span> One patient in the 1200-mg lanifibranor group was reported by the investigator to have nontreatment-related mild heart failure that did not lead to further investigation or hospitalization. Peripheral edema that was assessed by the investigator as being related to the active drug or placebo occurred in four patients (2%) in the lanifibranor groups (two in each group) and in no patient in the placebo group during the treatment period. One patient had severe peripheral edema but recovered after discontinuing the 1200-mg regimen of lanifibranor for 12 days; treatment was resumed without reoccurrence of edema. A mean increase of 2.7 kg (3.1%) from baseline in body weight was observed among the patients in the 1200-mg lanifibranor group, and a mean increase of 2.4 kg (2.6%) was observed among the patients in the 800-mg lanifibranor group (Fig. S7). Anemia was reported in six patients (7%) in the 1200-mg lanifibranor group, with the hemoglobin levels returning to pretreatment values after either investigator-initiated iron supplementation or discontinuation of lanifibranor. A relative reduction in hemoglobin levels of 5 to 6% from baseline was observed in the lanifibranor groups, as compared with a 1% reduction in the placebo group (Fig. S8). Kidney function (markers included creatinine and urea levels and estimated glomerular filtration rate) (Table S11) and bone turnover (markers included osteocalcin level and beta-CrossLaps value [the level of β-isomer of the C-terminal telopeptide of type I collagen, as measured with a CrossLaps osteometer, Biotech]) (Table S12) were not impaired.</div><div class="figure-wrap" data-presentation="diminished-in-flow"><header><div class="label">Table 3</div><nav><a href="#t3" title="Open in viewer" class="open-in-viewer" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2036205_t3.jpg"><i aria-hidden="true" class="icon-expand"></i></a></nav></header><figure id="t3" class="table"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><a aria-label="Open figure in viewer" class="open-in-viewer" data-index="0" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2036205_t3.jpg"><img src="/cms/10.1056/NEJMoa2036205/asset/27acf7f8-bff6-4f51-bdac-7132794565fd/assets/images/large/nejmoa2036205_t3.jpg" height="2985" width="1711" loading="lazy"></a></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders">Lanifibranor,<br>1200 mg<br>(N=83)</th><th class="txxx-borders">Lanifibranor,<br>800 mg<br>(N=83)</th><th class="txxr-borders">Placebo<br>(N=81)</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="3"><span>number (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">≥1 Adverse event</td><td class="xxxx-borders shading">62 (75)</td><td class="xxxx-borders shading">59 (71)</td><td class="xxxr-borders shading">50 (62)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Mild</td><td class="xxxx-borders">54 (65)</td><td class="xxxx-borders">51 (61)</td><td class="xxxr-borders">42 (52)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Moderate</td><td class="xxxx-borders shading">28 (34)</td><td class="xxxx-borders shading">20 (24)</td><td class="xxxr-borders shading">22 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Severe</td><td class="xxxx-borders">3 (4)</td><td class="xxxx-borders">3 (4)</td><td class="xxxr-borders">3 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Adverse event related to active drug or placebo, during the treatment period, as assessed by the investigator</td><td class="xxxx-borders shading">23 (28)</td><td class="xxxx-borders shading">25 (30)</td><td class="xxxr-borders shading">19 (23)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Adverse event that led to permanent discontinuation of the trial regimen</td><td class="xxxx-borders">3 (4)</td><td class="xxxx-borders">4 (5)</td><td class="xxxr-borders">3 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Adverse event related to active drug or placebo that led to discontinuation of the trial regimen</td><td class="xxxx-borders shading">2 (2)<a href="#t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">1 (1)<a href="#t3fn3" role="doc-noteref">‡</a></td><td class="xxxr-borders shading">2 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Serious adverse event</td><td class="xxxx-borders">7 (8)</td><td class="xxxx-borders">3 (4)</td><td class="xxxr-borders">3 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Death</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Serious adverse event related to active drug or placebo</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">2 (2)<a href="#t3fn4" role="doc-noteref">§</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Serious postprocedural condition linked to biopsy procedure</td><td class="xxxx-borders shading">3 (4)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging13">Other serious adverse event</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Wrist fracture</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Unstable angina</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Heart failure</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Gastroenteritis</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Pyelonephritis</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Pancreatitis</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Undifferentiated connective tissue disease</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Urticaria</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Foot operation</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Most frequent adverse events<a href="#t3fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Diarrhea</td><td class="xxxx-borders shading">10 (12)</td><td class="xxxx-borders shading">8 (10)</td><td class="xxxr-borders shading">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Fatigue<a href="#t3fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">11 (13)</td><td class="xxxx-borders">3 (4)</td><td class="xxxr-borders">8 (10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Nausea</td><td class="xxxx-borders shading">7 (8)</td><td class="xxxx-borders shading">8 (10)</td><td class="xxxr-borders shading">3 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Weight gain</td><td class="xxxx-borders">7 (8)</td><td class="xxxx-borders">8 (10)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Peripheral edema<a href="#t3fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">7 (8)</td><td class="xxxx-borders shading">5 (6)</td><td class="xxxr-borders shading">2 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Headache</td><td class="xxxx-borders">7 (8)</td><td class="xxxx-borders">4 (5)</td><td class="xxxr-borders">4 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Abdominal pain<a href="#t3fn8" role="doc-noteref">††</a></td><td class="xxxx-borders shading">5 (6)</td><td class="xxxx-borders shading">4 (5)</td><td class="xxxr-borders shading">4 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Dizziness</td><td class="xxxx-borders">6 (7)</td><td class="xxxx-borders">2 (2)</td><td class="xxxr-borders">3 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Anemia<a href="#t3fn9" role="doc-noteref">‡‡</a></td><td class="xxxx-borders shading">6 (7)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Constipation</td><td class="xxxx-borders">5 (6)</td><td class="xxxx-borders">3 (4)</td><td class="xxxr-borders">6 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging13 shading" data-xml-align="left">Increase in aminotransferase level<a href="#t3fn10" role="doc-noteref">§§</a></td><td class="xbxx-borders shading">3 (4)</td><td class="xbxx-borders shading">5 (6)</td><td class="xbxr-borders shading">1 (1)</td></tr></tbody></table></div><figcaption><div class="caption">Overview of Adverse Events That Occurred during the Treatment Period (Full Analysis Population).<a href="#t3fn1" role="doc-noteref">*</a></div><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="t3fn1" role="paragraph">The treatment period was defined as the period after the first dose up to 28 days after the last dose.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="t3fn2" role="paragraph">One patient had mild cardiac failure, and one patient had mild diarrhea, abdominal pain, and dizziness.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="t3fn3" role="paragraph">One patient had moderate diarrhea.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="t3fn4" role="paragraph">There were two suspected unexpected serious adverse reactions; one patient had mild cardiac failure, and one patient had moderate urticaria.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="t3fn5" role="paragraph">Adverse events are listed for those that occurred in more than 5% of patients in either lanifibranor group.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="t3fn6" role="paragraph">Fatigue included asthenia.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="t3fn7" role="paragraph">Cases of peripheral edema were assessed by the investigator as being drug-related in two patients (including one case of severe intensity) in the 1200-mg lanifibranor group and in two patients in the 800-mg lanifibranor group.</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="t3fn8" role="paragraph">Abdominal pain included upper and lower abdominal pain.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡‡</div><div id="t3fn9" role="paragraph">Anemia included iron deficiency anemia and decreased hemoglobin level.</div></div><div role="doc-footnote" data-has="label"><div class="label">§§</div><div id="t3fn10" role="paragraph">Increase in aminotransferase level included increased alanine aminotransferase level, increased aspartate aminotransferase level, or abnormal liver function test result.</div></div></div></figcaption></figure></div></section></section><section id="sec-3" data-type="discussion"><h2>Discussion</h2><div role="paragraph">In this phase 2, placebo-controlled trial of lanifibranor in patients with highly active NASH and fibrosis, the percentage of patients who had a reduction in activity of steatohepatitis was significantly higher among those who received the 1200-mg dose, but not among those who received the 800-mg dose, of lanifibranor for 24 weeks than among those who received placebo. The results of this trial also support the potential for benefits with lanifibranor with respect to many secondary end points, including hepatic fibrosis, lipid profile, and glycemic control.</div><div role="paragraph">NASH is the primary predictor of progressive hepatic fibrosis.<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13 r14" id="body-ref-r14" href-manipulated="true">13,14</a></sup> Patients with significant (moderate) or advanced hepatic fibrosis are at increased risk of cirrhosis,<sup><a href="#core-r15" role="doc-biblioref" data-xml-rid="r15 r16" id="body-ref-r16" href-manipulated="true">15,16</a></sup> which justifies the need for pharmacotherapy in patients with NASH and advanced fibrosis. Resolution of NASH has been shown to be associated with regression of hepatic fibrosis.<sup><a href="#core-r13" role="doc-biblioref" data-xml-rid="r13 r17" id="body-ref-r17" href-manipulated="true">13,17</a></sup> In this trial, a dose-dependent improvement in SAF-A score and its individual components was noted with lanifibranor. Resolution of NASH without worsening of fibrosis, a secondary end point, was observed in 49% of patients who received the 1200-mg dose of lanifibranor, as compared with 22% of patients in the placebo group. When the analysis was restricted to patients with significant (stage F2) or advanced (stage F3) fibrosis (i.e., those who compose the target population for the treatment of noncirrhotic NASH according to regulatory guidance), similar results were obtained, a finding that supports the potential for benefits with lanifibranor as compared with placebo.</div><div role="paragraph">In this trial, other findings from the secondary end-point analyses suggest that the 1200-mg dose of lanifibranor may have led to a regression of fibrosis. <a id="exam-tint-one-a"></a><a id="exam-tint-one-b"></a><a id="exam-tint-one-c"></a><span id="tint5" class="named-content" data-type="exam-tint" data-answer-ids="one-a one-b one-c">Fibrosis is the primary predictor of medical complications and death in patients with NASH.<sup><a href="#core-r18" role="doc-biblioref" data-xml-rid="r18" id="body-ref-r18" href-manipulated="true" aria-label="Reference 18">18</a></sup> Regression of fibrosis in NASH is associated with decreased risk of liver-related events<sup><a href="#core-r19" role="doc-biblioref" data-xml-rid="r19" id="body-ref-r19" href-manipulated="true" aria-label="Reference 19">19</a></sup> and is a surrogate end point for regulatory approval.</span><sup><a href="#core-r8" role="doc-biblioref" data-xml-rid="r8" id="body-ref-r8-2" href-manipulated="true" aria-label="Reference 8">8</a></sup> Although regression of fibrosis can be indirectly accomplished with long-term therapy to control disease activity, the combination of therapy to control disease activity and fibrogenesis, the goals of which are reflected in the composite end point of resolution of NASH and improvement in fibrosis stage of at least 1, could have a stronger and faster effect on disease progression.</div><div role="paragraph">Previous trials have also shown resolution of NASH with no worsening in fibrosis with other compounds.<sup><a href="#core-r20" role="doc-biblioref" data-xml-rid="r20 r21 r22 r23" id="body-ref-r23" href-manipulated="true">20-23</a></sup> Regression of fibrosis without worsening of NASH has been reported with a few other drugs.<sup><a href="#core-r24" role="doc-biblioref" data-xml-rid="r24 r25" id="body-ref-r25" href-manipulated="true">24,25</a></sup> None of these compounds were reported to have concomitant benefits with respect to both histologic end points.</div><div role="paragraph">The histologic results are supported by apparent improvements in several relevant metabolic, inflammatory, and fibrogenesis markers, including Pro-C3 and liver stiffness, but other markers of fibrosis (scores on the Enhanced Liver Fibrosis test and Fibrosis-4 index) did not improve. However, as changes in biomarkers are not fully validated as surrogates of histologic change, these results should be interpreted with caution, particularly in short-term trials.</div><div role="paragraph"><span id="tint6" class="named-content" data-type="exam-tint" data-answer-ids="three-d">There was a dose-dependent increase in serum adiponectin level, which suggests that there was an improvement in adipose-tissue function.<sup><a href="#core-r26" role="doc-biblioref" data-xml-rid="r26 r27" id="body-ref-r27" href-manipulated="true">26,27</a></sup> This improvement in adipose tissue function is most likely the main reason for the observed increase in body weight. Lanifibranor induced a histologic improvement despite this weight gain, which could be explained by the role of adipose-tissue dysfunction rather than overweight per se in the pathophysiology of NASH<sup><a href="#core-r28" role="doc-biblioref" data-xml-rid="r28" id="body-ref-r28" href-manipulated="true" aria-label="Reference 28">28</a></sup> and by a shift from visceral to metabolically healthy subcutaneous adipose tissue, a finding that was noted with other PPARγ agonists.</span><sup><a href="#core-r29" role="doc-biblioref" data-xml-rid="r29" id="body-ref-r29" href-manipulated="true" aria-label="Reference 29">29</a></sup></div><div role="paragraph">NASH is a risk factor for type 2 diabetes mellitus, which is associated with a higher risk of more-advanced fibrosis.<sup><a href="#core-r30" role="doc-biblioref" data-xml-rid="r30" id="body-ref-r30" href-manipulated="true" aria-label="Reference 30">30</a></sup> <a id="exam-tint-two-a"></a><span id="tint7" class="named-content" data-type="exam-tint" data-answer-ids="two-a">Lanifibranor appeared to improve histologic features in patients regardless of diabetes status.</span> Patients with diabetes who received lanifibranor had reductions in glycated hemoglobin level, a validated surrogate for improved outcomes,<sup><a href="#core-r31" role="doc-biblioref" data-xml-rid="r31 r32" id="body-ref-r32" href-manipulated="true">31,32</a></sup> and in other measures of glycemic control. Also, the patients who received lanifibranor had an increase in HDL cholesterol level and a decrease in serum triglyceride level, two major cardiovascular risk factors. Such metabolic improvements could be beneficial in a patient population at high risk for adverse cardiovascular outcomes.<sup><a href="#core-r3" role="doc-biblioref" data-xml-rid="r3" id="body-ref-r3-2" href-manipulated="true" aria-label="Reference 3">3</a></sup></div><div role="paragraph"><span id="tint8" class="named-content" data-type="exam-tint" data-answer-ids="one-d">Steatosis is a cardinal feature of NASH. The majority of patients with steatosis do not, however, show signs of liver damage.<sup><a href="#core-r33" role="doc-biblioref" data-xml-rid="r33" id="body-ref-r33" href-manipulated="true" aria-label="Reference 33">33</a></sup> While disease activity should reflect ongoing damage and inflammation, the inclusion of steatosis as part of a composite activity score introduces a risk that these outcomes may be overestimated. Moreover, although regression of steatosis was shown in conjunction with regression of NASH in several trials, the severity of steatosis can also decrease when disease progresses to cirrhosis.</span><sup><a href="#core-r34" role="doc-biblioref" data-xml-rid="r34" id="body-ref-r34" href-manipulated="true" aria-label="Reference 34">34</a></sup> We therefore used the SAF scoring system, which assesses steatosis separately from activity and accounts for necroinflammation without steatosis, in the selection of patients for the trial and to define the primary end point.<sup><a href="#core-r10" role="doc-biblioref" data-xml-rid="r10" id="body-ref-r10-4" href-manipulated="true" aria-label="Reference 10">10</a></sup> The use of the SAF-A score leads to a selection of patients with more-severe disease activity and fibrosis,<sup><a href="#core-r35" role="doc-biblioref" data-xml-rid="r35" id="body-ref-r35" href-manipulated="true" aria-label="Reference 35">35</a></sup> as was observed in the current trial, in which 76% of patients had significant or advanced fibrosis, despite the fact that no inclusion criterion with respect to fibrosis stage was set (except for the exclusion of patients with cirrhosis). The use of the SAF-A score enriched the trial with patients more likely to benefit from pharmacologic treatment. As for the other histologic end points, the validity of the use of the SAF-A score to define the primary end point as a surrogate for long-term outcomes warrants further study.</div><div role="paragraph">Lanifibranor is a first-in-class pan-PPAR agonist with the ability to activate the three PPAR isotypes.<sup><a href="#core-r6" role="doc-biblioref" data-xml-rid="r6" id="body-ref-r6-2" href-manipulated="true" aria-label="Reference 6">6</a></sup> The ability of lanifibranor to simultaneously improve pathways driving insulin resistance, reduce hepatic inflammation, and improve the fibrotic response suggests an effective multitargeted mechanism of action. The complex pathophysiology of NASH may require targeting multiple pathways, rather than a single pathway, for successful treatment.<sup><a href="#core-r36" role="doc-biblioref" data-xml-rid="r36" id="body-ref-r36" href-manipulated="true" aria-label="Reference 36">36</a></sup></div><div role="paragraph">Gastrointestinal adverse events, peripheral edema, anemia, and weight gain occurred more frequently with lanifibranor than with placebo. A reduction in hemoglobin levels was observed in the lanifibranor groups, a finding that is consistent with those in previous reports of other compounds with PPARγ agonism; such a reduction has several potential underlying mechanisms.<sup><a href="#core-r37" role="doc-biblioref" data-xml-rid="r37" id="body-ref-r37" href-manipulated="true" aria-label="Reference 37">37</a></sup> No effect on kidney function or markers of bone turnover was observed.</div><div role="paragraph">The majority of patients in this 24-week trial were White. To assess whether longer treatment would result in similar efficacy and whether this efficacy would apply to other racial and ethnic groups, some of which have a greater predisposition to NASH than others, an appropriate phase 3 trial of longer duration and with more extensive assessments for efficacy and safety is needed.</div><div role="paragraph">In this phase 2b trial of patients with active NASH, the percentage of patients who had a decrease of at least 2 points in the SAF-A score without worsening of fibrosis was significantly higher with the 1200-mg once-daily dose of lanifibranor than with placebo.</div></section>



        
        
</div></section><section id="backmatter" data-extent="backmatter" data-location="articleTab_article"><div class="core-container"><section id="backnotes" data-location="notes_article"><h2>Notes</h2><div data-type="data-sharing" role="paragraph">A <a href="#ap4">data sharing statement</a> provided by the authors is available with the full text of this article at NEJM.org.</div><div role="paragraph">Supported by <span class="named-content" data-type="funder">Inventiva Pharma</span>.</div><div role="paragraph"><a href="#ap3">Disclosure forms</a> provided by the authors are available with the full text of this article at NEJM.org.</div><div role="paragraph">We thank Daniel Beard for professional writing assistance and copyediting (paid for by MedEd Global Solutions through funding from Inventiva Pharma); Amalia Gastaldelli and Ralph Defronzo (members of the data and safety monitoring board); Jo Bilcke and Sereina Herzog (data and safety monitoring board statisticians); and Nicolas Abello, Nathalie Quiniou, Nathalie Sabin, Lucile Dzen, and Bruno Scherrer for conducting clinical operational oversight, data management, and statistical analyses.</div></section><section id="supplementary-materials" class="core-supplementary-materials"><h2>Supplementary Material</h2><div role="list"><div id="ap0" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Research Summary</span> <span class="core-filename">(nejmoa2036205_research-summary.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2036205/suppl_file/nejmoa2036205_research-summary.pdf" download="nejmoa2036205_research-summary.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2036205_research-summary.pdf" data-doi="10.1056/NEJMoa2036205">Download</a></li><li>347.03 KB</li></ul></div></div><div id="ap1" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Protocol</span> <span class="core-filename">(nejmoa2036205_protocol.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2036205/suppl_file/nejmoa2036205_protocol.pdf" download="nejmoa2036205_protocol.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2036205_protocol.pdf" data-doi="10.1056/NEJMoa2036205">Download</a></li><li>8.55 MB</li></ul></div></div><div id="ap2" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Supplementary Appendix</span> <span class="core-filename">(nejmoa2036205_appendix.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2036205/suppl_file/nejmoa2036205_appendix.pdf" download="nejmoa2036205_appendix.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2036205_appendix.pdf" data-doi="10.1056/NEJMoa2036205">Download</a></li><li>1.19 MB</li></ul></div></div><div id="ap3" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Disclosure Forms</span> <span class="core-filename">(nejmoa2036205_disclosures.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2036205/suppl_file/nejmoa2036205_disclosures.pdf" download="nejmoa2036205_disclosures.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2036205_disclosures.pdf" data-doi="10.1056/NEJMoa2036205">Download</a></li><li>1.16 MB</li></ul></div></div><div id="ap4" class="core-supplementary-material" role="listitem"><div class="core-description"><span class="core-label">Data Sharing Statement</span> <span class="core-filename">(nejmoa2036205_data-sharing.pdf)</span></div><div class="core-link"><ul><li><a href="/doi/suppl/10.1056/NEJMoa2036205/suppl_file/nejmoa2036205_data-sharing.pdf" download="nejmoa2036205_data-sharing.pdf" data-interactiontype="multimedia_download" data-multimedia-type="Supplementary Material" data-behavior="trackDownloadEvent" data-multimedia-filename="nejmoa2036205_data-sharing.pdf" data-doi="10.1056/NEJMoa2036205">Download</a></li><li>69.50 KB</li></ul></div></div></div></section><section id="bibliography" class="core-reference-list" role="doc-bibliography" data-location="references_article"><h2>References</h2><div role="list" data-method="clamp" id="collapsible-text"><div role="listitem" data-has="label"><div class="label">1.</div><div id="r1" class="citations"><div class="citation"><div class="citation-content">Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. <em>Nat Rev Gastroenterol Hepatol</em> 2018;15:11-20.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nrgastro.2017.109" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28930295/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000422819800010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global+burden+of+NAFLD+and+NASH%3A+trends%2C+predictions%2C+risk+factors+and+prevention.&amp;publication_year=2018&amp;journal=Nat+Rev+Gastroenterol+Hepatol&amp;pages=11-20&amp;doi=10.1038%2Fnrgastro.2017.109&amp;pmid=28930295" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="r2" class="citations"><div class="citation"><div class="citation-content">Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. <em>Nat Rev Gastroenterol Hepatol</em> 2018;15:425-439.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41575-018-0010-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29713021/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000436368300011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Risk+of+cardiomyopathy+and+cardiac+arrhythmias+in+patients+with+nonalcoholic+fatty+liver+disease.&amp;publication_year=2018&amp;journal=Nat+Rev+Gastroenterol+Hepatol&amp;pages=425-439&amp;doi=10.1038%2Fs41575-018-0010-0&amp;pmid=29713021" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="r3" class="citations"><div class="citation"><div class="citation-content">Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. <em>J Hepatol</em> 2016;65:425-443.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jhep.2016.04.005" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27091791/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000380516900026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Non-alcoholic+fatty+liver+disease+and+cardiovascular+risk%3A+pathophysiological+mechanisms+and+implications.&amp;publication_year=2016&amp;journal=J+Hepatol&amp;pages=425-443&amp;doi=10.1016%2Fj.jhep.2016.04.005&amp;pmid=27091791" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] disease, and metabolic dysfunction. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] risk for adverse cardiovascular outcomes. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="r4" class="citations"><div class="citation"><div class="citation-content">Francque S, Szabo G, Abdelmalek MF, et al. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. <em>Nat Rev Gastroenterol Hepatol</em> 2021;18:24-39.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41575-020-00366-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33093663/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000582363200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nonalcoholic+steatohepatitis%3A+the+role+of+peroxisome+proliferator-activated+receptors.&amp;publication_year=2021&amp;journal=Nat+Rev+Gastroenterol+Hepatol&amp;pages=24-39&amp;doi=10.1038%2Fs41575-020-00366-5&amp;pmid=33093663" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="r5" class="citations"><div class="citation"><div class="citation-content">Boubia B, Poupardin O, Barth M, et al. Design, synthesis, and evaluation of a novel series of indole sulfonamide peroxisome proliferator activated receptor (PPAR) α/γ/δ triple activators: discovery of lanifibranor, a new antifibrotic clinical candidate. <em>J Med Chem</em> 2018;61:2246-2265.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1021/acs.jmedchem.7b01285" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29446942/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000428356600005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Design%2C+synthesis%2C+and+evaluation+of+a+novel+series+of+indole+sulfonamide+peroxisome+proliferator+activated+receptor+%28PPAR%29+%CE%B1%2F%CE%B3%2F%CE%B4+triple+activators%3A+discovery+of+lanifibranor%2C+a+new+antifibrotic+clinical+candidate.&amp;publication_year=2018&amp;journal=J+Med+Chem&amp;pages=2246-2265&amp;doi=10.1021%2Facs.jmedchem.7b01285&amp;pmid=29446942" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="r6" class="citations"><div class="citation"><div class="citation-content">Wettstein G, Luccarini J-M, Poekes L, et al. The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis. <em>Hepatol Commun</em> 2017;1:524-537.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/hep4.1057" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29404476/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000453172300006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+new-generation+pan-peroxisome+proliferator-activated+receptor+agonist+IVA337+protects+the+liver+from+metabolic+disorders+and+fibrosis.&amp;publication_year=2017&amp;journal=Hepatol+Commun&amp;pages=524-537&amp;doi=10.1002%2Fhep4.1057&amp;pmid=29404476" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] efficacy than single or dual PPAR agonists. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r6-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] to activate the three PPAR isotypes. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="r7" class="citations"><div class="citation"><div class="citation-content">Lefere S, Puengel T, Hundertmark J, et al. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages. <em>J Hepatol</em> 2020;73:757-770.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jhep.2020.04.025" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32360434/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000572079900011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Differential+effects+of+selective-+and+pan-PPAR+agonists+on+experimental+steatohepatitis+and+hepatic+macrophages.&amp;publication_year=2020&amp;journal=J+Hepatol&amp;pages=757-770&amp;doi=10.1016%2Fj.jhep.2020.04.025&amp;pmid=32360434" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="r8" class="citations"><div class="citation"><div class="citation-content">Food and Drug Administration. Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: developing drugs for treatment. Guidance for industry. December 2018 (<a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/noncirrhotic-nonalcoholic-steatohepatitis-liver-fibrosis-developing-drugs-treatment">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/noncirrhotic-nonalcoholic-steatohepatitis-liver-fibrosis-developing-drugs-treatment</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Noncirrhotic+nonalcoholic+steatohepatitis+with+liver+fibrosis%3A+developing+drugs+for+treatment.+Guidance+for+industry." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] to cirrhosis and associated complications. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] end point for regulatory approval. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="r9" class="citations"><div class="citation"><div class="citation-content">Francque SM, Bedossa P, Abdelmalek MF, et al. A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: design of the NATIVE study. <em>Contemp Clin Trials</em> 2020;98:106170-106170.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cct.2020.106170" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33038502/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000593988500021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+randomised%2C+double-blind%2C+placebo-controlled%2C+multi-centre%2C+dose-range%2C+proof-of-concept%2C+24-week+treatment+study+of+lanifibranor+in+adult+subjects+with+non-alcoholic+steatohepatitis%3A+design+of+the+NATIVE+study.&amp;publication_year=2020&amp;journal=Contemp+Clin+Trials&amp;pages=106170-106170&amp;doi=10.1016%2Fj.cct.2020.106170&amp;pmid=33038502" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="r10" class="citations"><div class="citation"><div class="citation-content">Bedossa P, FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. <em>Hepatology</em> 2014;60:565-575.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/hep.27173" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24753132/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000339497600016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Utility+and+appropriateness+of+the+fatty+liver+inhibition+of+progression+%28FLIP%29+algorithm+and+steatosis%2C+activity%2C+and+fibrosis+%28SAF%29+score+in+the+evaluation+of+biopsies+of+nonalcoholic+fatty+liver+disease.&amp;publication_year=2014&amp;journal=Hepatology&amp;pages=565-575&amp;doi=10.1002%2Fhep.27173&amp;pmid=24753132" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] indicate more-severe disease activity. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] from F0 [no fibrosis] to F4 [cirrhosis]), </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] was also a criterion for eligibility. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] trial and to define the primary end point. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="r11" class="citations"><div class="citation"><div class="citation-content">Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. <em>Hepatology</em> 2005;41:1313-1321.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/hep.20701" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15915461/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000229517300014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Design+and+validation+of+a+histological+scoring+system+for+nonalcoholic+fatty+liver+disease.&amp;publication_year=2005&amp;journal=Hepatology&amp;pages=1313-1321&amp;doi=10.1002%2Fhep.20701&amp;pmid=15915461" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="r12" class="citations"><div class="citation"><div class="citation-content">Rinella ME, Tacke F, Sanyal AJ, Anstee QM. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. <em>J Hepatol</em> 2019;71:823-833.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jhep.2019.04.019" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31300231/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000488196300023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Report+on+the+AASLD%2FEASL+joint+workshop+on+clinical+trial+endpoints+in+NAFLD.&amp;publication_year=2019&amp;journal=J+Hepatol&amp;pages=823-833&amp;doi=10.1016%2Fj.jhep.2019.04.019&amp;pmid=31300231" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="r13" class="citations"><div class="citation"><div class="citation-content">Brunt EM, Kleiner DE, Wilson LA, Sanyal AJ, Neuschwander-Tetri BA. Improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: results from the Nonalcoholic Steatohepatitis Clinical Research Network treatment trials. <em>Hepatology</em> 2019;70:522-531.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/hep.30418" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30549292/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000478636000008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Improvements+in+histologic+features+and+diagnosis+associated+with+improvement+in+fibrosis+in+nonalcoholic+steatohepatitis%3A+results+from+the+Nonalcoholic+Steatohepatitis+Clinical+Research+Network+treatment+trials.&amp;publication_year=2019&amp;journal=Hepatology&amp;pages=522-531&amp;doi=10.1002%2Fhep.30418&amp;pmid=30549292" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r14" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] predictor of progressive hepatic fibrosis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with regression of hepatic fibrosis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="r14" class="citations"><div class="citation"><div class="citation-content">Kleiner DE, Brunt EM, Wilson LA, et al. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. <em>JAMA Netw Open</em> 2019;2(10):e1912565-e1912565.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jamanetworkopen.2019.12565" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31584681/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000497997100016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Association+of+histologic+disease+activity+with+progression+of+nonalcoholic+fatty+liver+disease.&amp;publication_year=2019&amp;journal=JAMA+Netw+Open&amp;pages=e1912565-e1912565&amp;doi=10.1001%2Fjamanetworkopen.2019.12565&amp;pmid=31584681" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="r15" class="citations"><div class="citation"><div class="citation-content">Loomba R, Adams LA. The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH. <em>Hepatology</em> 2019;70:1885-1888.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/hep.30946" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31520407/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000500824000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+20%25+rule+of+NASH+progression%3A+the+natural+history+of+advanced+fibrosis+and+cirrhosis+caused+by+NASH.&amp;publication_year=2019&amp;journal=Hepatology&amp;pages=1885-1888&amp;doi=10.1002%2Fhep.30946&amp;pmid=31520407" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="r16" class="citations"><div class="citation"><div class="citation-content">Pierantonelli I, Svegliati-Baroni G. Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH. <em>Transplantation</em> 2019;103(1):e1-e13.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/TP.0000000000002480" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30300287/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000455044100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nonalcoholic+fatty+liver+disease%3A+basic+pathogenetic+mechanisms+in+the+progression+from+NAFLD+to+NASH.&amp;publication_year=2019&amp;journal=Transplantation&amp;pages=e1-e13&amp;doi=10.1097%2FTP.0000000000002480&amp;pmid=30300287" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="r17" class="citations"><div class="citation"><div class="citation-content">Gehrke N, Schattenberg JM. Metabolic inflammation — a role for hepatic inflammatory pathways as drivers of comorbidities in nonalcoholic fatty liver disease? <em>Gastroenterology</em> 2020;158(7):1929-1947.e6.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1053/j.gastro.2020.02.020" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32068022/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000534022200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Metabolic+inflammation+%E2%80%94+a+role+for+hepatic+inflammatory+pathways+as+drivers+of+comorbidities+in+nonalcoholic+fatty+liver+disease%3F&amp;publication_year=2020&amp;journal=Gastroenterology&amp;pages=1929-1947.e6&amp;doi=10.1053%2Fj.gastro.2020.02.020&amp;pmid=32068022" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="r18" class="citations"><div class="citation"><div class="citation-content">Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. <em>Hepatology</em> 2017;65:1557-1565.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/hep.29085" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28130788/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000399459800011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Increased+risk+of+mortality+by+fibrosis+stage+in+nonalcoholic+fatty+liver+disease%3A+systematic+review+and+meta-analysis.&amp;publication_year=2017&amp;journal=Hepatology&amp;pages=1557-1565&amp;doi=10.1002%2Fhep.29085&amp;pmid=28130788" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="r19" class="citations"><div class="citation"><div class="citation-content">Sanyal AJ, Anstee QM, Trauner M, et al. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis (NASH). <em>Hepatology</em> 2020;72:67A-68A. abstract 90.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cirrhosis+regression+is+associated+with+improved+clinical+outcomes+in+patients+with+nonalcoholic+steatohepatitis+%28NASH%29.&amp;publication_year=2020&amp;pages=67A-68A" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="r20" class="citations"><div class="citation"><div class="citation-content">Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. <em>N Engl J Med</em> 2021;384:1113-1124.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_21_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2036205&amp;key=10.1056%2FNEJMoa2028395&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33185364/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000634797200011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+placebo-controlled+trial+of+subcutaneous+semaglutide+in+nonalcoholic+steatohepatitis.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=1113-1124&amp;doi=10.1056%2FNEJMoa2028395&amp;pmid=33185364" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="r21" class="citations"><div class="citation"><div class="citation-content">Ratziu V, de Guevara L, Safadi R, et al. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. <em>Nat Med</em> (in press).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Aramchol+in+patients+with+nonalcoholic+steatohepatitis%3A+a+randomized%2C+double-blind%2C+placebo-controlled+phase+2b+trial." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="r22" class="citations"><div class="citation"><div class="citation-content">Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. <em>N Engl J Med</em> 2010;362:1675-1685.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_23_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2036205&amp;key=10.1056%2FNEJMoa0907929&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20427778/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000277311200005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pioglitazone%2C+vitamin+E%2C+or+placebo+for+nonalcoholic+steatohepatitis.&amp;publication_year=2010&amp;journal=N+Engl+J+Med&amp;pages=1675-1685&amp;doi=10.1056%2FNEJMoa0907929&amp;pmid=20427778" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="r23" class="citations"><div class="citation"><div class="citation-content">Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <em>Lancet</em> 2019;394:2012-2024.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(19)32517-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31727409/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000500950200028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Resmetirom+%28MGL-3196%29+for+the+treatment+of+non-alcoholic+steatohepatitis%3A+a+multicentre%2C+randomised%2C+double-blind%2C+placebo-controlled%2C+phase+2+trial.&amp;publication_year=2019&amp;journal=Lancet&amp;pages=2012-2024&amp;doi=10.1016%2FS0140-6736%2819%2932517-6&amp;pmid=31727409" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="r24" class="citations"><div class="citation"><div class="citation-content">Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <em>Lancet</em> 2019;394:2184-2196.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(19)33041-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31813633/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000502546300028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Obeticholic+acid+for+the+treatment+of+non-alcoholic+steatohepatitis%3A+interim+analysis+from+a+multicentre%2C+randomised%2C+placebo-controlled+phase+3+trial.&amp;publication_year=2019&amp;journal=Lancet&amp;pages=2184-2196&amp;doi=10.1016%2FS0140-6736%2819%2933041-7&amp;pmid=31813633" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="r25" class="citations"><div class="citation"><div class="citation-content">Friedman SL, Ratziu V, Harrison SA, et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. <em>Hepatology</em> 2018;67:1754-1767.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/hep.29477" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28833331/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000430388500014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+randomized%2C+placebo-controlled+trial+of+cenicriviroc+for+treatment+of+nonalcoholic+steatohepatitis+with+fibrosis.&amp;publication_year=2018&amp;journal=Hepatology&amp;pages=1754-1767&amp;doi=10.1002%2Fhep.29477&amp;pmid=28833331" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="r26" class="citations"><div class="citation"><div class="citation-content">Gastaldelli A, Harrison SA, Belfort-Aguilar R, et al. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. <em>Hepatology</em> 2009;50:1087-1093.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/hep.23116" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19670459/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000270455800015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Importance+of+changes+in+adipose+tissue+insulin+resistance+to+histological+response+during+thiazolidinedione+treatment+of+patients+with+nonalcoholic+steatohepatitis.&amp;publication_year=2009&amp;journal=Hepatology&amp;pages=1087-1093&amp;doi=10.1002%2Fhep.23116&amp;pmid=19670459" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="r27" class="citations"><div class="citation"><div class="citation-content">Gastaldelli A, Harrison S, Belfort-Aguiar R, et al. Pioglitazone in the treatment of NASH: the role of adiponectin. <em>Aliment Pharmacol Ther</em> 2010;32:769-775.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1365-2036.2010.04405.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20662773/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000280972200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pioglitazone+in+the+treatment+of+NASH%3A+the+role+of+adiponectin.&amp;publication_year=2010&amp;journal=Aliment+Pharmacol+Ther&amp;pages=769-775&amp;doi=10.1111%2Fj.1365-2036.2010.04405.x&amp;pmid=20662773" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="r28" class="citations"><div class="citation"><div class="citation-content">Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. <em>JHEP Rep</em> 2019;1:312-328.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jhepr.2019.07.002" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32039382/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000648543000008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=From+NASH+to+diabetes+and+from+diabetes+to+NASH%3A+mechanisms+and+treatment+options.&amp;publication_year=2019&amp;journal=JHEP+Rep&amp;pages=312-328&amp;doi=10.1016%2Fj.jhepr.2019.07.002&amp;pmid=32039382" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="r29" class="citations"><div class="citation"><div class="citation-content">Balas B, Belfort R, Harrison SA, et al. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. <em>J Hepatol</em> 2007;47:565-570.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jhep.2007.04.013" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17560678/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000250025200020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pioglitazone+treatment+increases+whole+body+fat+but+not+total+body+water+in+patients+with+non-alcoholic+steatohepatitis.&amp;publication_year=2007&amp;journal=J+Hepatol&amp;pages=565-570&amp;doi=10.1016%2Fj.jhep.2007.04.013&amp;pmid=17560678" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="r30" class="citations"><div class="citation"><div class="citation-content">Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. <em>Lancet Diabetes Endocrinol</em> 2014;2:901-910.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-8587(14)70032-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24731669/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Non-alcoholic+fatty+liver+disease+as+a+cause+and+a+consequence+of+metabolic+syndrome.&amp;publication_year=2014&amp;journal=Lancet+Diabetes+Endocrinol&amp;pages=901-910&amp;doi=10.1016%2FS2213-8587%2814%2970032-4&amp;pmid=24731669" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="r31" class="citations"><div class="citation"><div class="citation-content">Ambrosi P, Daumas A, Villani P, Giorgi R. Glycosylated hemoglobin as a surrogate for the prevention of cardiovascular events in cardiovascular outcome trials comparing new antidiabetic drugs to placebo. <em>Cardiology</em> 2020;145:370-374.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1159/000506004" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32088710/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000605973200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Glycosylated+hemoglobin+as+a+surrogate+for+the+prevention+of+cardiovascular+events+in+cardiovascular+outcome+trials+comparing+new+antidiabetic+drugs+to+placebo.&amp;publication_year=2020&amp;journal=Cardiology&amp;pages=370-374&amp;doi=10.1159%2F000506004&amp;pmid=32088710" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="r32" class="citations"><div class="citation"><div class="citation-content">Food and Drug Administration. Table of surrogate endpoints that were the basis of drug approval or licensure. 2020 (<a href="https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure">https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Food+and+Drug+Administration.+Table+of+surrogate+endpoints+that+were+the+basis+of+drug+approval+or+licensure.+2020+%28https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdevelopment-resources%2Ftable-surrogate-endpoints-were-basis-drug-approval-or-licensure%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="r33" class="citations"><div class="citation"><div class="citation-content">Schuppan D, Surabattula R, Wang XY. Determinants of fibrosis progression and regression in NASH. <em>J Hepatol</em> 2018;68:238-250.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jhep.2017.11.012" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29154966/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000423962300003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Determinants+of+fibrosis+progression+and+regression+in+NASH.&amp;publication_year=2018&amp;journal=J+Hepatol&amp;pages=238-250&amp;doi=10.1016%2Fj.jhep.2017.11.012&amp;pmid=29154966" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="r34" class="citations"><div class="citation"><div class="citation-content">Caldwell SH, Lee VD, Kleiner DE, et al. NASH and cryptogenic cirrhosis: a histological analysis. <em>Ann Hepatol</em> 2009;8:346-352.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r34"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1665-2681(19)31748-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20009134/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000272586100009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=NASH+and+cryptogenic+cirrhosis%3A+a+histological+analysis.&amp;publication_year=2009&amp;journal=Ann+Hepatol&amp;pages=346-352&amp;doi=10.1016%2FS1665-2681%2819%2931748-X&amp;pmid=20009134" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="r35" class="citations"><div class="citation"><div class="citation-content">Nascimbeni F, Bedossa P, Fedchuk L, et al. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. <em>J Hepatol</em> 2020;72:828-838.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jhep.2019.12.008" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31862486/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000528847500013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+validation+of+the+FLIP+algorithm+and+the+SAF+score+in+patients+with+non-alcoholic+fatty+liver+disease.&amp;publication_year=2020&amp;journal=J+Hepatol&amp;pages=828-838&amp;doi=10.1016%2Fj.jhep.2019.12.008&amp;pmid=31862486" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="r36" class="citations"><div class="citation"><div class="citation-content">Konerman MA, Jones JC, Harrison SA. Pharmacotherapy for NASH: current and emerging. <em>J Hepatol</em> 2018;68:362-375.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jhep.2017.10.015" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29122694/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000423962300013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pharmacotherapy+for+NASH%3A+current+and+emerging.&amp;publication_year=2018&amp;journal=J+Hepatol&amp;pages=362-375&amp;doi=10.1016%2Fj.jhep.2017.10.015&amp;pmid=29122694" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">37.</div><div id="r37" class="citations"><div class="citation"><div class="citation-content">Hollenberg NK. Considerations for management of fluid dynamic issues associated with thiazolidinediones. <em>Am J Med</em> 2003;115:Suppl 8A:111S-115S.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r37"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.amjmed.2003.09.018" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/14678876/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000187311800019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Considerations+for+management+of+fluid+dynamic+issues+associated+with+thiazolidinediones.&amp;publication_year=2003&amp;journal=Am+J+Med&amp;pages=111S-115S&amp;doi=10.1016%2Fj.amjmed.2003.09.018&amp;pmid=14678876" target="_blank">Google Scholar</a></div></div></div></div></div></div><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary" aria-expanded="false" aria-controls="collapsible-text"><span>Show all references</span></button></div></section></div></section></div><div class="core-collateral"><div id="core-collateral-info" role="tabpanel" data-core-tabs="core-collateral-info" tabindex="-1" aria-labelledby="pane-core-collateral-info"><header><h2 id="pane-core-collateral-info"><i class="icon-info" aria-hidden="true"></i>Information &amp; Authors</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-information" role="tab" id="tab-information-label" aria-selected="true" class="active">Information</button><button aria-controls="tab-contributors" role="tab" id="tab-contributors-label" tabindex="-1" aria-selected="false">Authors</button></div><section id="tab-information" aria-labelledby="tab-information-label" role="tabpanel" tabindex="0"><h3>Information</h3><section class="core-self-citation"><h4>Published In</h4><div class="core-journal-presentation"><div class="core-journal-description"><div property="isPartOf" typeof="Periodical"><span property="name">New England Journal of Medicine</span></div><div class="core-enumeration"><a href="/toc/nejm/385/17"><span property="isPartOf" typeof="PublicationVolume">Volume <span property="volumeNumber">385</span></span> • <span property="isPartOf" typeof="PublicationIssue">Number <span property="issueNumber">17</span></span> • <span property="datePublished">October 21, 2021</span></a></div><div class="core-pagination"><span class="heading">Pages</span>: <span class="content"><span property="pageStart">1547</span>-<span property="pageEnd">1558</span></span></div></div></div></section><section class="core-copyright"><h4>Copyright</h4><div role="paragraph">Copyright © 2021 Massachusetts Medical Society. All rights reserved.</div><div>For personal use only. Any commercial reuse of NEJM Group content requires <a href="mailto:permissions@nejm.org">permission</a>.</div></section><section data-translation="YXQYoa2036205" class="core-component-translation"><h4>Translation</h4><div role="paragraph"><a target="_blank" href="https://nejmqianyan.cn/article/YXQYoa2036205?sg=AbW1N">Chinese Translation 中文翻译</a></div></section><section class="core-history"><h4>History</h4><div><b class="core-label">Published online</b>: October 20, 2021</div><div><b class="core-label">Published in issue</b>: October 21, 2021</div></section><section data-location="recirc_topics_article" class="core-classifications"><h4>Topics</h4><div class="keywords"><ol><li><a href="/browse/topic/diet-nutrition-gastroenterology" alt="View article keyword Diet/Nutrition (Gastroenterology)" data-interactiontype="article_recirculation_click">Diet/Nutrition (Gastroenterology)</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/gastroenterology-general" alt="View article keyword Gastroenterology General" data-interactiontype="article_recirculation_click">Gastroenterology General</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li><li><a href="/browse/topic/liver-disease" alt="View article keyword Liver Disease" data-interactiontype="article_recirculation_click">Liver Disease</a></li><li role="presentation" aria-hidden="true" class="list-line-break"></li></ol></div></section></section><section id="tab-contributors" aria-labelledby="tab-contributors-label" role="tabpanel" tabindex="-1"><h3>Authors</h3><section class="core-authors"><h4>Authors</h4><div role="paragraph"><span property="author" typeof="Person"><span property="givenName">Sven M.</span> <span property="familyName">Francque</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-7527-4714" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-7527-4714</a></span>, <span property="author" typeof="Person"><span property="givenName">Pierre</span> <span property="familyName">Bedossa</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Vlad</span> <span property="familyName">Ratziu</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Quentin M.</span> <span property="familyName">Anstee</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Elisabetta</span> <span property="familyName">Bugianesi</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Arun J.</span> <span property="familyName">Sanyal</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Rohit</span> <span property="familyName">Loomba</span>, <span property="honorificSuffix">M.D., M.H.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Stephen A.</span> <span property="familyName">Harrison</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Rozalina</span> <span property="familyName">Balabanska</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Lyudmila</span> <span property="familyName">Mateva</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Nicolas</span> <span property="familyName">Lanthier</span>, <span property="honorificSuffix">M.D., Ph.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-7651-9314" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-7651-9314</a></span>, <span property="author" typeof="Person"><span property="givenName">Naim</span> <span property="familyName">Alkhouri</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Christophe</span> <span property="familyName">Moreno</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jörn M.</span> <span property="familyName">Schattenberg</span>, <span property="honorificSuffix">M.D.</span> <a class="orcid-id" href="https://orcid.org/0000-0002-4224-4703" property="identifier" aria-label="ORCID identifier" target="_blank">https://orcid.org/0000-0002-4224-4703</a></span>, <span property="author" typeof="Person"><span property="givenName">Diana</span> <span property="familyName">Stefanova-Petrova</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Luisa</span> <span property="familyName">Vonghia</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Régine</span> <span property="familyName">Rouzier</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Maeva</span> <span property="familyName">Guillaume</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Alexander</span> <span property="familyName">Hodge</span>, <span property="honorificSuffix">M.B., B.S., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Manuel</span> <span property="familyName">Romero-Gómez</span>, <span property="honorificSuffix">M.D., Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Philippe</span> <span property="familyName">Huot-Marchand</span>, <span property="honorificSuffix">M.Sc.</span></span>, <span property="author" typeof="Person"><span property="givenName">Martine</span> <span property="familyName">Baudin</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Marie-Paule</span> <span property="familyName">Richard</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jean-Louis</span> <span property="familyName">Abitbol</span>, <span property="honorificSuffix">M.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Pierre</span> <span property="familyName">Broqua</span>, <span property="honorificSuffix">Ph.D.</span></span>, <span property="author" typeof="Person"><span property="givenName">Jean-Louis</span> <span property="familyName">Junien</span>, <span property="honorificSuffix">Ph.D.</span></span>, and <span property="author" typeof="Person"><span property="givenName">Manal F.</span> <span property="familyName">Abdelmalek</span>, <span property="honorificSuffix">M.D., M.P.H.</span></span>, for <span property="author" typeof="Person">the NATIVE Study Group<sup><a href="#fn1" role="doc-noteref">*</a></sup></span></div></section><section class="core-affiliations"><h4>Affiliations</h4><div property="affiliation" typeof="Organization"><span property="name">From Antwerp University Hospital and the Faculty of Medicine and Health Sciences, University of Antwerp, Antwerp (S.M.F., L.V.), and Service d’Hépato-Gastroentérologie, Cliniques Universitaires Saint-Luc, Université Catholique de Louvain (N.L.) and Cliniques Universitaires de Bruxelles–Hôpital Erasme, Université Libre de Bruxelles (C.M.), Brussels — all in Belgium; the Translational and Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, United Kingdom (P. Bedossa, Q.M.A.); Pitie–Salpétriêre Hospital, Institute of Cardiometabolism and Nutrition, Sorbonne Université, Paris (V.R.), Centre Hospitalier Universitaire Rangueil, Toulouse (M.G.), and Inventiva Pharma, Daix (P.H.-M., M.B., M.-P.R., J.-L.A., P. Broqua, J.-L.J.) — all in France; the Division of Gastroenterology, Department of Medical Sciences, University of Turin, Turin, Italy (E.B.); Virginia Commonwealth University, Richmond (A.J.S.); the University of California San Diego, La Jolla (R.L.); Pinnacle Clinical Research, San Antonio, TX (S.A.H.); Acibadem City Clinic Tokuda Hospital (R.B.), University Hospital “St. Ivan Rilski,” Medical University–Sofia (L.M.), and Diagnostic Consultation Center Alexandrovska (D.S.-P.) — all in Sofia, Bulgaria; Arizona Liver Health, Phoenix (N.A.); Metabolic Liver Research Program, Department of Medicine, University Medical Center, Mainz, Germany (J.M.S.); Cap Research, Quatre Bornes, Mauritius (R.R.); Monash Medical Centre, Clayton, VIC, Australia (A.H.); Virgen del Rocío University Hospital, Institute of Biomedicine of Seville, University of Seville, Seville, Spain (M.R.-G.); and Duke University Medical Center, Durham, NC (M.F.A.).</span></div></section><section class="core-authors-notes"><h4>Notes</h4><div role="doc-footnote">Address reprint requests to Dr. Francque at Universitair Ziekenhuis Antwerpen, Drie Eikenstraat 655, 2650, Edegem, Belgium, or at <a href="mailto:sven.francque@uza.be">sven.francque@uza.be</a>.</div><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="fn1" role="paragraph">A full list of the investigators in the NATIVE study group is provided in the <a href="#ap2">Supplementary Appendix</a>, available at NEJM.org.</div></div></section></section></div><div id="core-collateral-metrics" role="tabpanel" data-core-tabs="core-collateral-metrics" tabindex="-1" aria-labelledby="pane-core-collateral-metrics"><header><h2 id="pane-core-collateral-metrics"><i class="icon-timeline" aria-hidden="true"></i>Metrics &amp; Citations</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-metrics-inner" role="tab" id="tab-metrics-inner-label" aria-selected="true" class="active" data-interactiontype="article_tab" data-tabname="metricsWindow">Metrics</button><button aria-controls="tab-citations" role="tab" id="tab-citations-label" tabindex="-1" aria-selected="false" data-interactiontype="article_tab" data-tabname="metricsWindow">Citations<span class="citations-count">460</span></button></div><section id="tab-metrics-inner" aria-labelledby="tab-metrics-inner-label" role="tabpanel" tabindex="0"><h3>Metrics</h3><section>









    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="95ea9f58-ec0e-4db2-b2ab-280fc876af53" data-location="article_metrics_article">
        



        
            <h4 class="">
                Altmetrics
            </h4>
        
        <div data-badge-details="right" data-badge-type="large-donut" data-doi="10.1056/NEJMoa2036205" data-hide-no-mentions="true" data-link-target="_blank" class="altmetric-embed" data-uuid="1aa0b66c-d45c-d6a5-8210-95082856aa01"><div style="overflow:hidden;">
    <div class="altmetric-normal-legend">
        <a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=115509648" style="display:inline-block;">
                <img alt="Article has an altmetric score of 323" src="https://badges.altmetric.com/?size=320&amp;score=323&amp;types=mabtttwf" width="180" height="180" style="border:0; margin:0; max-width: none;">
        </a>
        <p class="altmetric-see-more-details" style="padding-top: 10px; text-align: center;"><a target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=115509648">See more details</a></p>
    </div>
    <div id="_altmetric_popover_el_1aa0b66c-d45c-d6a5-8210-95082856aa01" class="altmetric-embed right" style="margin:0; padding:0; display:inline-block; float:left; position:relative;">
        <div class="altmetric_container">
            <div class="altmetric-embed altmetric-popover-inner right">
                <div style="padding:0; margin: 0;" class="altmetric-embed altmetric-popover-content">
                        <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #FF0000;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=115509648&amp;tab=news">
          Picked up by <b>35</b> news outlets
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #ffd140;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=115509648&amp;tab=blogs">
          Blogged by <b>3</b>
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #74CFED;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=115509648&amp;tab=twitter">
          Posted by <b>99</b> X users
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #f27700;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=115509648&amp;tab=patents">
          Referenced in <b>2</b> patents
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #2445bd;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=115509648&amp;tab=facebook">
          On <b>1</b> Facebook pages
      </a>
    </div>
    <div style="padding-left: 10px; line-height:18px; border-left: 16px solid #958899;">
      <a class="link-to-altmetric-details-tab" target="_blank" href="https://www.altmetric.com/details.php?domain=www.nejm.org&amp;citation_id=115509648&amp;tab=wikipedia">
          Referenced in <b>7</b> Wikipedia pages
      </a>
    </div>

    <div class="altmetric-embed readers" style="margin-top: 10px;">
          <div class="altmetric-embed tip_mendeley" style="padding-left: 10px; line-height:18px; border-left: 16px solid #A60000;">
              <b>344</b> readers on Mendeley
          </div>
    </div>

                </div>
            </div>
        </div>
    </div>
</div></div>
<script async="" type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js" nonce="94d6a1b4040e8828-SJC"></script>

        </div>
    

</section></section><section id="tab-citations" aria-labelledby="tab-citations-label" role="tabpanel" tabindex="-1"><h3>Citations</h3><section>



        
            <h4 class="">
                Export citation
            </h4>
        
        <div class="citation-download cd-sec">
<p class="citation-download_msg">Select the format you want to export the citation of this publication.</p>
<form action="/action/downloadCitation" name="frmCitmgr" method="post" target="_self" class="citation-download_form"><input type="hidden" name="doi" value="10.1056/NEJMoa2036205"> <input type="hidden" name="downloadFileName" value="csp_385_"> <input type="hidden" name="include" value="abs">
<div class="dropdown dropdown-selectable dropdown-selectable--form-control"><input type="hidden" name="format" value=""> <label class="form-label">Format*</label> <button id="slct_format" type="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="btn dropdown-toggle d-flex align-items-center justify-content-between">Please Select </button>
<div aria-labelledby="slct_format" role="listbox" class="dropdown-menu"><a href="#" data-value="ris" class="dropdown-item">RIS (ProCite, Reference Manager)</a><a href="#" data-value="endnote" class="dropdown-item">EndNote</a><a href="#" data-value="bibtex" class="dropdown-item">BibTex</a><a href="#" data-value="medlars" class="dropdown-item">Medlars</a><a href="#" data-value="refworks" class="dropdown-item">RefWorks</a></div>
<div class="invalid-feedback">Please select an item in the list</div>
</div>
<div class="citation-download_checkbox"><label class="checkbox--primary"><input type="checkbox" name="direct" value="true"><span class="checkbox--primary-icons"><span class="checkbox--primary-unchecked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxUnchecked"></use></svg></span></span><span class="checkbox--primary-checked"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#toggles-checboxChecked"></use></svg></span></span></span><span class="checkbox--primary-label"><span class="checkbox--primary-label-text">Direct Import</span></span></label></div>
<div class="citation-download_btn"><button type="submit" name="submit" value="Download" class="ng-btn_default ng-btn_iconLeft" data-interactiontype="article_tools_citation_download" data-multimedia-type="Citation"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#citations"></use></svg></span><span class="ng-btn_text">Export citation</span></button></div>
</form></div>
</section><section>









    
    
        <div data-widget-def="UX3CitedByWidget" data-widget-id="efb4df9a-8e1a-47f9-bfb7-271959277a9f" data-location="citedby_article">
        



        
            <h4 class="">
                Cited by
            </h4>
        
        <section id="cited-by" class="cited-by"><div class="cited-by__wrapper"><div id="cited-by__content" class="cited-by__content"><ol data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2036205%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.385.issue-17%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" data-lazyload="false" data-total="460" class="cited-by__list list-unstyled"><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Rachelle Choi, </li><li class="list-inline-item cited-by__entry__author">Jatin Vemuri, </li><li class="list-inline-item cited-by__entry__author">Alekya Poloju, </li><li class="list-inline-item cited-by__entry__author">Rishi Raj, </li><li class="list-inline-item cited-by__entry__author">Anurag Mehta, </li><li class="list-inline-item cited-by__entry__author">Amon Asgharpour, </li><li class="list-inline-item cited-by__entry__author">Mohammad S. Siddiqui, </li><li class="list-inline-item cited-by__entry__author">Priyanka Majety, </li></ul><span class="cited-by__entry__title">Current and Emerging Treatments for Metabolic Associated Steatotic Liver Disease and Diabetes: A Narrative Review, </span><span class="cited-by__entry__series-title">Endocrines, </span><span class="cited-by__entry__volume"><strong>6</strong>, </span><span class="cited-by__entry__issue">2, </span><span class="cited-by__entry__page-range">(27), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3390/endocrines6020027" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3390/endocrines6020027</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3390/endocrines6020027" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Pierre-Emmanuel Rautou, </li><li class="list-inline-item cited-by__entry__author">Shivani Chotkoe, </li><li class="list-inline-item cited-by__entry__author">Louise Biquard, </li><li class="list-inline-item cited-by__entry__author">Guillaume Wettstein, </li><li class="list-inline-item cited-by__entry__author">Denise van der Graaff, </li><li class="list-inline-item cited-by__entry__author">Yao Liu, </li><li class="list-inline-item cited-by__entry__author">Joris De Man, </li><li class="list-inline-item cited-by__entry__author">Christophe Casteleyn, </li><li class="list-inline-item cited-by__entry__author">Sofie Thys, </li><li class="list-inline-item cited-by__entry__author">Winnok H. De Vos, </li><li class="list-inline-item cited-by__entry__author">Pierre Bedossa, </li><li class="list-inline-item cited-by__entry__author">Michael P. Cooreman, </li><li class="list-inline-item cited-by__entry__author">Martine Baudin, </li><li class="list-inline-item cited-by__entry__author">Jean-Louis Abitbol, </li><li class="list-inline-item cited-by__entry__author">Philippe Huot-Marchand, </li><li class="list-inline-item cited-by__entry__author">Lucile Dzen, </li><li class="list-inline-item cited-by__entry__author">Miguel Albuquerque, </li><li class="list-inline-item cited-by__entry__author">Pierre Broqua, </li><li class="list-inline-item cited-by__entry__author">Jean-Louis Junien, </li><li class="list-inline-item cited-by__entry__author">Luisa Vonghia, </li><li class="list-inline-item cited-by__entry__author">Manal F. Abdelmalek, </li><li class="list-inline-item cited-by__entry__author">Wilhelmus J. Kwanten, </li><li class="list-inline-item cited-by__entry__author">Valérie Paradis, </li><li class="list-inline-item cited-by__entry__author">Sven M. Francque, </li></ul><span class="cited-by__entry__title">Altered liver sinusoidal endothelial cells in MASLD and their evolution following lanifibranor treatment, </span><span class="cited-by__entry__series-title">JHEP Reports, </span><span class="cited-by__entry__volume"><strong>7</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(101366), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jhepr.2025.101366" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jhepr.2025.101366</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jhepr.2025.101366" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Silvia Sabatini, </li><li class="list-inline-item cited-by__entry__author">Amalia Gastaldelli, </li></ul><span class="cited-by__entry__title">Metabolic effects and mechanism of action of the pan-PPAR agonist lanifibranor, </span><span class="cited-by__entry__series-title">Journal of Hepatology, </span><span class="cited-by__entry__volume"><strong>82</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(950-952), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jhep.2025.03.003" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jhep.2025.03.003</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jhep.2025.03.003" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Diana Barb, </li><li class="list-inline-item cited-by__entry__author">Srilaxmi Kalavalapalli, </li><li class="list-inline-item cited-by__entry__author">Eddison Godinez Leiva, </li><li class="list-inline-item cited-by__entry__author">Fernando Bril, </li><li class="list-inline-item cited-by__entry__author">Philippe Huot-Marchand, </li><li class="list-inline-item cited-by__entry__author">Lucile Dzen, </li><li class="list-inline-item cited-by__entry__author">Jens T. Rosenberg, </li><li class="list-inline-item cited-by__entry__author">Jean-Louis Junien, </li><li class="list-inline-item cited-by__entry__author">Pierre Broqua, </li><li class="list-inline-item cited-by__entry__author">Andrea Ortiz Rocha, </li><li class="list-inline-item cited-by__entry__author">Romina Lomonaco, </li><li class="list-inline-item cited-by__entry__author">Jean-Louis Abitbol, </li><li class="list-inline-item cited-by__entry__author">Michael P. Cooreman, </li><li class="list-inline-item cited-by__entry__author">Kenneth Cusi, </li></ul><span class="cited-by__entry__title">Pan-PPAR agonist lanifibranor improves insulin resistance and hepatic steatosis in patients with T2D and MASLD, </span><span class="cited-by__entry__series-title">Journal of Hepatology, </span><span class="cited-by__entry__volume"><strong>82</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(979-991), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jhep.2024.12.045" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jhep.2024.12.045</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jhep.2024.12.045" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Limeng Li, </li><li class="list-inline-item cited-by__entry__author">Weiqi Gao, </li><li class="list-inline-item cited-by__entry__author">Fengyang Yao, </li><li class="list-inline-item cited-by__entry__author">Jiayi Li, </li><li class="list-inline-item cited-by__entry__author">Wei Sang, </li><li class="list-inline-item cited-by__entry__author">Ruiping Zhang, </li></ul><span class="cited-by__entry__title">Innovative nanomedicine approaches for the management of nonalcoholic fatty liver disease, </span><span class="cited-by__entry__series-title">Journal of Controlled Release, </span><span class="cited-by__entry__volume"><strong>382</strong>, </span><span class="cited-by__entry__page-range">(113680), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jconrel.2025.113680" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jconrel.2025.113680</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jconrel.2025.113680" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Haoran Zhong, </li><li class="list-inline-item cited-by__entry__author">Chen Liu, </li><li class="list-inline-item cited-by__entry__author">Zhiwei Huang, </li><li class="list-inline-item cited-by__entry__author">Peng Tan, </li><li class="list-inline-item cited-by__entry__author">Hao Chen, </li><li class="list-inline-item cited-by__entry__author">Wenguang Fu, </li></ul><span class="cited-by__entry__title">Crosstalk between Hepatic Stellate Cells and Hepatic Macrophages in Metabolic Dysfunction–Associated Steatohepatitis, </span><span class="cited-by__entry__series-title">The American Journal of Pathology, </span><span class="cited-by__entry__volume"><strong>195</strong>, </span><span class="cited-by__entry__issue">6, </span><span class="cited-by__entry__page-range">(1040-1056), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.ajpath.2025.02.003" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ajpath.2025.02.003</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ajpath.2025.02.003" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Xiangchang Zeng, </li><li class="list-inline-item cited-by__entry__author">Deliang Huang, </li><li class="list-inline-item cited-by__entry__author">Zhibin Zhu, </li><li class="list-inline-item cited-by__entry__author">Qingxian Cai, </li><li class="list-inline-item cited-by__entry__author">Yang Yang, </li><li class="list-inline-item cited-by__entry__author">Hongzhou Lu, </li><li class="list-inline-item cited-by__entry__author">Jun Chen, </li></ul><span class="cited-by__entry__title">Mechanism-guided drug development and treatment for liver fibrosis: a clinical perspective, </span><span class="cited-by__entry__series-title">Frontiers in Pharmacology, </span><span class="cited-by__entry__volume"><strong>16</strong>, </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.3389/fphar.2025.1574385" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.3389/fphar.2025.1574385</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.3389/fphar.2025.1574385" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Chang Jie Mick Lee, </li><li class="list-inline-item cited-by__entry__author">Leah B. Kosyakovsky, </li><li class="list-inline-item cited-by__entry__author">Muhammad Shahzeb Khan, </li><li class="list-inline-item cited-by__entry__author">Feng Wu, </li><li class="list-inline-item cited-by__entry__author">Guo Chen, </li><li class="list-inline-item cited-by__entry__author">Joseph A. Hill, </li><li class="list-inline-item cited-by__entry__author">Jennifer E. Ho, </li><li class="list-inline-item cited-by__entry__author">Roger S.-Y. Foo, </li><li class="list-inline-item cited-by__entry__author">Faiez Zannad, </li></ul><span class="cited-by__entry__title">Cardiovascular, Kidney, Liver, and Metabolic Interactions in Heart Failure: Breaking Down Silos, </span><span class="cited-by__entry__series-title">Circulation Research, </span><span class="cited-by__entry__volume"><strong>136</strong>, </span><span class="cited-by__entry__issue">11, </span><span class="cited-by__entry__page-range">(1170-1207), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1161/CIRCRESAHA.125.325602" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1161/CIRCRESAHA.125.325602</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1161/CIRCRESAHA.125.325602" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Lauren F. Uchiyama, </li><li class="list-inline-item cited-by__entry__author">Gabriel P.M. Ordonez, </li><li class="list-inline-item cited-by__entry__author">Khoi T. Pham, </li><li class="list-inline-item cited-by__entry__author">John P. Kennelly, </li><li class="list-inline-item cited-by__entry__author">Maykel López Rodríguez, </li><li class="list-inline-item cited-by__entry__author">Lany Tran, </li><li class="list-inline-item cited-by__entry__author">Peter Tontonoz, </li><li class="list-inline-item cited-by__entry__author">Alexander Nguyen, </li></ul><span class="cited-by__entry__title">PPARɑ variant V227A reduces plasma triglycerides through enhanced lipoprotein lipolysis, </span><span class="cited-by__entry__series-title">Journal of Lipid Research, </span><span class="cited-by__entry__volume"><strong>66</strong>, </span><span class="cited-by__entry__issue">5, </span><span class="cited-by__entry__page-range">(100806), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.jlr.2025.100806" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.jlr.2025.100806</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.jlr.2025.100806" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry border-bottom pb-16 mb-24"><ul class="cited-by__entry__authors list-inline"><li class="list-inline-item cited-by__entry__author">Kaiwen Lei, </li><li class="list-inline-item cited-by__entry__author">Yan Chen, </li><li class="list-inline-item cited-by__entry__author">Jianxing Wu, </li><li class="list-inline-item cited-by__entry__author">Yiyu Lin, </li><li class="list-inline-item cited-by__entry__author">Yan Bai, </li><li class="list-inline-item cited-by__entry__author">Hua Cao, </li><li class="list-inline-item cited-by__entry__author">Qishi Che, </li><li class="list-inline-item cited-by__entry__author">Jiao Guo, </li><li class="list-inline-item cited-by__entry__author">Zhengquan Su, </li></ul><span class="cited-by__entry__title">Mechanism of liver x receptor alpha in intestine, liver and adipose tissues in metabolic associated fatty liver disease, </span><span class="cited-by__entry__series-title">International Journal of Biological Macromolecules, </span><span class="cited-by__entry__volume"><strong>307</strong>, </span><span class="cited-by__entry__page-range">(142275), </span><span class="cited-by__entry__pub-date">(2025).</span><a href="https://doi.org/10.1016/j.ijbiomac.2025.142275" title="Crossref" target="_blank" class="cited-by__entry__doi">https://doi.org/10.1016/j.ijbiomac.2025.142275</a><div class="cited-by__entry__extra-links"><a href="https://doi.org/10.1016/j.ijbiomac.2025.142275" target="_blank" class="cited-by__entry__visitable">Crossref</a></div></li><li class="cited-by__entry--see-more"><a href="javascript:void(0)" data-source="/pb/widgets/citedBy?page=1&amp;widgetId=efb4df9a-8e1a-47f9-bfb7-271959277a9f&amp;pbContext=%3BrequestedJournal%3Ajournal%3Anejm%3Barticle%3Aarticle%3Adoi%5C%3A10.1056%2FNEJMoa2036205%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bissue%3Aissue%3Adoi%5C%3A10.1056%2Fnejm_2021.385.issue-17%3Bwgroup%3Astring%3AMMS+NextGen+Website+Group%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text%3Bwebsite%3Awebsite%3Amms-site%3Bjournal%3Ajournal%3Anejms" class="cited-by__see-more">See more</a></li></ol></div><div class="cited-by__spinner justify-content-center align-items-center d-none"><div role="status" class="spinner-border text-gray"><span class="sr-only">Loading...</span></div></div></div></section>

        </div>
    

</section></section></div><div id="core-collateral-fulltext-options" role="tabpanel" data-core-tabs="core-collateral-fulltext-options" tabindex="-1" aria-labelledby="pane-core-collateral-fulltext-options"><header><h2 id="pane-core-collateral-fulltext-options"><i class="icon-eye" aria-hidden="true"></i>View Options</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div class="section--wrapper"><h3>View options</h3><section class="format--pdf"><h4> <abbr title="Portable Document Format">PDF</abbr></h4><a href="https://www.nejm.org/doi/pdf/10.1056/NEJMoa2036205" class="btn btn--pdf" aria-label="View PDF" data-behavior="trackDownloadEvent" data-doi="10.1056/NEJMoa2036205" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2036205.pdf"><i aria-hidden="true" class="icon-pdf"></i><span>View PDF</span></a></section></div><!-- Its needed to duplicate this for PB check Collateral.js as well--></div><div id="core-collateral-media" role="tabpanel" data-core-tabs="core-collateral-media" tabindex="-1" aria-labelledby="pane-core-collateral-media"><header><h2 id="pane-core-collateral-media"><i class="icon-photo" aria-hidden="true"></i>Media</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><div role="tablist"><button aria-controls="tab-figures" role="tab" id="tab-figures-label" aria-selected="true" class="active">Figures</button><button aria-controls="tab-other" role="tab" id="tab-other-label" tabindex="-1" aria-selected="false" class="inactive" aria-disabled="true">Other</button></div><section id="tab-figures" aria-labelledby="tab-figures-label" role="tabpanel" tabindex="0"><h3>Figures</h3><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#figures"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-f0"><figure class="graphic"><a class="open-in-viewer" href="#f0" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2036205_f0.jpg"><img src="/cms/10.1056/NEJMoa2036205/asset/a58cb036-8840-44da-9a72-6e144a75ed7a/assets/images/large/nejmoa2036205_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"></a><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f0"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2036205_f0.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-f1"><figure class="graphic"><a class="open-in-viewer" href="#f1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2036205_f1.jpg"><img src="/cms/10.1056/NEJMoa2036205/asset/e1e19e7c-f802-4ca6-b949-9a3d304d32fe/assets/images/large/nejmoa2036205_f1.jpg" height="1307" width="2640" aria-labelledby="f1" loading="lazy"></a><figcaption><div class="caption">Response for Primary and Secondary Histologic End Points at Week 24.</div><div class="notes"><div role="doc-footnote">Analyses were performed with multiple imputation of missing data. Risk ratios, 95% confidence intervals, and P values were calculated with the Cochran–Mantel–Haenszel test stratified according to diabetic status at baseline. In the analysis of the primary end point, an ascending Hochberg procedure was used to adjust for multiplicity testing (each dose of lanifibranor was compared with placebo). Missing data for the 34 patients in the full analysis population (11 in the 800-mg lanifibranor group, 9 in the 1200-mg lanifibranor group, and 14 in the placebo group had missing biopsy samples at week 24) were handled with multiple imputation (details are provided in the <a href="#ap2">Supplementary Appendix</a>). The Steatosis, Activity, Fibrosis–Activity (SAF-A) score represents the activity part of the SAF scoring system that incorporates the scores for hepatocellular ballooning and lobular inflammation; SAF-A scores range from 0 to 4, with higher scores indicating more-severe disease activity. NASH denotes nonalcoholic steatohepatitis.</div></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#f1"><i class="icon-return" aria-hidden="true"></i><span>Go to Figure</span></a><a class="open-in-viewer" href="#f1" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2036205_f1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></section><section id="tab-other" aria-labelledby="tab-other-label" role="tabpanel" tabindex="-1"><h3>Other</h3></section></div><div id="core-collateral-tables" role="tabpanel" data-core-tabs="core-collateral-tables" tabindex="-1" aria-labelledby="pane-core-collateral-tables"><header><h2 id="pane-core-collateral-tables"><i class="icon-tables" aria-hidden="true"></i>Tables</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><!-- There is no content. --><div class="section--wrapper"><div class="text-right"><a class="btn btn--inverse  open-in-viewer" href="#tables"><span>Open all in viewer</span><i class="icon-open_in_new" aria-hidden="true"></i></a></div><div id="core-t1"><figure class="table"><a class="open-in-viewer" href="#t1" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2036205_t1.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2036205/asset/230be9c3-6e81-4301-bc47-be5bd7d33c6a/assets/images/large/nejmoa2036205_t1.jpg" height="2445" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Characteristic</th><th class="txxx-borders">Lanifibranor,<br>1200 mg<br>(N=83)</th><th class="txxx-borders">Lanifibranor,<br>800 mg<br>(N=83)</th><th class="txxx-borders">Placebo<br>(N=81)</th><th class="txxr-borders">Overall<br>(N=247)</th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Female sex — no. (%)</td><td class="xxxx-borders shading">49 (59)</td><td class="xxxx-borders shading">54 (65)</td><td class="xxxx-borders shading">41 (51)</td><td class="xxxr-borders shading">144 (58)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Age — yr</td><td class="xxxx-borders">52.2±13.8</td><td class="xxxx-borders">55.0±10.4</td><td class="xxxx-borders">53.4±13.1</td><td class="xxxr-borders">53.6±12.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">White race — no. (%)<a href="#core-t1fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">78 (94)</td><td class="xxxx-borders shading">80 (96)</td><td class="xxxx-borders shading">74 (91)</td><td class="xxxr-borders shading">232 (94)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Weight — kg</td><td class="xxxx-borders">93.0±19.9</td><td class="xxxx-borders">91.6±19.3</td><td class="xxxx-borders">95.1±17.3</td><td class="xxxr-borders">93.2±18.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Body-mass index</td><td class="xxxx-borders shading">33.3±5.5</td><td class="xxxx-borders shading">32.5±5.5</td><td class="xxxx-borders shading">32.8±5.1</td><td class="xxxr-borders shading">32.9±5.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Type 2 diabetes mellitus — no. (%)</td><td class="xxxx-borders">35 (42)</td><td class="xxxx-borders">33 (40)</td><td class="xxxx-borders">35 (43)</td><td class="xxxr-borders">103 (42)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Median time between screening biopsy and randomization (range) — mo</td><td class="xxxx-borders shading">2.4 (0.5–7.0)</td><td class="xxxx-borders shading">2.6 (0.5–9.2)</td><td class="xxxx-borders shading">2.0 (0.5–7.4)</td><td class="xxxr-borders shading">2.3 (0.5–9.2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Steatosis grade<a href="#core-t1fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders">2.6±0.6</td><td class="xxxx-borders">2.6±0.7</td><td class="xxxx-borders">2.5±0.7</td><td class="xxxr-borders">2.5±0.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Lobular inflammation grade<a href="#core-t1fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">1.5±0.5</td><td class="xxxx-borders shading">1.5±0.5</td><td class="xxxx-borders shading">1.5±0.5</td><td class="xxxr-borders shading">1.5±0.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Ballooning grade<a href="#core-t1fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">1.8±0.4</td><td class="xxxx-borders">1.7±0.4</td><td class="xxxx-borders">1.8±0.4</td><td class="xxxr-borders">1.8±0.4</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Fibrosis stage<a href="#core-t1fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders shading">2.1±0.8</td><td class="xxxx-borders shading">2.1±0.8</td><td class="xxxx-borders shading">2.0±0.9</td><td class="xxxr-borders shading">2.1±0.8</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Fibrosis stage F2 or F3 — no. (%)</td><td class="xxxx-borders">63 (76)</td><td class="xxxx-borders">68 (82)</td><td class="xxxx-borders">57 (70)</td><td class="xxxr-borders">188 (76)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">SAF-A score<a href="#core-t1fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">3.3±0.5</td><td class="xxxx-borders shading">3.2±0.5</td><td class="xxxx-borders shading">3.3±0.5</td><td class="xxxr-borders shading">3.3±0.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">NAS<a href="#core-t1fn8" role="doc-noteref">††</a></td><td class="xxxx-borders">5.9±0.9</td><td class="xxxx-borders">5.9±1.0</td><td class="xxxx-borders">5.9±1.1</td><td class="xxxr-borders">5.9±1.0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">NAS ≥6 — no. (%)</td><td class="xxxx-borders shading">61 (73)</td><td class="xxxx-borders shading">63 (76)</td><td class="xxxx-borders shading">56 (69)</td><td class="xxxr-borders shading">180 (73)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Alanine aminotransferase level — IU/liter</td><td class="xxxx-borders">63.6±43.4</td><td class="xxxx-borders">64.1±41.4</td><td class="xxxx-borders">56.9±31.6</td><td class="xxxr-borders">61.6±39.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Aspartate aminotransferase level — IU/liter</td><td class="xxxx-borders shading">43.9±24.8</td><td class="xxxx-borders shading">53.9±43.4</td><td class="xxxx-borders shading">43.3±24.1</td><td class="xxxr-borders shading">47.1±32.3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">γ-Glutamyltransferase level — IU/liter</td><td class="xxxx-borders">67.1±93.1</td><td class="xxxx-borders">101.6±146.1</td><td class="xxxx-borders">67.9±80.4</td><td class="xxxr-borders">78.9±111.2</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Fasting HDL cholesterol level — mmol/liter</td><td class="xxxx-borders shading">1.2±0.3</td><td class="xxxx-borders shading">1.3±0.3</td><td class="xxxx-borders shading">1.2±0.3</td><td class="xxxr-borders shading">1.2±0.3</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Fasting triglyceride level — mmol/liter</td><td class="xxxx-borders">2.0±0.9</td><td class="xxxx-borders">1.9±0.9</td><td class="xxxx-borders">2.0±0.8</td><td class="xxxr-borders">2.0±0.9</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Fasting glucose level — mmol/liter</td><td class="xxxx-borders shading">5.9±1.1</td><td class="xxxx-borders shading">6.2±1.8</td><td class="xxxx-borders shading">6.0±1.6</td><td class="xxxr-borders shading">6.0±1.5</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Glycated hemoglobin level — %</td><td class="xxxx-borders">6.1±0.7</td><td class="xxxx-borders">6.1±0.8</td><td class="xxxx-borders">6.0±0.7</td><td class="xxxr-borders">6.0±0.7</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01 shading" data-xml-align="left">Fasting insulin level — pmol/liter</td><td class="xbxx-borders shading">274.7±321.2</td><td class="xbxx-borders shading">231.9±191.9</td><td class="xbxx-borders shading">234.0±254.6</td><td class="xbxr-borders shading">246.9±260.7</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t1fn1" role="paragraph" data-to-manipulate="true">Plus–minus signs are means ±SD. To convert the values for high-density lipoprotein (HDL) cholesterol to milligrams per deciliter, divide by 0.02586. To convert the values for triglycerides to milligrams per deciliter, divide by 0.01129. To convert the values for glucose to milligrams per deciliter, divide by 0.01129. To convert the values for insulin to micrograms per liter, divide by 172.2.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t1fn2" role="paragraph" data-to-manipulate="true">Race or ethnic group is reported according to the record in the electronic case-report form, which included American Indian or Alaskan, Asian, Black or African American, Native Hawaiian or other Pacific Islander, White, or other.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t1fn3" role="paragraph" data-to-manipulate="true">Steatosis was assessed as the percentage of hepatocytes containing large and medium-sized intracytoplasmic lipid droplets (but not foamy microvesicles) and graded as 0 (&lt;5%), 1 (5 to 33%), 2 (34 to 66%), or 3 (≥67%), according to the Steatosis, Activity, Fibrosis (SAF) scoring system. Patients with grade 0 steatosis were excluded from the trial.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t1fn4" role="paragraph" data-to-manipulate="true">Lobular inflammation was classified as grade 1 (two small foci of inflammatory cells) or grade 2 (more than two foci of inflammatory cells), according to the SAF scoring system.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t1fn5" role="paragraph" data-to-manipulate="true">Ballooning was classified as grade 1 (round hepatocytes with pale cytoplasm and size similar to that of normal hepatocytes) or grade 2 (presence of enlarged hepatocytes with a diameter at least twice that of normal hepatocytes in a background of clear and round hepatocytes), according to the Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN) grading system.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t1fn6" role="paragraph" data-to-manipulate="true">Fibrosis was classified as stage F0 (no fibrosis), stage F1 (mild fibrosis), stage F2 (significant [moderate] fibrosis), stage F3 (advanced fibrosis), or stage F4 (cirrhosis), according to the SAF–NASH CRN staging system. Patients with stage F4 fibrosis were excluded from the trial.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t1fn7" role="paragraph" data-to-manipulate="true">The SAF-Activity (SAF-A) score ranges from 0 to 4; with higher scores indicating more-severe disease activity.</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="core-t1fn8" role="paragraph" data-to-manipulate="true">The Nonalcoholic Fatty Liver Disease Activity Score (NAS) ranges from 0 to 8. A score of 2 or less indicates “not NASH”; a score of 3 or 4, “borderline NASH,” and a score of 5 to 8, “definite NASH.”</div></div></div></figcaption></a><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline (Full Analysis Population).<a href="#core-t1fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t1"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t1" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2036205_t1.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t2"><figure class="table"><a class="open-in-viewer" href="#t2" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2036205_t2.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2036205/asset/d9835b28-f05d-4335-863c-24b1e449c7b9/assets/images/large/nejmoa2036205_t2.jpg" height="2393" width="1999" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">End Point</th><th class="txxx-borders">Lanifibranor, 1200 mg<br>(N=77)</th><th class="txxx-borders">Lanifibranor, 800 mg<br>(N=77)</th><th class="txxr-borders">Placebo<br>(N=74)</th></tr></thead><tbody><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Change from baseline in secondary end points (95% CI)</b><a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Total cholesterol — mmol/liter</td><td class="xxxx-borders">−0.07 (−0.22 to 0.07)</td><td class="xxxx-borders">−0.02 (−0.17 to 0.13)</td><td class="xxxr-borders">0.01 (−0.14 to 0.16)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Fasting HDL cholesterol — mmol/liter</td><td class="xxxx-borders shading">0.11 (0.06 to 0.15)</td><td class="xxxx-borders shading">0.16 (0.12 to 0.21)</td><td class="xxxr-borders shading">0.01 (−0.04 to 0.05)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Fasting LDL cholesterol — mmol/liter</td><td class="xxxx-borders">0.03 (−0.11 to 0.16)</td><td class="xxxx-borders">0.03 (−0.11 to 0.16)</td><td class="xxxr-borders">0.01 (−0.12 to 0.15)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Fasting triglycerides — mmol/liter</td><td class="xxxx-borders shading">−0.44 (−0.61 to −0.27)</td><td class="xxxx-borders shading">−0.49 (−0.66 to −0.31)</td><td class="xxxr-borders shading">0.06 (−0.12 to 0.23)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Fasting apolipoprotein A1 — mg/dl</td><td class="xxxx-borders">−4.39 (−8.64 to −0.13)</td><td class="xxxx-borders">−0.29 (−4.61 to 4.04)</td><td class="xxxr-borders">0.03 (−4.27 to 4.33)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Aspartate aminotransferase — U/liter</td><td class="xxxx-borders shading">−12.04 (−18.29 to −5.79)</td><td class="xxxx-borders shading">−15.11 (−21.43 to −8.80)</td><td class="xxxr-borders shading">−0.08 (−6.43 to 6.26)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Alanine aminotransferase — U/liter</td><td class="xxxx-borders">−24.54 (−32.06 to −17.01)</td><td class="xxxx-borders">−26.08 (−33.67 to −18.50)</td><td class="xxxr-borders">−1.40 (−9.04 to 6.25)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">γ-Glutamyltransferase — U/liter</td><td class="xxxx-borders shading">−27.87 (−38.88 to −16.86)</td><td class="xxxx-borders shading">−43.38 (−54.46 to −32.29)</td><td class="xxxr-borders shading">4.41 (−6.76 to 15.58)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Fasting glucose — mmol/liter</td><td class="xxxx-borders">−0.60 (−0.83 to −0.37)</td><td class="xxxx-borders">−0.78 (−1.01 to −0.55)</td><td class="xxxr-borders">0.24 (0.01 to 0.47)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Glycated hemoglobin — %</td><td class="xxxx-borders shading">−0.41 (−0.51 to −0.32)</td><td class="xxxx-borders shading">−0.38 (−0.47 to −0.28)</td><td class="xxxr-borders shading">0.07 (−0.02 to 0.17)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Fasting insulin — pmol/liter</td><td class="xxxx-borders">−114.91 (−138.09 to −91.73)</td><td class="xxxx-borders">−118.66 (−141.66 to −95.67)</td><td class="xxxr-borders">−35.7 (−58.59 to −12.82)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Fasting HOMA-IR index score<a href="#core-t2fn3" role="doc-noteref">‡</a></td><td class="xxxx-borders shading">−5.46 (−6.60 to −4.32)</td><td class="xxxx-borders shading">−5.79 (−6.92 to −4.65)</td><td class="xxxr-borders shading">−1.47 (−2.59 to −0.35)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Adiponectin — μg/ml</td><td class="xxxx-borders">17.12 (14.29 to 19.96)</td><td class="xxxx-borders">11.95 (8.97 to 14.94)</td><td class="xxxr-borders">−0.35 (−3.20 to 2.50)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">High-sensitivity CRP — mg/liter</td><td class="xxxx-borders shading">−1.37 (−2.28 to −0.46)</td><td class="xxxx-borders shading">−2.05 (−2.97 to −1.13)</td><td class="xxxr-borders shading">0.11 (−0.81 to 1.03)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Fibrinogen — g/liter</td><td class="xxxx-borders">−0.10 (−0.24 to 0.05)</td><td class="xxxx-borders">−0.17 (−0.32 to −0.02)</td><td class="xxxr-borders">0.02 (−0.12 to 0.17)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">α2-Macroglobulin — g/liter</td><td class="xxxx-borders shading">0.13 (0.04 to 0.22)</td><td class="xxxx-borders shading">0.15 (0.06 to 0.24)</td><td class="xxxr-borders shading">0.05 (−0.04 to 0.13)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Haptoglobin — g/liter</td><td class="xxxx-borders">−0.07 (−0.13 to 0)</td><td class="xxxx-borders">−0.05 (−0.12 to 0.01)</td><td class="xxxr-borders">0.05 (−0.01 to 0.12)</td></tr><tr data-type="row"><td class="xxlx-borders hanging01 shading"><b>Change from baseline in exploratory end points (95% CI)</b><a href="#core-t2fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxx-borders shading">&nbsp;</td><td class="xxxr-borders shading" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Fasting apolipoprotein B — mg/dl</td><td class="xxxx-borders">−11.61 (−15.64 to −7.57)</td><td class="xxxx-borders">−11.51 (−15.61 to −7.41)</td><td class="xxxr-borders">−1.85 (−5.79 to 2.09)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Fasting apolipoprotein C3 — μg/dl</td><td class="xxxx-borders shading">−9.98 (−17.74 to −2.22)</td><td class="xxxx-borders shading">−8.08 (−16.02 to −0.13)</td><td class="xxxr-borders shading">10.31 (2.67 to 17.94)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Pro-C3 — μg/liter</td><td class="xxxx-borders">−1.79 (−3.07 to −0.52)</td><td class="xxxx-borders">−3.93 (−5.26 to −2.61)</td><td class="xxxr-borders">−1.01 (−2.30 to 0.28)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">TIMP-1 to MMP-2 ratio</td><td class="xxxx-borders shading">−0.75 (−0.93 to −0.57)</td><td class="xxxx-borders shading">−0.69 (−0.88 to −0.50)</td><td class="xxxr-borders shading">−0.11 (−0.29 to 0.08)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01" data-xml-align="left">Cytokeratin 18 M30 — pmol/liter</td><td class="xxxx-borders">−315.55 (−441.55 to −189.55)</td><td class="xxxx-borders">−331.71 (−463.78 to −199.65)</td><td class="xxxr-borders">−105.03 (−232.86 to 22.80)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging01 shading" data-xml-align="left">Enhanced Liver Fibrosis test score<a href="#core-t2fn4" role="doc-noteref">§</a></td><td class="xxxx-borders shading">0.11 (−0.04 to 0.26)</td><td class="xxxx-borders shading">−0.19 (−0.35 to −0.04)</td><td class="xxxr-borders shading">−0.08 (−0.23 to 0.06)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging01" data-xml-align="left">Fibrosis-4 index score<a href="#core-t2fn5" role="doc-noteref">¶</a></td><td class="xbxx-borders">0.03 (−0.13 to 0.19)</td><td class="xbxx-borders">0 (−0.17 to 0.16)</td><td class="xbxr-borders">−0.03 (−0.19 to 0.13)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t2fn1" role="paragraph" data-to-manipulate="true">A total of 228 patients completed their week-24 visit. The analysis of each variable was conducted with data from approximately the same number of patients; there were some missing data from a small number of patients for certain variables. To convert the values for cholesterol to milligrams per deciliter, divide by 0.02586. To convert the values for fibrinogen to micromoles per liter, multiply by 2.94. CRP denotes C-reactive protein, LDL low-density lipoprotein, MMP-2 matrix metalloproteinase 2, Pro-C3 N-terminal type III collagen propeptide, and TIMP-1 tissue inhibitor of metalloproteinase 1.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t2fn2" role="paragraph" data-to-manipulate="true">Adjusted mean absolute changes and 95% confidence intervals were derived with the use of mixed models for repeated measures, with the absolute change from baseline of the continuous outcome as the end point, the time, trial group, diabetic status, trial-group–by–time interaction, and baseline value of the outcome as fixed effects; a time repeated effect within each subject; and an unstructured variance–covariance matrix.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t2fn3" role="paragraph" data-to-manipulate="true">The score on the homeostatic model assessment of insulin resistance (HOMA-IR) was calculated as follows: (fasting insulin [in micro–international units per milliliter]×fasting glucose [in milligrams per deciliter])/405. The conversion factor that was used for insulin was that 1 μU per milliliter was equal to 6.00 pmol per liter. Higher values indicate greater insulin resistance.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t2fn4" role="paragraph" data-to-manipulate="true">An Enhanced Liver Fibrosis test score of less than 7.7 indicates none to mild fibrosis, and a score of 11.3 or greater indicates cirrhosis.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t2fn5" role="paragraph" data-to-manipulate="true">A Fibrosis-4 index score of less than 1.45 indicates low probability of stage F3 or F4 fibrosis, and a score greater than 3.25 indicates a high probability of stage F3 or F4 fibrosis.</div></div></div></figcaption></a><figcaption><div class="caption">Laboratory Measures at Week 24 among the Patients in the Full Analysis Population Who Completed the Trial.<a href="#core-t2fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t2"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t2" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2036205_t2.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div><div id="core-t3"><figure class="table"><a class="open-in-viewer" href="#t3" data-index="0" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2036205_t3.jpg"><div class="graphic-wrap" data-presentation="suppressed-in-viewer"><img src="/cms/10.1056/NEJMoa2036205/asset/27acf7f8-bff6-4f51-bdac-7132794565fd/assets/images/large/nejmoa2036205_t3.jpg" height="2985" width="1711" loading="lazy"></div><div class="table-wrap catalyst-standard" data-presentation="suppressed-in-flow"><table data-shading="custom"><thead><tr class="head1" data-type="row head1"><th class="txlx-borders" data-xml-align="left">Event</th><th class="txxx-borders">Lanifibranor,<br>1200 mg<br>(N=83)</th><th class="txxx-borders">Lanifibranor,<br>800 mg<br>(N=83)</th><th class="txxr-borders">Placebo<br>(N=81)</th></tr><tr class="head3" data-type="row head3"><td class="xxlx-borders">&nbsp;</td><th class="xxxr-borders" colspan="3"><span>number (percent)</span></th></tr></thead><tbody><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">≥1 Adverse event</td><td class="xxxx-borders shading">62 (75)</td><td class="xxxx-borders shading">59 (71)</td><td class="xxxr-borders shading">50 (62)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Mild</td><td class="xxxx-borders">54 (65)</td><td class="xxxx-borders">51 (61)</td><td class="xxxr-borders">42 (52)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Moderate</td><td class="xxxx-borders shading">28 (34)</td><td class="xxxx-borders shading">20 (24)</td><td class="xxxr-borders shading">22 (27)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Severe</td><td class="xxxx-borders">3 (4)</td><td class="xxxx-borders">3 (4)</td><td class="xxxr-borders">3 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Adverse event related to active drug or placebo, during the treatment period, as assessed by the investigator</td><td class="xxxx-borders shading">23 (28)</td><td class="xxxx-borders shading">25 (30)</td><td class="xxxr-borders shading">19 (23)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Adverse event that led to permanent discontinuation of the trial regimen</td><td class="xxxx-borders">3 (4)</td><td class="xxxx-borders">4 (5)</td><td class="xxxr-borders">3 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03 shading" data-xml-align="left">Adverse event related to active drug or placebo that led to discontinuation of the trial regimen</td><td class="xxxx-borders shading">2 (2)<a href="#core-t3fn2" role="doc-noteref">†</a></td><td class="xxxx-borders shading">1 (1)<a href="#core-t3fn3" role="doc-noteref">‡</a></td><td class="xxxr-borders shading">2 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging03" data-xml-align="left">Serious adverse event</td><td class="xxxx-borders">7 (8)</td><td class="xxxx-borders">3 (4)</td><td class="xxxr-borders">3 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Death</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Serious adverse event related to active drug or placebo</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">2 (2)<a href="#core-t3fn4" role="doc-noteref">§</a></td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Serious postprocedural condition linked to biopsy procedure</td><td class="xxxx-borders shading">3 (4)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging13">Other serious adverse event</td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Wrist fracture</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Unstable angina</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Heart failure</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Gastroenteritis</td><td class="xxxx-borders">1 (1)</td><td class="xxxx-borders">0</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Pyelonephritis</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Pancreatitis</td><td class="xxxx-borders">0</td><td class="xxxx-borders">1 (1)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Undifferentiated connective tissue disease</td><td class="xxxx-borders shading">0</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23" data-xml-align="left">Urticaria</td><td class="xxxx-borders">0</td><td class="xxxx-borders">0</td><td class="xxxr-borders">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging23 shading" data-xml-align="left">Foot operation</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxx-borders shading">0</td><td class="xxxr-borders shading">0</td></tr><tr data-type="row"><td class="xxlx-borders hanging03">Most frequent adverse events<a href="#core-t3fn5" role="doc-noteref">¶</a></td><td class="xxxx-borders">&nbsp;</td><td class="xxxx-borders">&nbsp;</td><td class="xxxr-borders" data-xml-align="center">&nbsp;</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Diarrhea</td><td class="xxxx-borders shading">10 (12)</td><td class="xxxx-borders shading">8 (10)</td><td class="xxxr-borders shading">1 (1)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Fatigue<a href="#core-t3fn6" role="doc-noteref">‖</a></td><td class="xxxx-borders">11 (13)</td><td class="xxxx-borders">3 (4)</td><td class="xxxr-borders">8 (10)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Nausea</td><td class="xxxx-borders shading">7 (8)</td><td class="xxxx-borders shading">8 (10)</td><td class="xxxr-borders shading">3 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Weight gain</td><td class="xxxx-borders">7 (8)</td><td class="xxxx-borders">8 (10)</td><td class="xxxr-borders">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Peripheral edema<a href="#core-t3fn7" role="doc-noteref">**</a></td><td class="xxxx-borders shading">7 (8)</td><td class="xxxx-borders shading">5 (6)</td><td class="xxxr-borders shading">2 (2)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Headache</td><td class="xxxx-borders">7 (8)</td><td class="xxxx-borders">4 (5)</td><td class="xxxr-borders">4 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Abdominal pain<a href="#core-t3fn8" role="doc-noteref">††</a></td><td class="xxxx-borders shading">5 (6)</td><td class="xxxx-borders shading">4 (5)</td><td class="xxxr-borders shading">4 (5)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Dizziness</td><td class="xxxx-borders">6 (7)</td><td class="xxxx-borders">2 (2)</td><td class="xxxr-borders">3 (4)</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13 shading" data-xml-align="left">Anemia<a href="#core-t3fn9" role="doc-noteref">‡‡</a></td><td class="xxxx-borders shading">6 (7)</td><td class="xxxx-borders shading">1 (1)</td><td class="xxxr-borders shading">0</td></tr><tr data-xml-align="center" data-type="row"><td class="xxlx-borders hanging13" data-xml-align="left">Constipation</td><td class="xxxx-borders">5 (6)</td><td class="xxxx-borders">3 (4)</td><td class="xxxr-borders">6 (7)</td></tr><tr data-xml-align="center" data-type="row"><td class="xblx-borders hanging13 shading" data-xml-align="left">Increase in aminotransferase level<a href="#core-t3fn10" role="doc-noteref">§§</a></td><td class="xbxx-borders shading">3 (4)</td><td class="xbxx-borders shading">5 (6)</td><td class="xbxr-borders shading">1 (1)</td></tr></tbody></table></div><figcaption><div class="notes"><div role="doc-footnote" data-has="label"><div class="label">*</div><div id="core-t3fn1" role="paragraph" data-to-manipulate="true">The treatment period was defined as the period after the first dose up to 28 days after the last dose.</div></div><div role="doc-footnote" data-has="label"><div class="label">†</div><div id="core-t3fn2" role="paragraph" data-to-manipulate="true">One patient had mild cardiac failure, and one patient had mild diarrhea, abdominal pain, and dizziness.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡</div><div id="core-t3fn3" role="paragraph" data-to-manipulate="true">One patient had moderate diarrhea.</div></div><div role="doc-footnote" data-has="label"><div class="label">§</div><div id="core-t3fn4" role="paragraph" data-to-manipulate="true">There were two suspected unexpected serious adverse reactions; one patient had mild cardiac failure, and one patient had moderate urticaria.</div></div><div role="doc-footnote" data-has="label"><div class="label">¶</div><div id="core-t3fn5" role="paragraph" data-to-manipulate="true">Adverse events are listed for those that occurred in more than 5% of patients in either lanifibranor group.</div></div><div role="doc-footnote" data-has="label"><div class="label">‖</div><div id="core-t3fn6" role="paragraph" data-to-manipulate="true">Fatigue included asthenia.</div></div><div role="doc-footnote" data-has="label"><div class="label">**</div><div id="core-t3fn7" role="paragraph" data-to-manipulate="true">Cases of peripheral edema were assessed by the investigator as being drug-related in two patients (including one case of severe intensity) in the 1200-mg lanifibranor group and in two patients in the 800-mg lanifibranor group.</div></div><div role="doc-footnote" data-has="label"><div class="label">††</div><div id="core-t3fn8" role="paragraph" data-to-manipulate="true">Abdominal pain included upper and lower abdominal pain.</div></div><div role="doc-footnote" data-has="label"><div class="label">‡‡</div><div id="core-t3fn9" role="paragraph" data-to-manipulate="true">Anemia included iron deficiency anemia and decreased hemoglobin level.</div></div><div role="doc-footnote" data-has="label"><div class="label">§§</div><div id="core-t3fn10" role="paragraph" data-to-manipulate="true">Increase in aminotransferase level included increased alanine aminotransferase level, increased aspartate aminotransferase level, or abnormal liver function test result.</div></div></div></figcaption></a><figcaption><div class="caption">Overview of Adverse Events That Occurred during the Treatment Period (Full Analysis Population).<a href="#core-t3fn1" role="doc-noteref">*</a></div></figcaption></figure><div class="external-links"><a class="pill__to-original" href="#t3"><i class="icon-return" aria-hidden="true"></i><span>Go to Table</span></a><a class="open-in-viewer" href="#t3" data-interactiontype="multimedia_click" data-multimedia-type="Table" data-multimedia-filename="nejmoa2036205_t3.jpg"><span>Open in Viewer</span><i class="icon-expand" aria-hidden="true"></i></a></div></div></div></div><div id="core-collateral-share" role="tabpanel" data-core-tabs="core-collateral-share" tabindex="-1" aria-labelledby="pane-core-collateral-share"><header><h2 id="pane-core-collateral-share"><i class="icon-share" aria-hidden="true"></i>Share</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>Share</h3><div class="section--wrapper"><section><h4>CONTENT LINK</h4><div id="share-self"><p data-id="article-share-self-link" class="share-self__source">https://www.nejm.org/doi/full/10.1056/NEJMoa2036205</p><button data-id="article-share-access" aria-label="CONTENT LINK" class="share-self__action btn btn--inverse"><i aria-hidden="true" class="icon-copy-o"></i><span>Copy Link</span></button><div aria-live="polite" class="share-self__status"><p class="share-self__success"><i aria-hidden="true" class="icon-check_circle"></i><span>Copied!</span></p><p class="share-self__failed"><i aria-hidden="true" class="icon-x_btnclose"></i><span>Copying failed.</span></p></div></div></section><section data-location="share_tools_article"><h4>Share</h4><div class="share-buttons a2a a2a_kit" style="line-height: 16px;"><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i><span>Facebook</span></a><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i><span>X (formerly Twitter)</span></a><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i><span>LinkedIn</span></a><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i><span>email</span></a><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i><span>Bluesky</span></a></div></section></div></div><div data-location="references_article" id="core-collateral-references" role="tabpanel" aria-labelledby="pane-core-collateral-references" data-core-tabs="core-collateral-references" tabindex="-1"><header><h2 id="pane-core-collateral-references"><i aria-hidden="true" class="icon-references"></i>References</h2><button data-close="collateral" aria-label="Close"><i class="icon-close"></i></button></header><h3>References</h3><div role="list" class="section--wrapper"><div role="listitem" data-has="label"><div class="label">1.</div><div id="core-r1" class="citations"><div class="citation"><div class="citation-content">Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. <em>Nat Rev Gastroenterol Hepatol</em> 2018;15:11-20.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/nrgastro.2017.109" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28930295/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000422819800010" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Global+burden+of+NAFLD+and+NASH%3A+trends%2C+predictions%2C+risk+factors+and+prevention.&amp;publication_year=2018&amp;journal=Nat+Rev+Gastroenterol+Hepatol&amp;pages=11-20&amp;doi=10.1038%2Fnrgastro.2017.109&amp;pmid=28930295" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">2.</div><div id="core-r2" class="citations"><div class="citation"><div class="citation-content">Anstee QM, Mantovani A, Tilg H, Targher G. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease. <em>Nat Rev Gastroenterol Hepatol</em> 2018;15:425-439.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r3-1"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41575-018-0010-0" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29713021/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000436368300011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Risk+of+cardiomyopathy+and+cardiac+arrhythmias+in+patients+with+nonalcoholic+fatty+liver+disease.&amp;publication_year=2018&amp;journal=Nat+Rev+Gastroenterol+Hepatol&amp;pages=425-439&amp;doi=10.1038%2Fs41575-018-0010-0&amp;pmid=29713021" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">3.</div><div id="core-r3" class="citations"><div class="citation"><div class="citation-content">Francque SM, van der Graaff D, Kwanten WJ. Non-alcoholic fatty liver disease and cardiovascular risk: pathophysiological mechanisms and implications. <em>J Hepatol</em> 2016;65:425-443.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r3-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jhep.2016.04.005" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/27091791/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000380516900026" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Non-alcoholic+fatty+liver+disease+and+cardiovascular+risk%3A+pathophysiological+mechanisms+and+implications.&amp;publication_year=2016&amp;journal=J+Hepatol&amp;pages=425-443&amp;doi=10.1016%2Fj.jhep.2016.04.005&amp;pmid=27091791" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r3-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r3-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] disease, and metabolic dysfunction. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r3-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] risk for adverse cardiovascular outcomes. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">4.</div><div id="core-r4" class="citations"><div class="citation"><div class="citation-content">Francque S, Szabo G, Abdelmalek MF, et al. Nonalcoholic steatohepatitis: the role of peroxisome proliferator-activated receptors. <em>Nat Rev Gastroenterol Hepatol</em> 2021;18:24-39.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1038/s41575-020-00366-5" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33093663/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000582363200001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nonalcoholic+steatohepatitis%3A+the+role+of+peroxisome+proliferator-activated+receptors.&amp;publication_year=2021&amp;journal=Nat+Rev+Gastroenterol+Hepatol&amp;pages=24-39&amp;doi=10.1038%2Fs41575-020-00366-5&amp;pmid=33093663" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">5.</div><div id="core-r5" class="citations"><div class="citation"><div class="citation-content">Boubia B, Poupardin O, Barth M, et al. Design, synthesis, and evaluation of a novel series of indole sulfonamide peroxisome proliferator activated receptor (PPAR) α/γ/δ triple activators: discovery of lanifibranor, a new antifibrotic clinical candidate. <em>J Med Chem</em> 2018;61:2246-2265.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r5"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1021/acs.jmedchem.7b01285" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29446942/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000428356600005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Design%2C+synthesis%2C+and+evaluation+of+a+novel+series+of+indole+sulfonamide+peroxisome+proliferator+activated+receptor+%28PPAR%29+%CE%B1%2F%CE%B3%2F%CE%B4+triple+activators%3A+discovery+of+lanifibranor%2C+a+new+antifibrotic+clinical+candidate.&amp;publication_year=2018&amp;journal=J+Med+Chem&amp;pages=2246-2265&amp;doi=10.1021%2Facs.jmedchem.7b01285&amp;pmid=29446942" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">6.</div><div id="core-r6" class="citations"><div class="citation"><div class="citation-content">Wettstein G, Luccarini J-M, Poekes L, et al. The new-generation pan-peroxisome proliferator-activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis. <em>Hepatol Commun</em> 2017;1:524-537.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r6-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/hep4.1057" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29404476/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000453172300006" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+new-generation+pan-peroxisome+proliferator-activated+receptor+agonist+IVA337+protects+the+liver+from+metabolic+disorders+and+fibrosis.&amp;publication_year=2017&amp;journal=Hepatol+Commun&amp;pages=524-537&amp;doi=10.1002%2Fhep4.1057&amp;pmid=29404476" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r6-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r7" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] efficacy than single or dual PPAR agonists. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r6-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] to activate the three PPAR isotypes. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">7.</div><div id="core-r7" class="citations"><div class="citation"><div class="citation-content">Lefere S, Puengel T, Hundertmark J, et al. Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages. <em>J Hepatol</em> 2020;73:757-770.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r7"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jhep.2020.04.025" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32360434/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000572079900011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Differential+effects+of+selective-+and+pan-PPAR+agonists+on+experimental+steatohepatitis+and+hepatic+macrophages.&amp;publication_year=2020&amp;journal=J+Hepatol&amp;pages=757-770&amp;doi=10.1016%2Fj.jhep.2020.04.025&amp;pmid=32360434" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">8.</div><div id="core-r8" class="citations"><div class="citation"><div class="citation-content">Food and Drug Administration. Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: developing drugs for treatment. Guidance for industry. December 2018 (<a href="https://www.fda.gov/regulatory-information/search-fda-guidance-documents/noncirrhotic-nonalcoholic-steatohepatitis-liver-fibrosis-developing-drugs-treatment">https://www.fda.gov/regulatory-information/search-fda-guidance-documents/noncirrhotic-nonalcoholic-steatohepatitis-liver-fibrosis-developing-drugs-treatment</a>).</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r8-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Noncirrhotic+nonalcoholic+steatohepatitis+with+liver+fibrosis%3A+developing+drugs+for+treatment.+Guidance+for+industry." target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r8-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r8-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] to cirrhosis and associated complications. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r8-2" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] end point for regulatory approval. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">9.</div><div id="core-r9" class="citations"><div class="citation"><div class="citation-content">Francque SM, Bedossa P, Abdelmalek MF, et al. A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non-alcoholic steatohepatitis: design of the NATIVE study. <em>Contemp Clin Trials</em> 2020;98:106170-106170.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r9"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.cct.2020.106170" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33038502/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000593988500021" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+randomised%2C+double-blind%2C+placebo-controlled%2C+multi-centre%2C+dose-range%2C+proof-of-concept%2C+24-week+treatment+study+of+lanifibranor+in+adult+subjects+with+non-alcoholic+steatohepatitis%3A+design+of+the+NATIVE+study.&amp;publication_year=2020&amp;journal=Contemp+Clin+Trials&amp;pages=106170-106170&amp;doi=10.1016%2Fj.cct.2020.106170&amp;pmid=33038502" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">10.</div><div id="core-r10" class="citations"><div class="citation"><div class="citation-content">Bedossa P, FLIP Pathology Consortium. Utility and appropriateness of the fatty liver inhibition of progression (FLIP) algorithm and steatosis, activity, and fibrosis (SAF) score in the evaluation of biopsies of nonalcoholic fatty liver disease. <em>Hepatology</em> 2014;60:565-575.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r10-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/hep.27173" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24753132/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000339497600016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Utility+and+appropriateness+of+the+fatty+liver+inhibition+of+progression+%28FLIP%29+algorithm+and+steatosis%2C+activity%2C+and+fibrosis+%28SAF%29+score+in+the+evaluation+of+biopsies+of+nonalcoholic+fatty+liver+disease.&amp;publication_year=2014&amp;journal=Hepatology&amp;pages=565-575&amp;doi=10.1002%2Fhep.27173&amp;pmid=24753132" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r10-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r10-1" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] indicate more-severe disease activity. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r11" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] from F0 [no fibrosis] to F4 [cirrhosis]), </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-3" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>c [...] was also a criterion for eligibility. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r10-4" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>d [...] trial and to define the primary end point. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">11.</div><div id="core-r11" class="citations"><div class="citation"><div class="citation-content">Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. <em>Hepatology</em> 2005;41:1313-1321.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r11"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/hep.20701" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/15915461/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000229517300014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Design+and+validation+of+a+histological+scoring+system+for+nonalcoholic+fatty+liver+disease.&amp;publication_year=2005&amp;journal=Hepatology&amp;pages=1313-1321&amp;doi=10.1002%2Fhep.20701&amp;pmid=15915461" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">12.</div><div id="core-r12" class="citations"><div class="citation"><div class="citation-content">Rinella ME, Tacke F, Sanyal AJ, Anstee QM. Report on the AASLD/EASL joint workshop on clinical trial endpoints in NAFLD. <em>J Hepatol</em> 2019;71:823-833.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r12"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jhep.2019.04.019" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31300231/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000488196300023" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Report+on+the+AASLD%2FEASL+joint+workshop+on+clinical+trial+endpoints+in+NAFLD.&amp;publication_year=2019&amp;journal=J+Hepatol&amp;pages=823-833&amp;doi=10.1016%2Fj.jhep.2019.04.019&amp;pmid=31300231" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">13.</div><div id="core-r13" class="citations"><div class="citation"><div class="citation-content">Brunt EM, Kleiner DE, Wilson LA, Sanyal AJ, Neuschwander-Tetri BA. Improvements in histologic features and diagnosis associated with improvement in fibrosis in nonalcoholic steatohepatitis: results from the Nonalcoholic Steatohepatitis Clinical Research Network treatment trials. <em>Hepatology</em> 2019;70:522-531.</div><div class="external-links"><div class="to-citation__wrapper"><button aria-controls="to-citation__accordion-r13-core" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="Hide Citations" data-collapsed-title="Show Citations" class="accordion__toggle__title"></span></button></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/hep.30418" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30549292/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000478636000008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Improvements+in+histologic+features+and+diagnosis+associated+with+improvement+in+fibrosis+in+nonalcoholic+steatohepatitis%3A+results+from+the+Nonalcoholic+Steatohepatitis+Clinical+Research+Network+treatment+trials.&amp;publication_year=2019&amp;journal=Hepatology&amp;pages=522-531&amp;doi=10.1002%2Fhep.30418&amp;pmid=30549292" target="_blank">Google Scholar</a></div><div role="menu" aria-label="links" class="to-citation__accordion no-separator" id="to-citation__accordion-r13-core" style="display: none;"><ul role="none"><li role="none"><a class="to-citation" href="#body-ref-r14" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>a [...] predictor of progressive hepatic fibrosis. </span></a></li><li role="none"><a class="to-citation" href="#body-ref-r17" role="menuitem"><i aria-hidden="true" class="icon-return"></i><span>b [...] with regression of hepatic fibrosis. </span></a></li></ul></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">14.</div><div id="core-r14" class="citations"><div class="citation"><div class="citation-content">Kleiner DE, Brunt EM, Wilson LA, et al. Association of histologic disease activity with progression of nonalcoholic fatty liver disease. <em>JAMA Netw Open</em> 2019;2(10):e1912565-e1912565.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r14"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1001/jamanetworkopen.2019.12565" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31584681/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000497997100016" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Association+of+histologic+disease+activity+with+progression+of+nonalcoholic+fatty+liver+disease.&amp;publication_year=2019&amp;journal=JAMA+Netw+Open&amp;pages=e1912565-e1912565&amp;doi=10.1001%2Fjamanetworkopen.2019.12565&amp;pmid=31584681" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">15.</div><div id="core-r15" class="citations"><div class="citation"><div class="citation-content">Loomba R, Adams LA. The 20% rule of NASH progression: the natural history of advanced fibrosis and cirrhosis caused by NASH. <em>Hepatology</em> 2019;70:1885-1888.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/hep.30946" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31520407/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000500824000001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=The+20%25+rule+of+NASH+progression%3A+the+natural+history+of+advanced+fibrosis+and+cirrhosis+caused+by+NASH.&amp;publication_year=2019&amp;journal=Hepatology&amp;pages=1885-1888&amp;doi=10.1002%2Fhep.30946&amp;pmid=31520407" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">16.</div><div id="core-r16" class="citations"><div class="citation"><div class="citation-content">Pierantonelli I, Svegliati-Baroni G. Nonalcoholic fatty liver disease: basic pathogenetic mechanisms in the progression from NAFLD to NASH. <em>Transplantation</em> 2019;103(1):e1-e13.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r16"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1097/TP.0000000000002480" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/30300287/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000455044100001" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Nonalcoholic+fatty+liver+disease%3A+basic+pathogenetic+mechanisms+in+the+progression+from+NAFLD+to+NASH.&amp;publication_year=2019&amp;journal=Transplantation&amp;pages=e1-e13&amp;doi=10.1097%2FTP.0000000000002480&amp;pmid=30300287" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">17.</div><div id="core-r17" class="citations"><div class="citation"><div class="citation-content">Gehrke N, Schattenberg JM. Metabolic inflammation — a role for hepatic inflammatory pathways as drivers of comorbidities in nonalcoholic fatty liver disease? <em>Gastroenterology</em> 2020;158(7):1929-1947.e6.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r17"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1053/j.gastro.2020.02.020" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32068022/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000534022200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Metabolic+inflammation+%E2%80%94+a+role+for+hepatic+inflammatory+pathways+as+drivers+of+comorbidities+in+nonalcoholic+fatty+liver+disease%3F&amp;publication_year=2020&amp;journal=Gastroenterology&amp;pages=1929-1947.e6&amp;doi=10.1053%2Fj.gastro.2020.02.020&amp;pmid=32068022" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">18.</div><div id="core-r18" class="citations"><div class="citation"><div class="citation-content">Dulai PS, Singh S, Patel J, et al. Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis. <em>Hepatology</em> 2017;65:1557-1565.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r18"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/hep.29085" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28130788/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000399459800011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Increased+risk+of+mortality+by+fibrosis+stage+in+nonalcoholic+fatty+liver+disease%3A+systematic+review+and+meta-analysis.&amp;publication_year=2017&amp;journal=Hepatology&amp;pages=1557-1565&amp;doi=10.1002%2Fhep.29085&amp;pmid=28130788" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">19.</div><div id="core-r19" class="citations"><div class="citation"><div class="citation-content">Sanyal AJ, Anstee QM, Trauner M, et al. Cirrhosis regression is associated with improved clinical outcomes in patients with nonalcoholic steatohepatitis (NASH). <em>Hepatology</em> 2020;72:67A-68A. abstract 90.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r19"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Cirrhosis+regression+is+associated+with+improved+clinical+outcomes+in+patients+with+nonalcoholic+steatohepatitis+%28NASH%29.&amp;publication_year=2020&amp;pages=67A-68A" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">20.</div><div id="core-r20" class="citations"><div class="citation"><div class="citation-content">Newsome PN, Buchholtz K, Cusi K, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. <em>N Engl J Med</em> 2021;384:1113-1124.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_21_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2036205&amp;key=10.1056%2FNEJMoa2028395&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/33185364/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000634797200011" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+placebo-controlled+trial+of+subcutaneous+semaglutide+in+nonalcoholic+steatohepatitis.&amp;publication_year=2021&amp;journal=N+Engl+J+Med&amp;pages=1113-1124&amp;doi=10.1056%2FNEJMoa2028395&amp;pmid=33185364" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">21.</div><div id="core-r21" class="citations"><div class="citation"><div class="citation-content">Ratziu V, de Guevara L, Safadi R, et al. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. <em>Nat Med</em> (in press).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Aramchol+in+patients+with+nonalcoholic+steatohepatitis%3A+a+randomized%2C+double-blind%2C+placebo-controlled+phase+2b+trial." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">22.</div><div id="core-r22" class="citations"><div class="citation"><div class="citation-content">Sanyal AJ, Chalasani N, Kowdley KV, et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. <em>N Engl J Med</em> 2010;362:1675-1685.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="/servlet/linkout?suffix=e_1_3_5_23_2&amp;dbid=4&amp;doi=10.1056%2FNEJMoa2036205&amp;key=10.1056%2FNEJMoa0907929&amp;site=mms-site" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20427778/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000277311200005" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pioglitazone%2C+vitamin+E%2C+or+placebo+for+nonalcoholic+steatohepatitis.&amp;publication_year=2010&amp;journal=N+Engl+J+Med&amp;pages=1675-1685&amp;doi=10.1056%2FNEJMoa0907929&amp;pmid=20427778" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">23.</div><div id="core-r23" class="citations"><div class="citation"><div class="citation-content">Harrison SA, Bashir MR, Guy CD, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. <em>Lancet</em> 2019;394:2012-2024.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r23"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(19)32517-6" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31727409/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000500950200028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Resmetirom+%28MGL-3196%29+for+the+treatment+of+non-alcoholic+steatohepatitis%3A+a+multicentre%2C+randomised%2C+double-blind%2C+placebo-controlled%2C+phase+2+trial.&amp;publication_year=2019&amp;journal=Lancet&amp;pages=2012-2024&amp;doi=10.1016%2FS0140-6736%2819%2932517-6&amp;pmid=31727409" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">24.</div><div id="core-r24" class="citations"><div class="citation"><div class="citation-content">Younossi ZM, Ratziu V, Loomba R, et al. Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. <em>Lancet</em> 2019;394:2184-2196.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S0140-6736(19)33041-7" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31813633/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000502546300028" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Obeticholic+acid+for+the+treatment+of+non-alcoholic+steatohepatitis%3A+interim+analysis+from+a+multicentre%2C+randomised%2C+placebo-controlled+phase+3+trial.&amp;publication_year=2019&amp;journal=Lancet&amp;pages=2184-2196&amp;doi=10.1016%2FS0140-6736%2819%2933041-7&amp;pmid=31813633" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">25.</div><div id="core-r25" class="citations"><div class="citation"><div class="citation-content">Friedman SL, Ratziu V, Harrison SA, et al. A randomized, placebo-controlled trial of cenicriviroc for treatment of nonalcoholic steatohepatitis with fibrosis. <em>Hepatology</em> 2018;67:1754-1767.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r25"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/hep.29477" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/28833331/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000430388500014" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=A+randomized%2C+placebo-controlled+trial+of+cenicriviroc+for+treatment+of+nonalcoholic+steatohepatitis+with+fibrosis.&amp;publication_year=2018&amp;journal=Hepatology&amp;pages=1754-1767&amp;doi=10.1002%2Fhep.29477&amp;pmid=28833331" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">26.</div><div id="core-r26" class="citations"><div class="citation"><div class="citation-content">Gastaldelli A, Harrison SA, Belfort-Aguilar R, et al. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. <em>Hepatology</em> 2009;50:1087-1093.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1002/hep.23116" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/19670459/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000270455800015" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Importance+of+changes+in+adipose+tissue+insulin+resistance+to+histological+response+during+thiazolidinedione+treatment+of+patients+with+nonalcoholic+steatohepatitis.&amp;publication_year=2009&amp;journal=Hepatology&amp;pages=1087-1093&amp;doi=10.1002%2Fhep.23116&amp;pmid=19670459" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">27.</div><div id="core-r27" class="citations"><div class="citation"><div class="citation-content">Gastaldelli A, Harrison S, Belfort-Aguiar R, et al. Pioglitazone in the treatment of NASH: the role of adiponectin. <em>Aliment Pharmacol Ther</em> 2010;32:769-775.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r27"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1111/j.1365-2036.2010.04405.x" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20662773/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000280972200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pioglitazone+in+the+treatment+of+NASH%3A+the+role+of+adiponectin.&amp;publication_year=2010&amp;journal=Aliment+Pharmacol+Ther&amp;pages=769-775&amp;doi=10.1111%2Fj.1365-2036.2010.04405.x&amp;pmid=20662773" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">28.</div><div id="core-r28" class="citations"><div class="citation"><div class="citation-content">Gastaldelli A, Cusi K. From NASH to diabetes and from diabetes to NASH: mechanisms and treatment options. <em>JHEP Rep</em> 2019;1:312-328.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r28"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jhepr.2019.07.002" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32039382/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000648543000008" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=From+NASH+to+diabetes+and+from+diabetes+to+NASH%3A+mechanisms+and+treatment+options.&amp;publication_year=2019&amp;journal=JHEP+Rep&amp;pages=312-328&amp;doi=10.1016%2Fj.jhepr.2019.07.002&amp;pmid=32039382" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">29.</div><div id="core-r29" class="citations"><div class="citation"><div class="citation-content">Balas B, Belfort R, Harrison SA, et al. Pioglitazone treatment increases whole body fat but not total body water in patients with non-alcoholic steatohepatitis. <em>J Hepatol</em> 2007;47:565-570.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r29"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jhep.2007.04.013" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/17560678/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000250025200020" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pioglitazone+treatment+increases+whole+body+fat+but+not+total+body+water+in+patients+with+non-alcoholic+steatohepatitis.&amp;publication_year=2007&amp;journal=J+Hepatol&amp;pages=565-570&amp;doi=10.1016%2Fj.jhep.2007.04.013&amp;pmid=17560678" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">30.</div><div id="core-r30" class="citations"><div class="citation"><div class="citation-content">Yki-Järvinen H. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. <em>Lancet Diabetes Endocrinol</em> 2014;2:901-910.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r30"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S2213-8587(14)70032-4" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/24731669/" target="_blank">PubMed</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Non-alcoholic+fatty+liver+disease+as+a+cause+and+a+consequence+of+metabolic+syndrome.&amp;publication_year=2014&amp;journal=Lancet+Diabetes+Endocrinol&amp;pages=901-910&amp;doi=10.1016%2FS2213-8587%2814%2970032-4&amp;pmid=24731669" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">31.</div><div id="core-r31" class="citations"><div class="citation"><div class="citation-content">Ambrosi P, Daumas A, Villani P, Giorgi R. Glycosylated hemoglobin as a surrogate for the prevention of cardiovascular events in cardiovascular outcome trials comparing new antidiabetic drugs to placebo. <em>Cardiology</em> 2020;145:370-374.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1159/000506004" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/32088710/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000605973200007" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Glycosylated+hemoglobin+as+a+surrogate+for+the+prevention+of+cardiovascular+events+in+cardiovascular+outcome+trials+comparing+new+antidiabetic+drugs+to+placebo.&amp;publication_year=2020&amp;journal=Cardiology&amp;pages=370-374&amp;doi=10.1159%2F000506004&amp;pmid=32088710" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">32.</div><div id="core-r32" class="citations"><div class="citation"><div class="citation-content">Food and Drug Administration. Table of surrogate endpoints that were the basis of drug approval or licensure. 2020 (<a href="https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure">https://www.fda.gov/drugs/development-resources/table-surrogate-endpoints-were-basis-drug-approval-or-licensure</a>).</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r32"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar?q=Food+and+Drug+Administration.+Table+of+surrogate+endpoints+that+were+the+basis+of+drug+approval+or+licensure.+2020+%28https%3A%2F%2Fwww.fda.gov%2Fdrugs%2Fdevelopment-resources%2Ftable-surrogate-endpoints-were-basis-drug-approval-or-licensure%29." target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">33.</div><div id="core-r33" class="citations"><div class="citation"><div class="citation-content">Schuppan D, Surabattula R, Wang XY. Determinants of fibrosis progression and regression in NASH. <em>J Hepatol</em> 2018;68:238-250.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r33"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jhep.2017.11.012" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29154966/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000423962300003" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Determinants+of+fibrosis+progression+and+regression+in+NASH.&amp;publication_year=2018&amp;journal=J+Hepatol&amp;pages=238-250&amp;doi=10.1016%2Fj.jhep.2017.11.012&amp;pmid=29154966" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">34.</div><div id="core-r34" class="citations"><div class="citation"><div class="citation-content">Caldwell SH, Lee VD, Kleiner DE, et al. NASH and cryptogenic cirrhosis: a histological analysis. <em>Ann Hepatol</em> 2009;8:346-352.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r34"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/S1665-2681(19)31748-X" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/20009134/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000272586100009" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=NASH+and+cryptogenic+cirrhosis%3A+a+histological+analysis.&amp;publication_year=2009&amp;journal=Ann+Hepatol&amp;pages=346-352&amp;doi=10.1016%2FS1665-2681%2819%2931748-X&amp;pmid=20009134" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">35.</div><div id="core-r35" class="citations"><div class="citation"><div class="citation-content">Nascimbeni F, Bedossa P, Fedchuk L, et al. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. <em>J Hepatol</em> 2020;72:828-838.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r35"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jhep.2019.12.008" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/31862486/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000528847500013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Clinical+validation+of+the+FLIP+algorithm+and+the+SAF+score+in+patients+with+non-alcoholic+fatty+liver+disease.&amp;publication_year=2020&amp;journal=J+Hepatol&amp;pages=828-838&amp;doi=10.1016%2Fj.jhep.2019.12.008&amp;pmid=31862486" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">36.</div><div id="core-r36" class="citations"><div class="citation"><div class="citation-content">Konerman MA, Jones JC, Harrison SA. Pharmacotherapy for NASH: current and emerging. <em>J Hepatol</em> 2018;68:362-375.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r36"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.jhep.2017.10.015" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/29122694/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000423962300013" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Pharmacotherapy+for+NASH%3A+current+and+emerging.&amp;publication_year=2018&amp;journal=J+Hepatol&amp;pages=362-375&amp;doi=10.1016%2Fj.jhep.2017.10.015&amp;pmid=29122694" target="_blank">Google Scholar</a></div></div></div></div></div><div role="listitem" data-has="label"><div class="label">37.</div><div id="core-r37" class="citations"><div class="citation"><div class="citation-content">Hollenberg NK. Considerations for management of fluid dynamic issues associated with thiazolidinediones. <em>Am J Med</em> 2003;115:Suppl 8A:111S-115S.</div><div class="external-links"><div class="to-citation__wrapper"><a class="to-citation" href="#body-ref-r37"><i aria-hidden="true" class="icon-return"></i><span>Go to Citation</span></a></div><div class="core-xlink-crossref"><a href="https://doi.org/10.1016/j.amjmed.2003.09.018" target="_blank">Crossref</a></div><div class="core-xlink-pubmed"><a href="https://pubmed.ncbi.nlm.nih.gov/14678876/" target="_blank">PubMed</a></div><div class="core-xlink-isi"><a href="https://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&amp;DestApp=WOS_CPL&amp;UsrCustomerID=5e3815c904498985e796fc91436abd9a&amp;SrcAuth=atyponcel&amp;SrcApp=literatum&amp;DestLinkType=FullRecord&amp;KeyUT=000187311800019" target="_blank">Web of Science</a></div><div class="core-xlink-google-scholar"><a href="https://scholar.google.com/scholar_lookup?title=Considerations+for+management+of+fluid+dynamic+issues+associated+with+thiazolidinediones.&amp;publication_year=2003&amp;journal=Am+J+Med&amp;pages=111S-115S&amp;doi=10.1016%2Fj.amjmed.2003.09.018&amp;pmid=14678876" target="_blank">Google Scholar</a></div></div></div></div></div></div></div></div><aside data-core-aside="right-rail">



        
        <div id="DTM_Position_MedRectangle" class="ad">
 <!--emptycomment-->
</div>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="relatedArticlesWidget" data-widget-id="8206d5cd-cb8c-4ff9-8c46-3d22e0dee215" data-location="recirc_curatedRelated_article">
        



        
        <div class="ng-related-articles"><h3 class="ng-subsection-title"><span class="ng-subsection-title_text">Related articles</span></h3><ul class="ng-related-articles_list"><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Oct 20, 2021</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2029349" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">A.J. Sanyal and Others</span></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/editorial" class="issue-item_type">Editorial</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Oct 20, 2021</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMe2110989" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Nonalcoholic Steatohepatitis — Opportunities and Challenges</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">G. Garcia-Tsao</span></div></div></div></div></div></li><li class="ng-related-articles_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/correspondence" class="issue-item_type">Correspondence</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Jan 19, 2022</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMc2118255" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Nonalcoholic Fatty Liver Disease</a></h4><div class="issue-item_authors-and-text"></div></div></div></div></div></li></ul></div>

        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <div id="nejm_jobs" class="nejm_jobs"> <!-- top red rectangle --><div id="nejm-widget" class="nejm-widget" style="display: block;"><div class="nejm-widget_logo">	<a target="nejm-win" href="https://www.nejmcareercenter.org/?query=fjw">		<img alt="CareerCenter" src="https://apps1.nejmcareercenter.org/images/nejmCCID-JobsWidget.gif" width="140" height="36">	</a></div><div class="nejm-widget_cont"> <!-- content --><div class="nejm-widget_title">PHYSICIAN JOBS</div><div class="nejm-widget_date">June 10, 2025</div><div class="nejm-widget_item"><div><span> Missoula, Montana</span></div><div><span>Cardiology</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/883925/western-montana-cardiologist-opportunity-new-heart-center-minutes-from-outdoor-adventures/?query=fjwp&amp;rid=338868">Western Montana Cardiologist Opportunity, NEW Heart Center, Minutes from Outdoor Adventures</a></div></div><div class="nejm-widget_item"><div><span> West Roxbury, Massachusetts</span></div><div><span>Primary Care</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/878575/adult-primary-care-physician-internal-medicine-family-medicine-chestnut-hill-west-roxbury/?query=fjwp&amp;rid=980">Adult Primary Care Physician - Internal Medicine/Family Medicine - Chestnut Hill-West Roxbury</a></div></div><div class="nejm-widget_item"><div><span> Santa Rosa, California</span></div><div><span>Internal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/886952/physician-internal-medicine-hoen-/?query=fjwf&amp;rid=845674">Physician, Internal Medicine (Hoen)</a></div></div><div class="nejm-widget_item"><div><span> Texas</span></div><div><span>Internal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/889047/physician-internal-medicine-hospitalist/?query=fjwf&amp;rid=385607">Physician - Internal Medicine Hospitalist</a></div></div><div class="nejm-widget_item"><div><span> Glen Cove, New York</span></div><div><span>ENT / Head &amp; Neck Surgery</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/588782/northwell-health-otolaryngology-generalist-sleep-medicine/?query=fjwp&amp;rid=3059">Northwell Health Otolaryngology - Generalist / Sleep Medicine</a></div></div><div class="nejm-widget_item"><div><span> Philadelphia, Pennsylvania</span></div><div><span>Internal Medicine</span></div><div><a target="nejm-job-win" onmouseover="jlho(this);" onmouseout="jlou(this);" href="https://www.nejmcareercenter.org/job/886161/instructor/?query=fjwf&amp;rid=271428">Instructor</a></div></div></div> <!-- content --> <!-- footer --></div> <!-- nejm-widget --></div><script src="https://apps1.nejmcareercenter.org/?width=300&amp;sp=all"></script>




        
        <div class="ng-page_layout-sidebarSpacing"></div>










    
    
        <div data-widget-def="literatumAd" data-widget-id="001e4aa7-b6fe-4b21-9d5b-5bde81227c67" id="ad-article-right-rail-300x250-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <a href="/action/clickThrough?id=128743&amp;url=https%3A%2F%2Fstore.nejm.org%2Fsignup%2Fnejm%2Fregister%2Fnotablearticles2024%3Fpromo%3DONFQNAR4%26query%3Dcm-ra%26utm_source%3Dnejm%26utm_medium%3Dcm%26utm_campaign%3Dna24&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2036205&amp;pubId=41290485&amp;placeholderId=101337&amp;productId=1007"><img src="/sda/128743/rightRail--notable24_001.jpg" width="300" height="250"></a>
            
        </div>
    

    

    



        </div>
    





        
        <div class="ng-page_layout-sidebarSpacing"></div>




        
        <script src="https://widgets.nejm.org/onepub-widgets/loader/webcomponents-loader.js" async="" nonce="94d6a1b4040e8828-SJC">
<script src="https://widgets.nejm.org/onepub-widgets/loader/polyfill-support.js"  nonce="94d6a1b4040e8828-SJC"></script>
<script src="https://widgets.nejm.org/onepub-widgets/more-like-this.js" type="module" nonce="94d6a1b4040e8828-SJC"></script>

<more-like-this class="onepub-widget" dataid="onepub-more-like-this" collections="catalyst-article, clinician-article, evidence-article, nejm-ai-article, nejm-article" headertitle="More Like This" maxitems="5"><!----><div class="more-like-this onepub-more-like-this_"><!--?lit$654381221$--><onepub-fonts><wc-fetch></wc-fetch><!--?lit$654381221$--><div class="mlt-wrapper"><div class="mlt-header-container"><div class="mlt-header-content-left"><div class="mlt-header-title-container"><span class="mlt-header-title">More Like This</span></div><!--?lit$654381221$--></div></div><div class="mlt-body"><!--?lit$654381221$--><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$654381221$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$654381221$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$654381221$-->Aug 10, 2023</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2210054?query=recirc_Semantic" target="_self">Systemic Inflammation and Normocytic Anemia in DOCK11 Deficiency</a></div><div class="mlt-article-authors"><!--?lit$654381221$-->J. Block and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$654381221$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$654381221$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$654381221$-->Jul 25, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2401943?query=recirc_Semantic" target="_self">Tirzepatide for Metabolic Dysfunction–Associated Steatohepatitis with Liver Fibrosis</a></div><div class="mlt-article-authors"><!--?lit$654381221$-->R. Loomba and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$654381221$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$654381221$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$654381221$-->Jul 25, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2401755?query=recirc_Semantic" target="_self">A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis</a></div><div class="mlt-article-authors"><!--?lit$654381221$-->A.J. Sanyal and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$654381221$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$654381221$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$654381221$-->Feb 08, 2024</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2309000?query=recirc_Semantic" target="_self">A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis</a></div><div class="mlt-article-authors"><!--?lit$654381221$-->S.A. Harrison and Others</div></div><!----><!----><div class="mlt-article-container"><div class="mlt-article-container-header"><a data-location="recirc_Semantic" class="mlt-article-type nejm" href="https://www.nejm.org/browse/nejm-article-type/original-article" target="_self"><!--?lit$654381221$-->Original Article</a> <span class="mlt-article-site-label"><!--?lit$654381221$-->NEJM</span> <span class="mlt-article-pubdate"><!--?lit$654381221$-->Feb 20, 2025</span></div><div class="mlt-article-title"><a data-location="recirc_Semantic" href="https://www.nejm.org/doi/full/10.1056/NEJMoa2408835?query=recirc_Semantic" target="_self">Microvascular Inflammation of Kidney Allografts and Clinical Outcomes</a></div><div class="mlt-article-authors"><!--?lit$654381221$-->M. Sablik and Others</div></div><!----></div><div class="mlt-footer"></div></div></onepub-fonts><style>:host{display:block}@keyframes fadeIn{0%{opacity:0}100%{opacity:1}}.more-like-this{max-width:25rem}.more-like-this *{font-variant-numeric:lining-nums}.mlt-wrapper{animation:fadeIn 1s}.mlt-header-container{border-bottom:#4d4d4d solid .0625rem;border-top:#4d4d4d solid .125rem}.mlt-header-title{color:#1a1a1a;display:block;font-family:var(--sans-serif);font-size:1rem;font-weight:700;letter-spacing:.02rem;line-height:1.5rem;padding-bottom:.94rem;padding-top:.94rem;text-transform:uppercase}.mlt-header-description{color:#333;display:block;font-family:ff-scala-sans-pro;font-size:.75rem;letter-spacing:.05rem;margin-top:-.5rem;padding-bottom:1rem;text-transform:uppercase}.mlt-article-container{border-bottom:#e5e5e5 solid .0625rem;margin-top:1.38rem}.mlt-article-container-header{font-family:var(--sans-serif);font-size:.6875rem;letter-spacing:.04em;line-height:1.125rem;margin:0 0 1rem;text-transform:uppercase}.mlt-article-type{font-weight:700;line-height:1.25rem;letter-spacing:.04rem;text-decoration:none}.mlt-article-type:hover{text-decoration:underline}.nejm{color:#f30}.nejm-ai{color:#006197}.nejm-catalyst{color:#5708a6}.nejm-evidence{color:#69a323}.mlt-article-site-label::after,.mlt-article-type::after{border-right:1px solid #e5e5e5;content:'';display:inline;padding:.1875rem .375rem .125rem 0;margin:0 .375rem 0 0}.mlt-article-pubdate{color:#666;font-style:normal;font-weight:700;line-height:1.25rem;letter-spacing:.04em}.mlt-article-authors{color:#666;font-family:var(--sans-serif);font-size:1rem;font-style:normal;font-weight:400;letter-spacing:normal;line-height:1.5rem;margin-bottom:1.38rem}.mlt-article-site-label{color:#666;font-style:normal;font-weight:700;letter-spacing:.04em}.mlt-article-title{margin-bottom:.5rem}.mlt-article-title>a{background-image:linear-gradient(#f30,#f30);background-position:0 90%;background-repeat:no-repeat;background-size:0 0;color:#1a1a1a;font-family:var(--quadraat-web);font-size:1.25rem;font-style:normal;font-weight:700;letter-spacing:normal;line-height:1.8rem;margin:1.5rem 0 .35rem 0;text-decoration:none;transition:background .25s ease-in-out}.mlt-article-title>a:hover{background-position:0 98%;background-size:100% .125rem;text-decoration:none}.skeleton-card{box-shadow:0 0 4px 1px rgba(0,0,0,.1);margin:1rem 0;padding:1rem}</style></div></more-like-this>




        
        <div><div class="pb-dropzone" data-pb-dropzone="col-0" title="col-0"></div></div>










    
    
        <div data-widget-def="UX3HTMLWidget" data-widget-id="ad06db99-f228-4c92-9ad7-c4ae0fdbdbf1" id="bc-web-rec">
        



        
        <!-- BlueConic TEST empty HTML widget with DIV wrapper with id=bc-web-rec -->

        </div>
    

</aside></article><div data-extent="article-wrapper"><div class="core-container"></div><div class="after-credits"><div class="core-container"><a href="/doi/pdf/10.1056/NEJMoa2036205?download=true" id="downloadPdfUrl" data-doi="10.1056/NEJMoa2036205" data-behavior="trackDownloadEvent" data-interactiontype="article_tools_download_pdf" data-multimedia-type="Article PDF" data-multimedia-filename="nejmoa2036205.pdf"><span>Download PDF</span></a></div></div></div><script id="axel-publication-metadata" type="application/json">{"doi":"10.1056/NEJMoa2036205"}
</script><script type="text/javascript" data-ot-ignore="data-ot-ignore" defer="defer" src="https://static.addtoany.com/menu/page.js" class="optanon-category-C0004 ot-vscat-C0004"></script><div class="articles-nav"></div><template id="figure_nav_template"><nav><a href="#" title="Open in viewer" class="open-in-viewer"><i aria-hidden="true" class="icon-expand"></i></a></nav></template><template id="fv_panel_template" data-sharesocial="Share"><div class="fv__panel js--hidden"><div class="fv__panel__text"><div class="fv__panel__contentTitle"></div><div class="fv__panel__contentText"></div></div></div></template>
<template id="fv_directory_template" data-overlay="View figure"><div class="fv__directory"><div class="fv__header"><nav class="tab__nav"></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"></div></div></template><template id="fv_directory_tabItem_template" data-figures="Figures" data-others="Others" data-tables="Tables"><button role="tab" data-toggle="tab" class="tab__nav__item"></button></template>
<template id="fv_lightbox_template" data-sr-back="Go to figure location within the article" data-sr-closealt="Close" data-sr-download="Toggle download panel" data-sr-download-pptx="Download PPT" data-sr-info="Toggle information panel" data-sr-panel="Close panel" data-sr-share="Toggle share panel" data-sr-zoom="Zoom" data-text-close="Back to article" data-text-nav-figures="All figures" data-text-nav-others="All others" data-text-nav-tables="All tables" data-text-viewall="View all material" data-title-back="Back to article" data-title-closealt="Close" data-title-download="Download" data-title-download-pptx="Download PPT" data-title-info="Info" data-title-share="Share" data-title-zoom="Zoom"></template>
<template id="fv_toolbar_template"><div class="fv__toolbar__info"><strong class="fv__toolbar__contentTitle uppercase"></strong><p class="fv__toolbar__contentText"></p></div></template><template id="toCitationLink" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></a></div></template><template id="toCitationButton" data-citation="Citation" data-footnote="Footnote"><div class="to-citation__wrapper"><button class="to-citation"><i aria-hidden="true" class="icon-return"></i><span>Go to</span></button></div></template><template id="toCitationAccordion" data-collapse-citation="Hide Citations" data-expand-citation="Show Citations" data-collapse-footnote="Hide Footnotes" data-expand-footnote="Show Footnotes"><div class="to-citation__wrapper"><button aria-controls="aria-controls" aria-expanded="false" aria-label="Toggle citations menu" class="to-citation__toggle"><i aria-hidden="true" class="icon-plus"></i><span data-expand-title="data-expand-title" data-collapsed-title="data-collapsed-title" class="accordion__toggle__title"></span></button><div role="menu" aria-label="links" class="to-citation__accordion no-separator"><ul></ul></div></div></template><template id="toCitationAccordionItem"><li><a class="to-citation"><i aria-hidden="true" class="icon-return"></i><span></span></a></li></template><template id="citations_truncate_template"><div class="citations-truncation"><button data-label-expand="Show all references" data-label-collapse="Show fewer" data-label-remaining="references remaining" class="btn btn--secondary"><span>Show all references</span></button></div></template><template id="collateral_texts_template" data-references="References" data-figure="Go to Figure" data-media="Go to Media" data-more="More" data-original="Go to original" data-table="Go to Table" data-inviewer="Open in Viewer" data-allinviewer="Open all in viewer"><svg data-tags="copyright" viewBox="0 0 24 24"><path d="M12 20.016q3.281 0 5.648-2.368T20.016 12t-2.368-5.648T12 3.984 6.352 6.352 3.984 12t2.368 5.648T12 20.016zm0-18q4.125 0 7.055 2.93T21.985 12t-2.93 7.055T12 21.985t-7.055-2.93T2.015 12t2.93-7.055T12 2.015zm-.14 7.125q-1.876 0-1.876 2.718v.282q0 2.718 1.875 2.718.704 0 1.172-.398t.469-1.008h1.781q0 1.172-1.031 2.063-.984.843-2.39.843-1.876 0-2.86-1.125t-.984-3.093v-.282q0-1.921.937-3 1.125-1.265 2.906-1.265 1.547 0 2.438.89.984.985.984 2.297H13.5q0-.328-.14-.61-.235-.468-.329-.562-.469-.468-1.172-.468z"></path></svg><span>Request permissions</span><i aria-hidden="true" class="icon-open_in_new"></i></template><template id="collapsible_authors_template"><button aria-expanded="false" data-expandable="all" data-label-expand="Expand All" data-label-collapse="Collapse All" class="collateral-contributors-control"><span>Expand All</span></button></template>
<template id="collapsible_tables_collapse_template"><div class="collapsible-figure-btn__wrapper expanded"><button aria-expanded="true" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-up"></i><span class="text-uppercase">Collapse</span></button></div></template>
<template id="collapsible_tables_expand_template"><div class="collapsible-figure-btn__wrapper collapsed"><button aria-expanded="false" class="btn collapsible-figure-btn btn--inverse"><i aria-hidden="true" class="icon-arrow-down"></i><span class="text-uppercase">Expand Table</span></button></div></template><template id="authorsAffiliationsLink"><a href="#tab-contributors" class="to-authors-affiliations">Authors Info &amp; Affiliations</a></template>

        <div role="navigation" aria-label="Sticky Navigation" class="st-header"><div class="st-header__content"><div class="st-header__item st-header__menu"></div><div class="st-header__current st-header__item"><div class="st-header__label">Now Reading:</div><div class="st-header__title">A Randomized, Controlled Trial of the Pan-PPAR Agonist Lanifibranor in NASH</div></div><div class="st-header__share st-header__item"><div class="share-dropblock dropdown"><a id="sticky-header-dropBlock" href="#" role="button" data-toggle="dropdown" aria-haspopup="true" aria-expanded="false" class="dropdown-toggle"><span title="" data-toggle="tooltip" data-trigger="hover" data-original-title="Share options"><span class="sr-only">Share</span><i aria-hidden="true" class="icon-share"></i></span></a><div aria-labelledby="sticky-header-dropBlock" data-location="share_tools_article" class="dropdown-menu"><ul class="rlist--inline a2a a2a_kit" style="line-height: 16px;"><li><a href="/#facebook" aria-label="Share on Facebook" data-id="article-share-facebook" rel="nofollow noopener" role="link" target="_blank" title="Share on Facebook" class="btn btn--facebook a2a_button_facebook" data-interactiontype="social"><i aria-hidden="true" class="icon-facebook"></i></a></li><li><a href="/#twitter" aria-label="Share on X (formerly Twitter)" data-id="article-share-twitter" rel="nofollow noopener" role="link" target="_blank" title="Share on X (formerly Twitter)" class="btn btn--twitter a2a_button_twitter" data-interactiontype="social"><i aria-hidden="true" class="icon-twitter"></i></a></li><li><a href="/#linkedin" aria-label="Share on LinkedIn" data-id="article-share-linkedin" rel="nofollow noopener" role="link" target="_blank" title="Share on LinkedIn" class="btn btn--linkedin a2a_button_linkedin" data-interactiontype="social"><i aria-hidden="true" class="icon-linkedin"></i></a></li><li><a href="/#email" aria-label="Share on email" data-id="article-share-email" rel="nofollow noopener" role="link" target="_blank" title="Share on email" class="btn btn--email a2a_button_email" data-interactiontype="content_email_click"><i aria-hidden="true" class="icon-mail"></i></a></li><li><a href="/#bluesky" aria-label="Share on Bluesky" data-id="article-share-bluesky" rel="nofollow noopener" role="link" target="_blank" title="Share on Bluesky" class="btn btn--bluesky a2a_button_bluesky" data-interactiontype="social"><i aria-hidden="true" class="icon-bluesky"></i></a></li></ul></div></div></div><div class="st-header__nav st-header__item"><div class="content-navigation"><a href="/doi/full/10.1056/NEJMp2113422" aria-label="Previous article" aria-disabled="false" class="content-navigation__prev"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>PREVIOUS ARTICLE</h6><div>Peak Moments — When Kindergarten Is High Risk</div></div></div><i aria-hidden="true" class="icon-arrow-left"></i><span>Previous</span></a><a href="/doi/full/10.1056/NEJMoa2029349" aria-label="Next article" aria-disabled="false" class="content-navigation__next"><div aria-hidden="true" class="content-navigation__hint"><div class="content-navigation__hint__content"><h6>NEXT ARTICLE</h6><div>Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease</div></div></div><span>Next</span><i aria-hidden="true" class="icon-arrow-right"></i></a></div></div></div><div class="st-header__track"><div id="progress-tracker" class="st-header__tracker" style="width: 0px;"></div></div></div><div class="fv figureViewer js--has-focus-mode"><div class="fv__directory" data-core-tabs="default" style="display: flex;"><div class="fv__header"><nav class="tab__nav" role="tablist"><button role="tab" data-toggle="tab" class="tab__nav__item active" aria-controls="#tab-pane-figures" aria-selected="true">Figures</button><button role="tab" data-toggle="tab" class="tab__nav__item" aria-controls="#tab-pane-tables" tabindex="-1" aria-selected="false">Tables</button></nav><a href="#" title="Close figure viewer" class="fv__close"><i aria-hidden="true" class="icon-close"></i></a></div><div class="fv__content tab__content"><div class="tab__pane fv__list fv__list--figures" id="tab-pane-figures" aria-label="All figures" tabindex="0" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f0" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2036205_f0.jpg"><img src="/cms/10.1056/NEJMoa2036205/asset/a58cb036-8840-44da-9a72-6e144a75ed7a/assets/images/large/nejmoa2036205_f0.jpg" height="3416" width="2640" aria-labelledby="f0" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title"></div><div class="fv__item__description"><figcaption>Download a PDF of the <a href="#ap0">Research Summary</a>.</figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view fv__fit" href="#fv-f1" data-type="figures" data-interactiontype="multimedia_click" data-multimedia-type="Figure" data-multimedia-filename="nejmoa2036205_f1.jpg"><img src="/cms/10.1056/NEJMoa2036205/asset/e1e19e7c-f802-4ca6-b949-9a3d304d32fe/assets/images/large/nejmoa2036205_f1.jpg" height="1307" width="2640" aria-labelledby="f1" loading="lazy"><span class="fv__fit--overlay"><span>View figure</span></span></a><div class="fv__item__title">Figure 1</div><div class="fv__item__description"><figcaption><div class="caption">Response for Primary and Secondary Histologic End Points at Week 24.</div><div class="notes"><div role="doc-footnote">Analyses were performed with multiple imputation of missing data. Risk ratios, 95% confidence intervals, and P values were calculated with the Cochran–Mantel–Haenszel test stratified according to diabetic status at baseline. In the analysis of the primary end point, an ascending Hochberg procedure was used to adjust for multiplicity testing (each dose of lanifibranor was compared with placebo). Missing data for the 34 patients in the full analysis population (11 in the 800-mg lanifibranor group, 9 in the 1200-mg lanifibranor group, and 14 in the placebo group had missing biopsy samples at week 24) were handled with multiple imputation (details are provided in the <a href="#ap2">Supplementary Appendix</a>). The Steatosis, Activity, Fibrosis–Activity (SAF-A) score represents the activity part of the SAF scoring system that incorporates the scores for hepatocellular ballooning and lobular inflammation; SAF-A scores range from 0 to 4, with higher scores indicating more-severe disease activity. NASH denotes nonalcoholic steatohepatitis.</div></div></figcaption></div></div></div><div class="tab__pane fv__list fv__list--tables" id="tab-pane-tables" aria-label="All tables" tabindex="-1" role="tabpanel"><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t1" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 1</div><div class="fv__item__description"><figcaption><div class="caption">Demographic and Clinical Characteristics of the Patients at Baseline (Full Analysis Population).<a href="#fv-t1fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t2" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 2</div><div class="fv__item__description"><figcaption><div class="caption">Laboratory Measures at Week 24 among the Patients in the Full Analysis Population Who Completed the Trial.<a href="#fv-t2fn1" role="doc-noteref">*</a></div></figcaption></div></div><div class="fv__item"><a class="fv__open-item fv__item__view" href="#fv-t3" data-type="tables" data-interactiontype="multimedia_click" data-multimedia-type="Table"><i class="icon-tables"></i></a><div class="fv__item__title">Table 3</div><div class="fv__item__description"><figcaption><div class="caption">Overview of Adverse Events That Occurred during the Treatment Period (Full Analysis Population).<a href="#fv-t3fn1" role="doc-noteref">*</a></div></figcaption></div></div></div></div></div></div><div class="references-pop-up fade" aria-hidden="true"><div class="references-pop-up__heading text-dark d-flex align-items-center"><div class="references-pop-up__title flex-grow-1">Reference <span class="references-pop-up__heading-number">1</span></div><a class="references-pop-up__close text-dark" href="#" title="close pop-up" tabindex="-1" aria-hidden="true"><i class="icon-close" aria-hidden="true"></i></a></div><div class="references-pop-up__items citations to-citation__accordion external-links"></div></div></main>
    

</div>

                    
                        



        
        <div class="ng-page_layout ng-page_layout-fullWidth"><div class="container-fluid"><div class="row"><div class="col-12">



        
        




        
        <div class="ng-page_layout-contentSpacing"></div>










    
    
        <div data-widget-def="oneSearchMultiSearch" data-widget-id="778b3ad8-1a8d-43d8-8196-63b03df4a138" data-location="recirc_inIssue_bottom_article">
        



        
        <div class="os-ms os-ms-more-from-issue"><h3 class="ng-subsection-title"><a href="/toc/nejm/385/17" class="ng-subsection-title_link animation-icon-shift"><span class="ng-subsection-title_text">More from Vol. 385 No. 17</span><span class="ng-subsection-title_icon"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-longArrowRight"></use></svg></span></span></a></h3><ul class="os-ms-more-from-issue_list"><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Oct 21, 2021</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2034279" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline"><em>AQP1</em> Promoter Variant, Water Transport, and Outcomes in Peritoneal Dialysis</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J. Morelle and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/original-article" class="issue-item_type">Original Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Oct 21, 2021</span></li><li data-toggle="tooltip" data-original-title="Video" class="issue-item_meta-item"><span role="img" aria-label="Video" tabindex="0" class="issue-item_video"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#tooltip-video"></use></svg></span></span></li><li class="issue-item_meta-item"><span class="issue-item_free">FREE</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMoa2103329" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Obesity-Associated <em>GNAS</em> Mutations and the Melanocortin Pathway</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">E. Mendes de Oliveira and Others</span></div></div></div></div></div></li><li class="os-ms-more-from-issue_item"><div class="issue-item issue-item_sm"><div class="issue-item_meta"><ul class="issue-item_meta-list clearfix"><li class="issue-item_meta-item"><a href="/browse/nejm-article-type/review-article" class="issue-item_type">Review Article</a></li><li class="issue-item_meta-item"><span class="issue-item_date">Oct 21, 2021</span></li></ul></div><div class="issue-item_row"><div class="issue-item_left"><div class="issue-item_content clearfix"><h4 class="issue-item_title"><a href="/doi/full/10.1056/NEJMra1916062" data-interactiontype="article_recirculation_click" class="issue-item_title-link animation-underline">Point-of-Care Ultrasonography</a></h4><div class="issue-item_authors-and-text"><span class="issue-item_authors">J.L. Díaz-Gómez, P.H. Mayo, and S.J. Koenig</span></div></div></div></div></div></li></ul></div>

        </div>
    

</div></div></div></div>

                    
                        



        
        <div class="ng-page_layout-bottomAd"><div class="container-fluid"><div class="row"><div class="col-12">









    
    
        <div data-widget-def="literatumAd" data-widget-id="7e022d0d-4a48-44a7-af66-033cf5c13eb8" id="ad-article-bottom-FULLx320-1">
        



        
        



    
        <div class="pb-house-message adplaceholder exists">
            <!-- START: Circulation Footer 3 -->
<aside class="g-cta-subscribe">
	<style>
.bads_footer-banner24-ONJQNRF1{background:url(/pb-assets/contextual_messaging/footer-yel-background-2x-1513629627453.jpg) center center no-repeat;padding:20px;display:block;margin:0;min-height:inherit;background-size:cover;text-decoration:none!important;color:#1a1a1a;text-align:left}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:42px;line-height:44px;letter-spacing:.2px;margin:0 0 20px;font-family:ff-quadraat-web-pro,sans-serif;font-weight:600}.bads_footer-banner24-ONJQNRF1-inner{max-width:1300px;margin:0 auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions .a-btn{width:130px;padding-left:12px}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{position:static;color:#000;font-size:18px;line-height:27px;border:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:20px 0 20px 0;list-style-type:none;padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login a{color:#0a68ad}.bads_clearfix:after{visibility:hidden;display:block;font-size:0;content:" ";clear:both;height:0}.bads_clearfix{display:block}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{float:left;width:50%;padding:30px 0}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{float:left;padding-left:30px;width:50%}.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{display:block;max-width:100%;height:auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:18px;text-transform:uppercase;line-height:24px;font-weight:600;margin:-15px 0 0;letter-spacing:.2px}@media only screen and (max-width:480px){.bads_footer-banner24-ONJQNRF1-inner .bads_device-img,.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{width:100%;float:none}.bads_footer-banner24-ONJQNRF1-inner .bads_device-img{padding-left:0}.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:27px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding-top:0;padding-bottom:0}.bads_footer-banner24-ONJQNRF1{height:auto}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__actions{margin:0 0 12px;list-style-type:none}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{line-height:25px;font-size:15px;margin-bottom:10px}.bads_footer-banner24-ONJQNRF1 .bads_device-img{width:280px!important;margin:0 auto}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 3px;font-size:14px}}@media only screen and (min-width:480px) and (max-width:1024px){.bads_footer-banner24-ONJQNRF1 .g-cta-subscribe__title{font-size:20px;line-height:30px;margin-bottom:15px}.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:0}.bads_footer-banner24-ONJQNRF1-inner .g-cta-subscribe__login{font-size:14px}.bads_footer-banner24-ONJQNRF1 .bads_h5{font-size:13px;margin-top:0}}@media only screen and (min-width:1025px) and (max-width:1200px){.bads_footer-banner24-ONJQNRF1-inner .bads_subs-btn{padding:10px 0}.bads_footer-banner24-ONJQNRF1 .bads_h5{margin:0 0 5px}}@media only screen and (min-width:1401px){.bads_footer-banner24-ONJQNRF1 .bads_device-img>img{float:right}}
	</style>
	<div class="bads_footer-banner24-ONJQNRF1">
	  <div class="bads_footer-banner24-ONJQNRF1-inner bads_clearfix">
		 <div class="bads_subs-btn">
			<p class="g-cta-subscribe__title">Tap into groundbreaking research and clinically relevant insights</p>
			<ul class="g-cta-subscribe__actions">
				<li class="g-cta-subscribe__actions-primary">
				  <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dsubscribe%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2036205%26promo%3DONFQNRF1&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2036205&amp;pubId=41290485&amp;placeholderId=101336&amp;productId=1035" class="ng-btn_primary ng-btn_iconRight"><span class="ng-btn_text">Subscribe </span><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#arrows-longArrowRight"></use></svg></span></a>
				</li>
			</ul>
			<p class="g-cta-subscribe__login">Already a subscriber? <a href="/action/clickThrough?id=127716&amp;url=%2Faction%2FstoreProxy%3Faction%3Dactivate%26url%3Dhttps%253A%252F%252Fwww.nejm.org%252Fdoi%252Ffull%252F10.1056%252FNEJMoa2036205%26promo%3DONFQANR4&amp;loc=%2Fdoi%2Ffull%2F10.1056%2FNEJMoa2036205&amp;pubId=41290485&amp;placeholderId=101336&amp;productId=1035">Activate</a> your online access.</p>
		 </div>

		<div class="bads_device-img">
		   <img src="/sda/127716/footer-devices-2x.png" alt="Devices">
		</div>
	   </div>
	</div>
</aside>
<!--/END: Circulation Footer 3 -->
            
        </div>
    

    

    



        </div>
    

</div></div></div></div>

                    
                        



        
        <footer class="ng-footer footer__top" style="position: relative;"><div data-location="footer" class="ng-footer_columns"><div class="container-fluid"><div class="row"><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">ARTICLE CATEGORIES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item">
        <a href="/browse/nejm-article-category/research" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Research</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/review" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reviews</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/clinical-cases" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Clinical Cases</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/perspective" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Perspective</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/commentary" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Commentary</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/browse/nejm-article-category/other" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Other</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/medical-article-index" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Browse all Articles</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/toc/nejm/current" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Current Issue</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/loi/nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Issue Index</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">RESOURCES</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Authors &amp; Reviewers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/author-center/home" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Submit a Manuscript</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Subscribers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://tools.ovid.com/ovidtools/nejm.html" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Administrators</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/media" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Media</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/how-to-advertise" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertisers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/information-for-subscription-agents" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Agents</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/permissions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Permissions &amp; Licensing</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/reprints" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Reprints</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a>
    </li>
</ul>
</div></div></div><div class="col-lg-4 col-md-6 col-sm-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="About us">ABOUT US</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/about-nejm/about-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">About NEJM</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmgroup.org/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM Group</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Products &amp; Services</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/editors-and-publishers" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Editors &amp; Publishers</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/advertising-policies" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Advertising Policies</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/contact-nejm" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text" aria-label="Contact us">Contact Us</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions?#Accessibility" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Accessibility</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/frequently-asked-questions" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">FAQs</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/help" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Help</span></a></li>
    <li class="ng-footer_column-list-item"><a href="mailto:sitefeedback@nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Site Feedback</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">SUBSCRIPTIONS</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=subscribe&amp;promo=ONF4NRS3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Subscribe</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=renew&amp;product=nejm&amp;promo=ONFLNRR3&amp;prc=ONFARN52" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Renew</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=activate&amp;promo=ONFLNAA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Activate Subscription</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC4" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Manage Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=paybill&amp;product=nejm&amp;promo=BNFLPBA1" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Pay Bill</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.wolterskluwer.com/en/solutions/ovid/nejm-complete-collection" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Institutional Sales</span></a></li>    
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/special-content" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Special Content</span></a></li>
</ul>
</div></div></div><div class="col-lg-4 col-md-12 ng-footer_column"><div class="row"><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title">STAY CONNECTED</h4>
<ul class="ng-footer_column-list">
    <li class="ng-footer_column-list-item"><a href="https://myaccount.nejm.org/emails?section=NEJM" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Email Alerts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/action/storeProxy?action=register&amp;promo=ONFLNRC3" class="ng-footer_column-link animation-underline ro-mode_disabled"><span class="ng-footer_column-link-text">Create Account</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/products-and-services" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Apps</span></a></li>
    <li class="ng-footer_column-list-item"><a href="https://www.nejmcareercenter.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">NEJM CareerCenter</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Podcasts</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/rss-feed/" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">RSS Feed</span></a></li>
    <li class="ng-footer_column-list-item"><a href="/about-nejm/institutional-access" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-text">Remote Access</span></a></li>
</ul>
</div><div class="col-6 ng-footer_column-nested">



        
        <h4 class="ng-footer_column-title" aria-label="Follow us">FOLLOW US</h4>
<ul class="ng-footer_column-list">
<li class="ng-footer_column-list-item"><a href="https://www.facebook.com/TheNewEnglandJournalofMedicine" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-facebook"></use></svg></span></span><span class="ng-footer_column-link-text">Facebook</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://twitter.com/nejm" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-twitter"></use></svg></span></span><span class="ng-footer_column-link-text">X (formerly Twitter)</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.instagram.com/nejm/" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-instagram"></use></svg></span></span><span class="ng-footer_column-link-text">Instagram</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.youtube.com/user/NEJMvideo" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-youtube"></use></svg></span></span><span class="ng-footer_column-link-text">Youtube</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.linkedin.com/company/nejm-group" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-linkedin"></use></svg></span></span><span class="ng-footer_column-link-text">LinkedIn</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://bsky.app/profile/nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-bluesky"></use></svg></span></span><span class="ng-footer_column-link-text">Bluesky</span></a></li>
<li class="ng-footer_column-list-item"><a href="https://www.tiktok.com/@nejm.org" target="_blank" rel="noopener" class="ng-footer_column-link animation-underline"><span class="ng-footer_column-link-icon"><span class="icon-component"><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#social-tiktok"></use></svg></span></span><span class="ng-footer_column-link-text">TikTok</span></a></li>
</ul>
</div></div></div></div></div></div><div data-location="footer" class="ng-footer_journals"><div class="container-fluid"><div class="row"><div class="col-12">



        
        <h4 class="ng-footer_journals-label">JOURNALS</h4>
<ul class="ng-footer_journals-list">
<li class="ng-footer_journals-item"><a href="https://www.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">The New England Journal of Medicine</a></li>
<li class="ng-footer_journals-item"><a href="https://catalyst.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Catalyst Innovations in Care Delivery</a></li>
<li class="ng-footer_journals-item"><a href="https://evidence.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM Evidence</a></li>
<li class="ng-footer_journals-item"><a href="https://ai.nejm.org/" target="_blank" rel="noopener" class="ng-footer_journals-link">NEJM AI</a></li>
</ul>
</div></div></div></div><div data-location="legal" class="ng-footer_bottom"><div class="container-fluid"><div class="row"><div class="col-lg-7 col-md-6 ng-footer_bottom-left">



        
        <p>Copyright © 2025 <a href="https://www.massmed.org/" target="_blank" rel="noopener" class="ng-footer_bottom-link"><b>Massachusetts Medical Society</b></a>. All rights reserved, including those for text and data mining, AI training, and similar technologies. Electronic ISSN 1533-4406. Print ISSN 0028-4793.The content of this site is intended for health care professionals.</p>
</div><div class="col-lg-5 col-md-6 ng-footer_bottom-right">



        
        <style>
  #teconsent a {
    color: #666;
    text-decoration: none;
  }
  #teconsent a:hover {
    color: #666;
    text-decoration: underline;
  }
</style>
<ul class="ng-footer_bottom-list">
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/copyright-information.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Copyright</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/terms-of-use.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Terms</a></li>
<li class="ng-footer_bottom-list-item"><a href="https://www.nejmgroup.org/legal/privacy-policy.htm" target="_blank" rel="noopener" class="ng-footer_bottom-link">Privacy Policy</a></li>
<li class="ng-footer_bottom-list-item"><span id="teconsent" consent="undefined" aria-label="Open Cookie Preferences Modal" role="complementary"><a role="link" id="icon-id06019573689471068" tabindex="0" lang="en" aria-haspopup="dialog" aria-label="Cookie Preferences, opens a dedicated popup modal window" class="truste_cursor_pointer">Cookie Preferences</a></span></li>
</ul>
<a href="https://www.nejmgroup.org/" title="NEJM Group" target="_blank" rel="noopener" class="ng-footer_logo-link"><img src="/specs/products/mms-nextgen/mms/releasedAssets/images/other-images/logo_group.svg" alt="NEJM Group logo" class="ng-footer_logo" loading="lazy" width="103" height="40"></a>
</div></div></div></div><div data-show-after="400" class="back-to-top back-to-top--align-right  "><button data-snap="footer__top" class="back-to-top__action position-relative p-0 m-0 border-0 d-flex flex-column align-items-center justify-content-center"><svg viewBox="0 0 36 36" class="position-relative"><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" class="back-to-top__action__ring-bg"></path><path d="M18 2.0845 a 15.9155 15.9155 0 0 1 0 31.831 a 15.9155 15.9155 0 0 1 0 -31.831" stroke-dasharray="0, 100" class="back-to-top__action__ring"></path></svg><span class="back-to-top__action-icon position-absolute d-flex"><span class="icon-component "><svg aria-hidden="true" style=""><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons-3acb348e68a3edd0c676698e8d598c68.spritemap.svg#arrows-up"></use></svg></span></span><span class="sr-only">Back to top</span></button></div></footer>

                    
                        



        
        <!-- TrustArc: Banner -->
<div id="consent_blackbar"><style>  #consent_blackbar{    position:relative;    width:100%;    z-index: 999999;  }    #trustarc-banner-overlay {  background-color: rgb(0, 0, 0);   opacity: 0.3;   position: fixed;   z-index: 1000000;   width: 100%;  height: 100%;   top: 0px;   left: 0px;   overflow: hidden;}.truste-title {  /*font-family: "Source Sans Pro", sans-serif;  font-size: 23px;  font-style: normal;  font-stretch: normal;*/  color: #222;  margin-bottom: 20px;  text-align: center;/*  font-weight:bold;*/}.truste-footer {  margin: 0 auto;      }.truste-left {  margin: 0px 0px 15px 15px;/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;    */}.truste-banner { margin: 0 auto; }.truste-messageColumn {/*font-family: "Source Sans Pro", sans-serif;  font-size: 14px;*/  color: #666666;  margin: 0px;}#truste-consent-button, #truste-consent-required {    background-color: #FF1E00;    color: #F2F1F1;    padding: 5px 10px;    border: 1px solid #FF1E00;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }      #truste-show-consent {    background-color: #FF1E00;    color: #F2F1F1;    border: 1px solid #FF1E00;    padding: 5px 10px;    border-radius: 0px;    cursor: pointer;    text-transform:uppercase;/*    font-family: "Source Sans Pro",sans-serif;    font-size: 15px;*/  }div.truste-consent-track-class {  position: fixed;  z-index:9999999;   background: #666;   border: 1px solid #333;    /*padding: 10px 60px;*/    bottom:0px;    right:0px;    left:0px;    margin: 10px;}.truste-left {  margin: 0;}div.text-content {  display: flex;  flex-direction: column;  align-self: baseline;}#truste-consent-text {    /*font-family: "Source Sans Pro", sans-serif;    font-size: 16px;*/    color: #fff;    margin: 15px 0px;}.truste-footer {  padding-top: 15px;}#truste-consent-content {  margin: 0 auto;    padding: 0 10px;    max-width: 1366px;}.truste-consent-footer {  display: none;}.flex-container {  display: block;  align-items: center;  justify-content: space-between;}#truste-consent-buttons {  float: right;  margin: 10px 5px 10px 0px;}#truste-show-consent { background: #F30 !important;}#truste-consent-button, #truste-consent-required { background: #F30 !important; } /* MEDIA QUERIES */  @media screen and (max-width: 500px) {  #truste-consent-track {    padding: 5px 20px;  }  }@media screen and (max-width: 375px) {  .truste-buttonsColumn {    float: none;    margin: 0;  }  #truste-consent-button, #truste-consent-required, #truste-show-consent {    width: 100%;    margin-bottom: 5px;  }          #truste-consent-buttons {  float: none;  margin: 10px 0px 10px 0px;	}}</style><div id="truste-consent-track" style="display: block; opacity: 1;">  <div id="trustarc-banner-overlay"></div>  <div class="truste-consent-track-class">    <div id="truste-consent-content" class="truste-banner">        <div class="flex-container">          <div class="text-content">            <div id="truste-consent-text" class="truste-messageColumn">This site uses cookies and related technologies, as described in our privacy policy, for purposes that may include site operation, analytics, enhanced user experience, or advertising. You may choose to consent to our use of these technologies, or manage your own preferences.                       </div>          </div>          <div id="truste-consent-buttons" class="truste-buttonsColumn">            <button id="truste-show-consent" aria-haspopup="dialog">Manage Settings</button>      <button id="truste-consent-button">Accept</button>      <!-- <button id="truste-consent-required">Decline All</button> -->          </div>        </div>                <div style="clear:both;"></div>    </div>  </div></div><!--emptycomment--></div>
<!-- /TrustArc: Banner -->

                    
                        



        
        <link rel="stylesheet" href="https://cssjs.nejm.org/mmsWidgets.css"><script nonce="94d6a1b4040e8828-SJC" type="text/javascript" src="https://cssjs.nejm.org/mmsWidgets.js"></script><script nonce="94d6a1b4040e8828-SJC" type="text/javascript">var litSSO = {
    "ucid": null,
    "accessToken": null,
    "authState": null
};

var loginUri = '/action/doSsoLogin';
var logoutUri = '/action/doLogout';

displayAuthenticatedMessage();

mmsWidgets.init({
    clientId: 'qsra7g4d6jwdsgn3zbe6udp6r6278mr9',
    origin: 'NEJM',
    xdReceiver: 'http://www.nejm.org/pb-assets/sso/xd.html',
    isFullPageSignIn: isSignInPage(),
    debug: true,

    onReady: function (e) {
        console.log('<<<<<<<<<< client: received onReady event.');
        $("A.litSsoLogin").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0) {
                mmsWidgets.signIn(e);
                return false;
            }
        });
        $("A.litSsoLogout").click(function (e) {
            mmsWidgets.signOut(e);
            return false;
        });
        $("A.litSsoCreate").click(function (e) {
            mmsWidgets.showRegModal(e);
            return false;
        });
        $("A.litSsoSubscribe").click(function (e) {
            if (!$(e.currentTarget).hasClass("noMd") || $(e.currentTarget).parents(".header_sm-login").length === 0)
                location.assign(e.currentTarget.href);
            return false;
        });
        if (window.doSSOLogin) {
            window.setTimeout(function () {
                mmsWidgets.signIn();
            }, 500);
        }
        ;
    },
    onLoginSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLoginSuccess event.' + JSON.stringify(e));

        const redirectUrl = getRedirectUri(window.location.search, location.href.replace(window.location.origin, ""));
        document.cookie = "skipSso=; expires=; path=/";
        if (!litSSO.ucid || e.ucid != litSSO.ucid || !litSSO.accessToken || e.accessToken != litSSO.accessToken) {
            location.assign(loginUri + "?ucid=" + e.profile.ucid
                + "&accessToken=" + e.accessToken
                + "&authState=" + e.authState
                + "&email=" + encodeURIComponent(e.profile.email)
                + "&givenNames=" + e.profile.givenName
                + "&surname=" + e.profile.familyName
                + "&redirectUri=" + redirectUrl
                + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                + "&rememberMe=" + e.rememberMe);
        }
    },
    onAuthStateReady: function (e) {
        console.log('<<<<<<<<<< client: received onAuthStateReady event.' + JSON.stringify(e))

        var isMmsSsoAuthenticated = (e.authState && e.authState !== "anonymous" && e.authState !== "lead" && e.ucid && e.accessToken) ? true : false;
        var isLitSsoAuthenticated = (litSSO.ucid && litSSO.accessToken && litSSO.authState) ? true : false;
        console.log('           isMmsSsoAuthenticated=' + isMmsSsoAuthenticated + ', isLitSsoAuthenticated=' + isLitSsoAuthenticated);

        if (isMmsSsoAuthenticated) {
            if (!isLitSsoAuthenticated || litSSO.ucid != e.ucid) {
                if (window.skipSso)
                    document.cookie = "skipSso=" + encodeURIComponent(e.ucid) + "; expires=; path=/";

                if (!window.skipSso && document.cookie.indexOf("skipSso=" + encodeURIComponent(e.ucid)) == -1) {
                    location.assign(loginUri + "?ucid=" + e.profile.ucid
                        + "&accessToken=" + e.accessToken
                        + "&authState=" + e.authState
                        + "&email=" + encodeURIComponent(e.profile.email)
                        + "&givenNames=" + e.profile.givenName
                        + "&surname=" + e.profile.familyName
                        + "&redirectUri=" + location.href.replace(window.location.origin, "")
                        + "&uccLastUpdatedDate=" + encodeURIComponent(e.profile.uccLastUpdatedDate)
                        + "&rememberMe=" + e.rememberMe);
                } else
                    console.log('**** client: Skip SSO ****');
            } else if (e.accessToken !== litSSO.accessToken)
                updateLitSession(e.ucid, e.accessToken);
        } else if (isLitSsoAuthenticated)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));

        if (document.getElementById("ssoerr-ucid"))
            document.getElementById("ssoerr-ucid").innerHTML = e.ucid;

    },
    onRegistrationSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onRegistrationSuccess event.' + JSON.stringify(e))
        document.cookie = "skipSso=; expires=; path=/";
        var uccLastUpdatedDate = '1812-01-01 00:00:00.1 +0000';
        location.assign(loginUri + "?ucid=" + e.profile.ucid
            + "&accessToken=" + e.accessToken
            + "&authState=" + e.authState
            + "&email=" + encodeURIComponent(e.profile.email)
            + "&givenNames=" + e.profile.givenName
            + "&surname=" + e.profile.familyName
            + "&redirectUri=" + location.href.replace(window.location.origin, "")
            + "&uccLastUpdatedDate=" + encodeURIComponent(uccLastUpdatedDate)
            + "&rememberMe=" + e.rememberMe);
    },
    onLogoutSuccess: function (e) {
        console.log('<<<<<<<<<< client: received onLogoutSuccess event.' + JSON.stringify(e))

        document.cookie = "skipSso=; expires=; path=/";
        location.assign(logoutUri);
    },
});

function updateLitSession(ucid, accessToken) {
    $.ajax({
        method: "GET",
        url: "/action/doSsoSessionUpdate",
        data: {ucid: ucid, accessToken: accessToken},
        success: function (callData, textStatus) {
            console.log("Session accessToken updated")
            litSSO.accessToken = accessToken
        },
        error: function (jqXHR, textStatus, errorThrown) {
            alert("Your website session has expired and will now be reset.")
            console.log("Session update failed: " + jqXHR.responseText)
            location.assign(logoutUri + "?redirectUri=" + encodeURIComponent(location.href.replace(window.location.origin, "")));
        }
    });
}

function getRedirectUri(location, fallback) {
    const urlParams = new URLSearchParams(location);
    const uriUrlParam = urlParams.get('uri');
    if (uriUrlParam)
        return encodeURIComponent(uriUrlParam);
    else
        return encodeURIComponent(fallback);
}

function isSignInPage() {
    return document.querySelector('meta[name="pbContext"]').content.indexOf("customPage:string:/sign-in") > -1;
}

function displayAuthenticatedMessage() {
    if (isSignInPage()) {
        var div = document.getElementById('authMsg');
        if ("" === "PersonUser") {
            div.innerHTML += "You are already signed in to " + window.location.origin.replace("https://", "").replace("www.", "") + ". If you would like to sign in with a different email address, please use the form below.";
        } else {
            div.innerHTML = '';
        }
    }
}</script>

                    
                
            </div>
        </div><iframe name="trustarc_notice" id="trustarcNoticeFrame" title="Trustarc Cross-Domain Consent Frame" src="https://consent.trustarc.com/get?name=crossdomain.html&amp;domain=nejm.com" style="display: none;"></iframe><script src="https://consent.trustarc.com/asset/notice.js/v/v1.7-1576" async="async" crossorigin="" importance="high" nonce="94d6a1b4040e8828-SJC"></script>
        


        
        

            <script src="/products/mms-nextgen/mms/releasedAssets/js/build.lazyload.bundle-c8c4e7d20884f81951fb.js" nonce="94d6a1b4040e8828-SJC"></script>

        <script src="/products/mms-nextgen/mms/releasedAssets/js/main.bundle-3819a02ec7bc2aca01ec.js" nonce="94d6a1b4040e8828-SJC"></script>
        


<div id="adModal" tabindex="-1" aria-labelledby="exampleModalCenterTitle" class="ng-modal modal" style="display: none;" aria-hidden="true">
    <div role="document" class="ng-modal_dialog modal-dialog modal-dialog-centered ad-promoLayer">
        <div class="ng-modal_content modal-content p-0">
            <div class="ng-modal_body modal-body m-0">
                <div class="ng-modal_header modal-header">
                    <button type="button" data-dismiss="modal" aria-label="Close" class="ng-modal_close close"><span aria-hidden="true"><span class="icon-component "><svg aria-hidden="true"><use xlink:href="/specs/products/mms-nextgen/mms/releasedAssets/icons/icons.spritemap.svg#close"></use></svg></span></span>
                    </button>
                </div>

            </div>
        </div>
    </div>
</div>
<script type="text/javascript" src="/wro/1125813~product.js" nonce="94d6a1b4040e8828-SJC"></script>








<input id="showLayers" type="hidden" value="true">

    <!-- placeholder id=null, description=ad-layer-config -->
    <!-- placeholder id=null, description=ad-lauchLayer-1 -->
    <!-- placeholder id=null, description=ad-layer-promo-1 -->

    <input id="firstAd" type="hidden" value="">
    <input id="secondAd" type="hidden" value="">

    
    
    

    
    
    <input id="IsInstitution" type="hidden" value="false">
    <input id="IsSubscriber" type="hidden" value="true">
    <input id="CustomerId" type="hidden" value="">


<script type="text/javascript" nonce="94d6a1b4040e8828-SJC">
  jQuery.extend(jQuery.mmsLayers.config, {
    rules: [{
      "name": "Launch Layer Ad",
      "frequency": 30,
      "showOnPage": 5,
      "enabled": false,
      "cookieName": "MarketingLaunchLayer",
      "styleClass": "launchLayer"
    },
    {
      "name": "Promo Layer Ad",
      "frequency": 14,
      "enabled": true,
      "cookieName": "PromoLayer",
      "styleClass": "promoLayer"
    },
    {
      "name": "Interstitial Ad",
      "frequency": 7,
      "enabled": false,
      "cookieName": "InterstitialAd"
    },
    {
      "name": "Iperceptions - Ion Layer Ad",
      "showOnPage": 1,
      "enabled": false,
      "test": false,
      "cookieName":"Iperceptions"
    }]
 });
</script>

















    <script type="text/javascript" nonce="94d6a1b4040e8828-SJC">
        $(document).ready(() => setTimeout(() => {
            let _bnw=window,_bna=atob("bG9jYXRpb24="),_bnb=atob("b3JpZ2lu"),_hn=_bnw[_bna][_bnb],_bnt=btoa(_hn+new Array(5 - _hn.length % 4).join(" "));
            $.get("/resource/lodash?t="+_bnt);
        },4000));
    </script>












    

    
    

    
    
    
    
        
            
                <script type="text/javascript" src="/wro/1125813~article-metrics.js" nonce="94d6a1b4040e8828-SJC"></script>
            
            
            
        
    




<script type="text/javascript" src="/wro/1125813~full-text-analytics.js" nonce="94d6a1b4040e8828-SJC"></script>


    


            <script>(function(){function c(){var b=a.contentDocument||a.contentWindow.document;if(b){var d=b.createElement('script');d.innerHTML="window.__CF$cv$params={r:'94d6a1b3fba58828',t:'MTc0OTUzNTA1MS4wMDAwMDA='};var a=document.createElement('script');a.nonce='';a.src='/cdn-cgi/challenge-platform/scripts/jsd/main.js';document.getElementsByTagName('head')[0].appendChild(a);";b.getElementsByTagName('head')[0].appendChild(d)}}if(document.body){var a=document.createElement('iframe');a.height=1;a.width=1;a.style.position='absolute';a.style.top=0;a.style.left=0;a.style.border='none';a.style.visibility='hidden';document.body.appendChild(a);if('loading'!==document.readyState)c();else if(window.addEventListener)document.addEventListener('DOMContentLoaded',c);else{var e=document.onreadystatechange||function(){};document.onreadystatechange=function(b){e(b);'loading'!==document.readyState&&(document.onreadystatechange=e,c())}}}})();</script><iframe height="1" width="1" style="position: absolute; top: 0px; left: 0px; border: none; visibility: hidden;"></iframe><script defer="" src="https://static.cloudflareinsights.com/beacon.min.js/vcd15cbe7772f49c399c6a5babf22c1241717689176015" integrity="sha512-ZpsOmlRQV6y907TI0dKBHq9Md29nnaEIPlkf84rnaERnq6zvWvPUqr2ft8M1aS28oN72PdrCzSjY4U6VaAw1EQ==" data-cf-beacon="{&quot;rayId&quot;:&quot;94d6a1b3fba58828&quot;,&quot;serverTiming&quot;:{&quot;name&quot;:{&quot;cfExtPri&quot;:true,&quot;cfEdge&quot;:true,&quot;cfOrigin&quot;:true,&quot;cfL4&quot;:true,&quot;cfSpeedBrain&quot;:true,&quot;cfCacheStatus&quot;:true}},&quot;version&quot;:&quot;2025.5.0&quot;,&quot;token&quot;:&quot;f55e150c7a5f4a4ab9ef82f4a1c9c43c&quot;}" crossorigin="anonymous"></script><div style="display:none;" id="signInEmbedded" class="ucc-fullpage-signin ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Sign In</h1>
  </div>    
  <div class="capture_signin">
    {* #signInForm *}
    <div class="ucc-form-inner-wrapper">
      {* signInEmailAddress *}
      {* currentPassword *}
      <div style="padding-top:10px;">
          <div class="capture_form_item capture_form_rememberme">
          <label class="ucc-form-checkbox">                
            <input checked="checked" id="ucc-remember-me-cb-embedded" name="ucc-remember-me-cb-embedded" type="checkbox" value="true">
            <span>Remember Me</span>
          </label>                           
          </div>
          <div class="capture_form_item capture_form_forgotpwd">
            <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
          </div>
      </div>
      <div class="capture_form_item">      
        <button id="ucc-sign-in-submit-embedded" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
      </div>
      <div class="capture_form_item capture_form_footer">
        <div class="ucc-no-acct-msg">Don't have an account?</div>
        <div class="ucc-no-acct-msg-2">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
          <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
        </div>
      </div>
      <div class="capture_form_item capture_form_submit">
        
      </div>      
    </div>
    {* /signInForm *}
  </div>
</div><div style="display:none;" id="forgotPassword" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Forgot Password</h1>
  </div>   
  <div class="ucc-form-inner-wrapper">
  <p style="color:black">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
  </div> 
  <div class="capture_forgotpassword">
    {* #forgotPasswordForm *}      
      <div class="ucc-form-inner-wrapper">
        {* forgotPasswordEmailAddress *}
        {* captcha *}
        <div class="capture_form_item" style="padding-top: 20px;">        
          <input id="ucc-widget-forgotpwd-submit" value="Continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
        </div>
      </div>
    {* /forgotPasswordForm *}
  </div>
  </div><div style="display:none;" id="forgotPasswordSuccess" class="ucc-widgets-nejm-next">
  <div class="capture_header">
    <h1>Create New Password</h1>
  </div>    
  <div class="capture_forgotpassword">
      <div class="ucc-form-inner-wrapper">
        <p style="padding-top: 30px; padding-bottom: 30px;">We've sent an email with instructions to create a new password. Your existing password has not been changed.</p>        
        <div class="capture_form_item">      
          <button class="capture_btn capture_primary capture-full-width-btn" onclick="janrain.capture.ui.modal.close()">CLOSE</button>
        </div>
      </div>
  </div>
  </div><div style="display:none;" id="resetPassword" class="ucc-widgets-nejm-next">
      <div class="row">      
        <div class="col-md-8 col-md-offset-2 reset-pwd-info"><p>To reset your password, enter a new password twice and click the 'Reset Password' button.</p></div>
      </div>
      <div class="col-md-4 col-md-offset-4">
        {* #changePasswordFormNoAuth *}
          {* newPassword *}
          {* newPasswordConfirm *}     
          <div class="capture_form_item">
            <input value="RESET PASSWORD" type="submit" class="capture_btn capture_primary capture-full-width-btn">
          </div>
          {* /changePasswordFormNoAuth *}
      </div>
    </div><div style="display:none;" id="resetPasswordSuccess">
        <div class="reset-pwd-info">
          <div class="reset-pwd-success-welcome"></div>
          <p class="reset-pwd-success-msg">Your password has been reset. You will need to <a href="/signin" onclick="mmsWidgets.signIn(event)">sign in</a> again using your new password to access site content and features.</p>
          <p class="reset-pwd-success-nav"></p>
        </div>      
    </div><div style="display:none;" id="resetPasswordRequestCode" class="ucc-widgets-nejm-next">
        {* #resetPasswordForm *}
        <div class="capture_form_error">The link that you followed to reset your password has expired.</div>
          <div class="col-md-8 col-md-offset-2">
            <p class="reset-pwd-info">Enter the email address associated with your account then click Continue. We will email you a link to a page where you can easily create a new password.</p>
          </div>
          <div class="col-md-4 col-md-offset-4">
            {* signInEmailAddress *}
            <div class="capture_form_item">
              <input value="continue" type="submit" class="capture_btn capture_primary capture-full-width-btn">
            </div>
          </div>
        {* /resetPasswordForm *}
    </div><div style="display:none;" id="resetPasswordRequestCodeSuccess">
      <div class="reset-pwd-info">
        <p>If the address matches an existing account, you will receive an email with instructions to reset your password.</p>
        <p class="reset-pwd-success-nav"></p>
      </div>
  </div>

        
        
    

<div id="addtoany" style="position: static;"><div class="a2a_overlay" id="a2a_overlay"></div><div id="a2a_modal" class="a2a_modal a2a_hide" role="dialog" tabindex="-1" aria-label=""><div class="a2a_modal_body a2a_menu a2a_hide" id="a2a_copy_link"><label for="a2a_copy_link_text" id="a2a_copy_link_icon" class="a2a_svg a2a_s_link a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><title>Copy link</title><path fill="#FFF" d="M7.591 21.177c0-.36.126-.665.377-.917l2.804-2.804a1.235 1.235 0 0 1 .913-.378c.377 0 .7.144.97.43-.026.028-.11.11-.255.25-.144.14-.24.236-.29.29a2.82 2.82 0 0 0-.2.256 1.056 1.056 0 0 0-.177.344 1.43 1.43 0 0 0-.046.37c0 .36.126.666.377.918a1.25 1.25 0 0 0 .918.377c.126.001.251-.015.373-.047.125-.037.242-.096.345-.175.09-.06.176-.127.256-.2.1-.094.196-.19.29-.29.14-.142.223-.23.25-.254.297.28.445.607.445.984 0 .36-.126.664-.377.916l-2.778 2.79a1.242 1.242 0 0 1-.917.364c-.36 0-.665-.118-.917-.35l-1.982-1.97a1.223 1.223 0 0 1-.378-.9l-.001-.004Zm9.477-9.504c0-.36.126-.665.377-.917l2.777-2.79a1.235 1.235 0 0 1 .913-.378c.35 0 .656.12.917.364l1.984 1.968c.254.252.38.553.38.903 0 .36-.126.665-.38.917l-2.802 2.804a1.238 1.238 0 0 1-.916.364c-.377 0-.7-.14-.97-.418.026-.027.11-.11.255-.25a7.5 7.5 0 0 0 .29-.29c.072-.08.139-.166.2-.255.08-.103.14-.22.176-.344.032-.12.048-.245.047-.37 0-.36-.126-.662-.377-.914a1.247 1.247 0 0 0-.917-.377c-.136 0-.26.015-.37.046-.114.03-.23.09-.346.175a3.868 3.868 0 0 0-.256.2c-.054.05-.15.148-.29.29-.14.146-.222.23-.25.258-.294-.278-.442-.606-.442-.983v-.003ZM5.003 21.177c0 1.078.382 1.99 1.146 2.736l1.982 1.968c.745.75 1.658 1.12 2.736 1.12 1.087 0 2.004-.38 2.75-1.143l2.777-2.79c.75-.747 1.12-1.66 1.12-2.737 0-1.106-.392-2.046-1.183-2.818l1.186-1.185c.774.79 1.708 1.186 2.805 1.186 1.078 0 1.995-.376 2.75-1.13l2.803-2.81c.751-.754 1.128-1.671 1.128-2.748 0-1.08-.382-1.993-1.146-2.738L23.875 6.12C23.13 5.372 22.218 5 21.139 5c-1.087 0-2.004.382-2.75 1.146l-2.777 2.79c-.75.747-1.12 1.66-1.12 2.737 0 1.105.392 2.045 1.183 2.817l-1.186 1.186c-.774-.79-1.708-1.186-2.805-1.186-1.078 0-1.995.377-2.75 1.132L6.13 18.426c-.754.755-1.13 1.672-1.13 2.75l.003.001Z"></path></svg></label><input id="a2a_copy_link_text" type="text" title="Copy link" readonly=""><div id="a2a_copy_link_copied">✓</div></div><div class="a2a_modal_body a2a_menu a2a_thanks a2a_hide" id="a2a_thanks"><div class="a2a_localize" data-a2a-localize="inner,ThanksForSharing">Thanks for sharing!</div></div></div><div class="a2a_menu a2a_full a2a_localize" id="a2apage_full" role="dialog" tabindex="-1" aria-label="Share" data-a2a-localize="title,Share"><div class="a2a_full_header"><div id="a2apage_find_container" class="a2a_menu_find_container"><label for="a2apage_find" id="a2apage_find_icon" class="a2a_svg a2a_s_find"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" aria-hidden="true"><title>Find any service</title><path fill="#CCC" d="M19.7 18.2l-4.5-4.5c.7-1.1 1.2-2.3 1.2-3.6 0-3.5-2.8-6.3-6.3-6.3s-6.3 2.8-6.3 6.3 2.8 6.3 6.3 6.3c1.4 0 2.6-.4 3.6-1.2l4.5 4.5c.6.6 1.3.7 1.7.2.5-.4.4-1.1-.2-1.7zm-9.6-3.6c-2.5 0-4.5-2.1-4.5-4.5 0-2.5 2.1-4.5 4.5-4.5 2.5 0 4.5 2.1 4.5 4.5s-2 4.5-4.5 4.5z"></path></svg></label><input id="a2apage_find" class="a2a_menu_find a2a_localize" type="text" autocomplete="off" title="Find any service" data-a2a-localize="title,FindAnyServiceToAddTo"></div></div><div class="a2a_full_services" id="a2apage_full_services" role="presentation"></div><div class="a2a_full_footer"><a href="https://www.addtoany.com" title="Share Buttons" rel="noopener" target="_blank"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span>AddToAny</a></div></div><div id="a2apage_dropdown" class="a2a_menu a2a_mini a2a_localize a2a_hide" tabindex="-1" aria-label="Share" data-a2a-localize="label,Share"><div class="a2a_mini_services" id="a2apage_mini_services"></div><div id="a2apage_cols_container" class="a2a_cols_container"><div class="a2a_col1" id="a2apage_col1"></div><div id="a2apage_2_col1" class="a2a_hide"></div><div class="a2a_clear"></div></div><div class="a2apage_wide a2a_wide"><a href="#addtoany" id="a2apage_show_more_less" class="a2a_more a2a_localize" title="Show all" data-a2a-localize="title,ShowAll"><span class="a2a_svg a2a_s__default a2a_s_a2a a2a_logo_color"><svg focusable="false" xmlns="http://www.w3.org/2000/svg" viewBox="0 0 32 32"><g fill="#FFF"><path d="M14 7h4v18h-4z"></path><path d="M7 14h18v4H7z"></path></g></svg></span><span class="a2a_localize" data-a2a-localize="inner,More">More…</span></a></div></div><div style="height: 1px; width: 1px; position: absolute; z-index: 100000; top: 0px; visibility: hidden;"><iframe id="a2a_sm_ifr" title="AddToAny Utility Frame" aria-hidden="true" src="https://static.addtoany.com/menu/sm.25.html#type=core&amp;event=load" style="height: 1px; width: 1px; border: 0px; left: 0px; top: 0px; position: absolute; z-index: 100000; display: none;"></iframe></div></div><zal-vjftoairbeny></zal-vjftoairbeny><div role="status" aria-live="assertive" aria-relevant="additions" class="ui-helper-hidden-accessible"></div><div id="janrainEngageEmbed" style="display: none;"><div class="janrainContent" style="width: 380px !important; height: 156px !important; padding-left: 5px !important; padding-right: 5px !important; box-sizing: content-box !important; background-color: rgb(255, 255, 255) !important; border: 1px solid rgb(192, 192, 192) !important; border-radius: 10px !important; overflow: hidden !important; position: relative !important;"><div id="janrainView"><div class="janrainHeader" style="background-color: rgb(255, 255, 255) !important; font-size: 14px !important; color: rgb(102, 102, 102) !important; position: relative !important; height: 20px !important; left: -5px !important; padding: 5px 5px 0px !important; white-space: nowrap !important; width: 380px !important; z-index: 100 !important; border-radius: 10px 10px 0px 0px !important; text-align: left !important;"><div style="padding-left: 1px !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important;">Sign in using your account with</div></div><div id="janrainProviderPages" style="padding-top: 5px; left: 5px; position: absolute;"><div class="janrainPage" pageindex="0"><ul class="providers" id="janrainProviders_0" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-aol" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="1" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-aol" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-aol" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">AOL</span></a></li><li id="janrain-openid" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="3" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-openid" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-openid" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">OpenID</span></a></li></ul><ul class="providers" id="janrainProviders_1" style="float: left !important; list-style-type: none !important; margin: 0px !important; padding: 0px !important;"><li id="janrain-yahoo" role="button" style="list-style: none !important; height: 30px !important; width: 185px !important; margin-top: 0px !important; margin-right: 5px !important; margin-bottom: 5px !important; position: relative !important; border: 1px solid rgb(204, 204, 204) !important; border-radius: 5px !important; cursor: pointer !important; white-space: nowrap !important; overflow: hidden !important; background-image: -webkit-linear-gradient(bottom, rgb(238, 238, 238), rgb(255, 255, 255)) !important;"><a tabindex="2" href="javascript:void(0);" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; font-size: 12px !important; line-height: 14px !important; margin-left: auto !important; margin-right: auto !important; text-decoration: none !important; display: block !important; padding-left: 5px !important; padding-right: 5px !important; text-align: left !important; width: auto !important;"><span class="janrain-provider-icon-24 janrain-provider-icon-yahoo" style="margin-top: 3px !important; background-color: transparent !important;"></span><span class="janrain-provider-text-color-yahoo" style="font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; cursor: pointer !important; margin-left: 7px !important; text-align: left !important; margin-top: 9px !important; vertical-align: top !important; display: inline-block !important;">Yahoo!</span></a></li></ul></div></div><div style="background-color: rgb(255, 255, 255) !important; width: 380px !important; height: 10px !important; position: absolute !important; left: 0px !important; padding-left: 5px !important; padding-right: 5px !important; padding-bottom: 5px !important; bottom: 0px !important; font-size: 10px !important; text-align: left !important; color: rgb(102, 102, 102) !important; font-family: Helvetica, &quot;lucida grande&quot;, Verdana, sans-serif !important; border-radius: 0px 0px 10px 10px !important;"><div style="padding-left: 1px !important;"><a href="http://janrain.com/products/engage/social-login?utm_source=mms.rpxnow.com&amp;utm_medium=Partner&amp;utm_campaign=attribution" target="_blank">Social Login by Janrain</a></div></div></div></div></div><script type="text/javascript" src="https://api.altmetric.com/v1/internal-556fdf0f/doi/10.1056/nejmoa2036205?callback=_altmetric.embed_callback&amp;domain=www.nejm.org&amp;cache_until=2-10"></script><iframe name="captureIFrame_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" data-transactionid="20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" id="captureIFrame_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" src="about:blank" class="" data-captureiframeloadeventbound="yes" style="display: none;"></iframe><div id="janrainModalOverlay" style="inset: 0px; position: fixed; background-color: rgb(0, 0, 0); opacity: 0.4; display: none; z-index: 1000;"></div><div id="janrainModal" style="width: 380px; height: 131px; position: absolute; z-index: 1000; display: none;"><a href="#" class="janrain_modal_closebutton" style="position: absolute; cursor: pointer; z-index: 1000;">X</a><div style="display: block;" id="signIn" class="ucc-widgets-nejm-next janrain-capture-ui capture-ui-content capture_screen_container" data-capturescreenname="signIn" data-captureventadded="true">
    <div class="capture_header">
      <h1>Sign In</h1>
    </div>    
    <div class="capture_signin">
      <form id="capture_signIn_signInForm" name="signInForm" data-capturefield="signInForm" action="https://mms.us.janraincapture.com/widget/traditional_signin.jsonp" class="capture_form capture_signInForm" method="POST" novalidate="novalidate" data-transactionid="20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" target="captureIFrame_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" accept-charset="UTF-8" next="{&quot;noop&quot;:&quot;&quot;}"><div id="capture_signIn_signInForm_defaultSavedProfileMessage"></div><div id="capture_signIn_signInForm_errorMessages"></div><input id="capture_signIn_utf8" data-capturefield="undefined" value="✓" type="hidden" class="capture_utf8" name="utf8"><input id="capture_signIn_screen_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" data-capturefield="undefined" value="signIn" type="hidden" class="capture_screen_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" name="capture_screen"><input id="capture_signIn_js_version_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" data-capturefield="undefined" value="d445bf4" type="hidden" class="capture_js_version_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" name="js_version"><input id="capture_signIn_transactionId_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" data-capturefield="undefined" value="20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" type="hidden" class="capture_transactionId_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" name="capture_transactionId"><input id="capture_signIn_form_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" data-capturefield="undefined" value="signInForm" type="hidden" class="capture_form_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" name="form"><input id="capture_signIn_flow_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" data-capturefield="undefined" value="standard" type="hidden" class="capture_flow_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" name="flow"><input id="capture_signIn_client_id_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" data-capturefield="undefined" value="qsra7g4d6jwdsgn3zbe6udp6r6278mr9" type="hidden" class="capture_client_id_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" name="client_id"><input id="capture_signIn_redirect_uri_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" data-capturefield="undefined" value="https://www.nejm.org" type="hidden" class="capture_redirect_uri_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" name="redirect_uri"><input id="capture_signIn_response_type_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" data-capturefield="undefined" value="code" type="hidden" class="capture_response_type_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" name="response_type"><input id="capture_signIn_flow_version_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" data-capturefield="undefined" value="20240514181256512029" type="hidden" class="capture_flow_version_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" name="flow_version"><input id="capture_signIn_settings_version_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" data-capturefield="undefined" value="" type="hidden" class="capture_settings_version_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" name="settings_version"><input id="capture_signIn_locale_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" data-capturefield="undefined" value="en-US" type="hidden" class="capture_locale_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" name="locale"><input id="capture_signIn_recaptcha_version_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" data-capturefield="undefined" value="2" type="hidden" class="capture_recaptcha_version_20oja7w2eyj84r1vvfxnf2ozbzr8kvpnwjth1sw0" name="recaptchaVersion">
      <div class="ucc-form-inner-wrapper">
        <div id="capture_signIn_form_item_signInEmailAddress" class="capture_form_item capture_email capture_form_item_signInEmailAddress" data-capturefield="undefined"><label for="capture_signIn_signInEmailAddress">Email Address</label><input id="capture_signIn_signInEmailAddress" data-capturefield="signInEmailAddress" value="" type="email" class="capture_signInEmailAddress capture_required capture_text_input" placeholder="Email Address" name="signInEmailAddress"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="signInEmailAddress">Validating</div><div class="capture_tip_error" data-elementname="signInEmailAddress"></div></div>
        <div id="capture_signIn_form_item_currentPassword" class="capture_form_item capture_password capture_form_item_currentPassword" data-capturefield="undefined"><label for="capture_signIn_currentPassword">Password</label><input id="capture_signIn_currentPassword" data-capturefield="currentPassword" value="" type="password" class="capture_currentPassword capture_required capture_text_input" placeholder="Password" name="currentPassword"><div class="capture_tip" style="display:none;"></div><div class="capture_tip_validating" data-elementname="currentPassword">Validating</div><div class="capture_tip_error" data-elementname="currentPassword"></div></div>
        <div style="padding-top:10px;">
            <div class="capture_form_item capture_form_rememberme">
                <label class="ucc-form-checkbox">                
                    <input checked="checked" id="ucc-remember-me-cb" name="ucc-remember-me-cb" type="checkbox" value="true">
                    <span>Remember Me</span>
                </label>          
            </div>
            <div class="capture_form_item capture_form_forgotpwd">
              <a role="button" class="ucc-anchor-button" data-capturescreen="forgotPassword">Forgot your password?</a>
            </div>
        </div>
        <div class="capture_form_item">
          <button id="ucc-sign-in-submit" class="capture_primary capture-full-width-btn" type="submit">Sign In</button>
        </div>
       
        <div class="capture_form_item">
          <div class="ucc-no-acct-msg">Don't have an account?</div>
          <div class="ucc-no-acct-msg-2" id="signInModalCreateAccountLink">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event); mmsWidgets.showRegAuto(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

          <div class="ucc-no-acct-msg-2" id="signInModalCloseLink" style="display:none">
          <a role="button" class="ucc-anchor-button" onclick="mmsWidgets.closeSignIn(event);">Create Account</a>
            <span></span><a href="https://store.nejm.org/nejm?promo=ONF4NRS1">Subscribe</a>
          </div>

        </div>
     
        <div class="capture_form_item capture_form_submit">
          
        </div>      
      </div>
      </form>
    </div>
  </div></div></body></html>